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Summary
The principle aim o f this study was to characterise the controlling mechanisms 
involved in the release of drug from a matrix of which the major components are a 
combination o f a heterodisperse and a homodisperse polysaccharide.
In systems containing the xanthan / locust bean gum combination alone, hydration of 
the polymers is instantaneous on wetting and pores or "shunt routes" in the matrix 
allow fluid to penetrate into the core. Uneven wetting of the polysaccharides occurs 
and in the gel-glass transition area, we propose the existance of pockets of dry 
polysaccharide and drug, surrounded by a hydrated barrier of gel which slows the 
dissolution and diffusion processes. Another controlling influence is the synergistic 
interaction specific to the xanthan / locust bean gum polysaccharides which increases 
the viscosity, strength and durability of the gel. The rate controlling gel takes time to 
form after initial wetting and hydration resulting in an initial burst of drug release.
Other methods of manipulating drug release involves the use of third components 
with the polysaccharide combination. Sugar components were found to increase the 
release rate as the solubility of the sugar allows fluid to penetrate into the compact 
more quickly. The release rate was decreased by including carbomer a polymer 
which hydrates and gels quickly blocking shunt routes and delaying release. 
Carbomer may also be capable of forming hydrogen bonds with the polysaccharides 
producing a highly complex three component gel network. Ions were also shown to 
increase the drug release rate from the polysaccharides. Sodium ions interfered in the 
bond formation between the polysaccharides and promoted self-association of the 
xanthan molecules.
Finally the nature of the drug itself is a factor in control of the release rate. A drug 
capable o f forming hydrogen bonds with the polysaccharides delays the diffusion of 
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1. Introduction.
1.1. Tablets and Oral Therapy.
If a new drug is to be accepted and widely used by prescribers and the general public, 
it has to be presented in an easily manageable and user friendly form. This means that 
drugs are seldom presented in their pure form but are incorporated into preparations 
which can range from the very simple to extremely complex drug delivery systems. 
The main aim of any medicine is to produce a predictable therapeutic response to the 
drug. It must however be possible to manufacture the preparation easily and cost 
effectively on a large scale and the final product must be a technologically 
reproducible and robust system [1].
The most commonly used route for administration of drugs to the body is the oral 
route. It is a safe, simple and well accepted method of administration which allows 
delivery of drugs locally to the gastro-intestinal tract as well as to the systemic 
circulation. The commonest disadvantages in use of the oral route lie, in the slower 
onset o f action of the drug when compared to the parenteral route and the 
unsuitability of some chemical compounds for delivery by the oral route e.g. insulin 
which is denatured by the enzymes of the gastro-intestinal tract [2].
The most common form of oral therapy is the compacted tablet. References to 
dosage forms recognisable as proto-tablets are contained in Assyrian and Egyptian 
texts dating to around 2000BC [3], In 1843 William Brockedon published what is 
now recognised as the first information on a process to produce compacts of graphite 
and other material. He was granted a patent for "manufacturing pills and medicated 
lozenges by causing materials in a state of granulation, dust or powder to be made 
into form and solidified by pressure in dies". The pressure was applied by a hammer
[4].
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The first British Pharmacopoeial monograph was for glyceryl trinitrate tablets and 
appeared in 1885, however due to difficulties in the production of acceptable quality 
dosage forms with adequate uniform dosing, the next monograph to be included did 
not appear until 1945. Today the British Pharmacopoeia contains over 300 
monographs for tablets of various drugs which is, far greater than for any other 
dosage form. The tablet has many benefits for both manufacturer, prescriber and 
patient. For the manufacturer they are very economical to produce, can be 
manufactured at a very high rate, provide good dose uniformity and are very stable, 
both chemically, microbially, physically and mechanically. They can easily be marked 
for identification purposes by using embossed punches or by over-printing and are 
very difficult to adulterate as has occurred in the case of hard gelatin capsules, which 
have been the subject of criminal tampering. Tablets are also a very flexible dosage 
form that can be manipulated to provide many different types of release patterns and 
formulated for other administration routes e.g. rectal or vaginal. To the patient they 
provide a portable, manageable and easily consumable method of self-medication [5].
1.2. Controlled Release.
The drug treatment for most diseases is based on repetitive doses at regular intervals, 
set according to the biological half-life of a given drug. The aim is to produce a near 
constant plasma concentration of drug in the therapeutic concentration range for an 
acceptably long period. To achieve this in practice is difficult as the plasma 
concentration oscillates between repeated doses due to the absorption, distribution, 
metabolism and elimination of the drug. The magnitude of these fluctuations may 
result in the patients plasma concentration falling outside the therapeutic range. 
Many of the antibiotics including phenoxymethylpenicillin, have a very short half-life 
and require frequent regular dosing to maintain a therapeutic concentration. This 
means that missed doses and the overnight period may leave the patient open to 
symptomatic breakthrough. Perhaps most significantly, it has been reported that 
there is a direct correlation between a lack of patient compliance and frequent dosage
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regimes. Sustained release formulations help to overcome or reduce some of these 
disadvantages. In such systems, drug release is designed to occur at a continuous 
rate for a more extended period of time. [6] [7]
7.2.7. History o f controlled release dosage forms.
The first controlled release dosage forms can be traced back to Greco-Roman times 
at least 2000 years ago and were coated pills. The first written record mentioning 
coated pills appears in early Islamic literature and it recommends the coating of pills 
with a mucilage of psyllium seeds. Later the "silvering" or "gilding" of pills was used 
in Islamic countries to mask the bitter taste o f the pill contents and to improve the 
appearance of the dosage form, however it undoubtedly changed the release profile 
[8], This practice was adopted in Europe from the beginning of the 10th century and 
later the coating changed to a talc-mucilage combination which gave the pills an 
iridescent finish resembling pearls. This pearl coating technique was used extensively 
into the 20th century. Both the metallic coated dosage forms and the "pearls" forms 
a water and acid resistant coat around the pill and it is unlikely any medicament 
escaped into the patient [9],
In the mid to late 1800's coating technology made big advances with the first reports 
of gelatin coats [10], sugar coats [11] and the first enteric coats [12] using the natural 
gum extract shellac. The first commercially marketable approach to sustained release 
was reported by Blythe and used drug-containing beads which were coated with 
different combinations of fats and waxes [13], but it was not until the late 1940's and 
early 1950's that sustained release dosage forms made a significant commercial and 
clinical impact. The first sustained action tablets were "repeated action" tablets in 
which drug-containing tablet cores were surrounded by an enteric coat. This 
provided a two step release in the gastro-intestinal system but unfortunately these 
types of products were sensitive to physiological variables such as gastric emptying
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and tended to give blood levels with large peaks and troughs rather than a smooth 
time profile.
In 1950 it was suggested by Saunders and Srivastava that drug release could be 
extended by binding drug molecules to ion-exchange resin [14]. Other methods of  
delaying drug release from different dosage forms followed. These included two 
layered tablets, one layer giving immediate release while the second layer 
incorporated hydrogenated castor oil and ethylcellulose and provided the sustained 
release [15]. A variant of this approach was based on compacting a sustained release 
core and surrounding it with a compacted immediate release layer [16]. The 
Spansule® was first marketed by Smith, Kline and French Laboratories of 
Philadelphia in 1958 and was the first true prolonged release dosage form available. 
It was a formulation of chlorpheniramine of small beads coated with different 
concentrations of water soluble polymer designed to release at different rates [13].
In 1953 the term pharmacokinetics was first used by the German pharmacologist, 
Dost [17]. Pharmacokinetics and pharmacodynamics now form an essential basis for 
the development and quantitative evaluation of extended release dosage forms. It 
was considered that minimising the peaks and troughs of cyclic drug levels could be 
realised by a zero order or constant rate drug release profile and by 1971 a wide 
variety o f devices had been developed to achieve these aims. Systems, including 
transdermal patches [18], drug infusion pumps [19], ophthalmic inserts [20] [21] and 
intra-uterine devices [22], as well as oral delivery systems were all developed for 
clinical use, although many apart from those for oral and transdermal use were later 
withdrawn. Sustained and controlled release technology has subsequently developed 
into an important discipline in the pharmaceutical industry which is intensively 
researched and commercialised. Many hundreds of papers are published annually 
covering aspects in the field of controlled drug delivery, a large proportion of which 
relates to oral systems.
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1,2.2. Terminology o f controlled release systems.
The British Pharmacopoeia 1993 defines modified release dosage forms, as drug 
release characteristics which are extended, or delayed by the conditions at the 
dissolution site in the gastro-intestinal tract. The modifications are designed to 
accomplish therapeutic goals or improve convenience in dosage regimens which are 
not offered by conventional dosage forms. Under the general description o f modified 
release, two main sub-divisions of release behaviour can, be defined:
• Delayed release dosage forms [23] [24] which do not allow an immediate release 
and only allow release from the dosage form a measurable time after 
administration but which may be very rapidly achieved at that trigger time e.g. 
enteric coated tablets [25].
• Extended release dosage forms may be defined as those systems that allow at 
least a two-fold reduction in the dosing frequency compared to conventional 
dosage forms. These types of dosage forms are also known as sustained release 
[26] [27] or timed release [28] [29] and dissolution profiles are chosen to 
accomplish therapeutic or patient treatment adherence objectives not offered by 
conventional release dosage forms. The aim is to quickly provide, a therapeutic 
drug level that is maintained for 8-12 hours with only a single dose 
administration, in the case of drugs with short biological half-lives [30].
It is generally considered that a controlled release [31] [32] dosage form, due to its 
special design and construction, delivers drug in a measured, controlled and 
predictable manner [33],
The terminology used within the area of modified, prolonged, sustained and 
controlled release has been confusing and no internationally accepted standard 
definitions have been developed. This has lead to researchers and manufacturers
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developing their own terms for their prolonged action delivery systems and particular 
patterns of release. Many terms have been utilised to describe extended release 
dosage forms including gradual release [34], long-term release [35], prolonged 
release [36] [3 7] and slow release [38].
1.2.3. Considerations for controlled release systems.
When designing a controlled release system a number of factors have to be 
considered to produce a safe and effective system. The ideal controlled release 
system should not be sensitive to physiological and environmental factors 
encountered in the gastro-intestinal tract, however, this is very difficult to achieve in 
practice. Factors such as the rate of gastric emptying, changing gut pH, the presence 
of food and food type in the stomach, physical position of patient i.e. standing up or 
lying down, the age of the patient, excitation or mental state of the patient and the 
disease state can all influence the way a dosage system works. Most of these factors 
not only differ between patients but also vary within the same patient. To combat 
this the dosage form should function on several levels and should not just be aimed at 
one particular physical feature of the gut i.e. there should be several mechanisms of 
action to reduce the sensitivity of the system to environmental factors. The systems 
also need to flexible and be able to handle a wide variety of drugs and dosage levels 
to make it viable as a commercial system and yet aesthetically acceptable to the 
patient. They are also required to be stable in terms of chemical and physical stability 
to make them viable commercially [39].
The aim with all controlled release dosage forms is to produce a steady state blood or 
tissue level which is in the therapeutic range, without being toxic, for an extended 
period of time. This produces improved and more efficient control of disease states 
and maintains drug levels above the minimum required to prevent breakthrough of 
symptoms e.g. asthma or depression. There is also a reduced occurrence of systemic 
side effects experienced by patients due to the peak plasma levels being in the toxic
16
range immediately after administration. Furthermore there is a reduced risk of local 
side effects since there is no dose "overloading" or dumping as can occur with 
immediate release dosage forms. There is a reduction in the total quantity of drug 
administered over a treatment period as controlled release maximises the availability 
of the drug using a minimum dose. Longer intervals between doses allow the patient 
uninterrupted nights as there is no longer a requirement for inconvenient 
administration times. Controlled drug release systems also improve drug absorption, 
as the release can be targeted into specific regions of the gastro-intestinal tract e.g. 
ileum for captopril and colon for diltiazem
Controlled release can offer more cost effective illness management in terms of a 
reduction in the number o f hospital visits required and a reduction in the hours lost at 
work due to poorly controlled disease states. These systems also simplify the dosage 
regimens which equates with better compliance which should translate to improved 
control of the disease state.
Although these systems provide manufacturers and clinicians with a wider choice of 
options in the therapeutic approach to treating a disease, they also have to be aware 
of the limitations of such systems. Drugs with a biological half life of between two 
and six hours only are appropriate for controlled release formulation [40]. Drugs 
with a half life shorter than two hours require a very high maintenance dose to 
produce continuous therapy which necessitates very large dosage forms. Drugs with 
very long half lives risk accumulation in the blood plasma due to the low metabolism 
and elimination rates. Potent drugs are not suitable for controlled release as there 
may be significant risks to the patient if dose dumping occurs. Also for drugs with a 
narrow therapeutic window there is a risk of toxicity occurring between different 
individual patients because of varying rates of absorption, metabolism and 
elimination.
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It is difficult to terminate treatment rapidly once the dosage form has been 
swallowed. The maximum period of time for which a therapeutic response can be 
maintained is limited by the gastro-intestinal transit time which varies both between 
and within individuals. The average time for mouth to anus transit is twelve hours, to 
which the time for elimination of the drug may be added. There is also a risk of 
severe local side effects if the dosage form becomes stationary or lodged producing 
high drug concentrations in a localised area [41]. Controlled release dosage forms 
normally have a higher unit cost compared to conventional dosage forms but this has 
to be balanced against the lower frequency of administration during the treatment 
period [42].
1.3. Oral Controlled Release Dosage Form Designs.
There are a number of techniques used to extend drug action including chemical 
modification of the drug or biological approaches where elimination of the drug from 
the body can be suppressed. The majority of methods however are based on 
formulation of the drugs into dosage forms based on well known physico-chemical 
principles and can be classified according to the mechanism controlling the release of 
the drug [43],
• Diffusion controlled systems.
• Membrane (reservoir) systems.
• Rigid matrices.











Diffusion-controlled systems have been widely used as drug delivery systems. These 
materials do not generally interact with the dissolution medium or the gastro­
intestinal fluids.
1.3.1.1. Membrane (reservoir) systems.
Membrane systems consist of a core containing formulated excipients and drug into a 
tablet and surrounded by an insoluble, polymeric membrane or film which acts as a 
diffusion barrier. Drug release occurs by diffusion of the dissolution media into the 
system, dissolution o f the drug and then counter-diffusion of the drug solution out 
through the polymer membrane [44].
The overall rate determining step in the release process is the diffusion of the drug 
through the membrane. Release from reservoir systems can be described by 
equations derived from Fick's first law of diffusion and can provide constant or zero 
order release, characterised by Equation 1.3.1 (Q is % cumulative release of drug, k 
is a kinetic constant and t is time), provided there is a saturated concentration of drug 
within the core and a constant concentration gradient across the membrane is 
maintained. However as the reservoir becomes depleted towards the end of release 
the rate o f delivery drops away [45]. There can be an initial burst of release from 
these systems and this is due to migration of the drug into the membrane [46].
Q =kt Equation 1.3.1
The rate of release can be adjusted, by varying the characteristics of the membrane to 
increase or decrease diffusion rates. An example of a diffusion controlling film coat 
is provided by a mixed membrane of ethylcellulose and methylcellulose which has 
been used to coat aspirin particles. The methylcellulose is soluble in aqueous media 
and dissolves out of the mixed film leaving small channels which fill with gastro-
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intestinal fluid facilitating drug dissolution and diffusion across the membrane into the 
bulk [47].
Another approach is to coat particles or granules of drug with different thicknesses of 
slowly soluble material such as celluloses, polyethylene glycol or waxes. Varying 
release rates can be achieved by adjusting the thickness and permeability of the 
coatings [48]. The coated particles can then be compressed into tablets or placed 
into capsules.
Advantages of such systems are that they can be simple and cheap to manufacture 
once the initial formulation problems have been overcome. Disadvantages include 
the problem of drug being dumped if the film coat is imperfectly formed or 
subsequently pierced or damaged, with a risk of toxic side effects [49].
1.3.1.2.______Rigid matrix systems.
Inert matrices are used to prepare monolithic matrices for oral controlled release. As 
in reservoir systems the release is governed by Fick's first law of diffusion however in 
these systems the release is concentration dependant. The drug dissolves and diffuses 
away from the device, as time progresses the pathlength for diffusion increases and 
the concentration gradient decreases [50][51], The drug release rate therefore is not 
constant in relation to time as in zero order, but follows a square root of time 
dependency characterised by equation 1.3.2, [52].
i
Q =k t2 Equation 1.3.2
The drug can be dispersed between the polymer network from which it diffuses or 
dissolved within the polymer material from which the dissolution medium leaches the 
drug. Materials used in these formulations include polyvinylacetate, ethylcellulose,
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polymethacrylate and polyethylene [53][54]. Release rate is dependant on several 
factors including the concentration of the drug, the type of polymer used and the size 
and length of the pores [55].
Advantages of these systems are that accidental rupture is not likely to be fatal to a 
patient and generally the systems are easy to manufacture. The time dependant 
release profile is a disadvantage which has been overcome by employing 
unconventional shapes to compensate for the increasing diffusional pathlength and 
achieve zero order release [56]. Zero order release may also be achieved if 
formulated where a boundary layer is formed around the matrix and diffusion through 
this becomes the rate limiting step [57].
1.3.2. Modulated-release systems.
In these types of systems, release is controlled by external stimuli, which may, for 
example, alter the permeability of the polymer and allow release of immobilised drug. 
In some systems the stimuli are environmental changes within the body which elicit 
the change in the delivery system [58]. These include pH [59][60], temperature 
[61][62]. In other systems the stimulus is external i.e. applied outside the body and 
includes magnetism [63] and ultrasound [64]. The advantage of these systems is that 
it may now be possible to develop a self contained but responsive delivery device for 
difficult to control conditions such as diabetes [65].
1.3.3. Solvent-activated systems.
1.3.3.1. Osmotic-controiled systems.
All controlled release systems with a restrictive portal require an energy source to 
drive drug out of the reservoir. This may take the form of diffusion, however a more 
energetic physico-chemical process occurs when an osmotic gradient is produced.
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Osmotic dosage systems were developed specifically to achieve zero order release. 
A semi-permeable membrane formed around a core containing an osmotically active 
drug or a drug and an osmotic agent. The semi-permeable membrane allows water 
from the gastro-intestinal contents to diffuse into the device along the osmotic 
gradient. The internalised water dissolves the drug, however this solution is unable 
to counter-diffuse out of the core because of the semi-permeable characteristics of 
the film. The continuing diffusion of water and lack of effusion of solution causes a 
rise in internal pressure within the tablet core. A small "hole" is produced by the 
action of a laser on the membrane and this allows the drug to be "pumped" out of the 
device which occurs when the build up of hydrostatic pressure within the device 
forces out the drug solution or suspension [66].
The release rate is determined by a number of factors including the size of the orifice 
which is critical and must be well defined for the system if zero order release is to be 
obtained [67]. The characteristics of the semi-permeable membrane including 
permeability and thickness are also important to the release rate. It is possible to 
achieve much higher rates of delivery with these systems than with the solution- 
diffiision systems. An advantage of this system is that the driving force for release is 
osmotic pressure and is independent of factors such as pH or hydrodynamic 
conditions which enable it to resist differences in drug released when administered in 
fed or fasted conditions. Disadvantages include failure of the device due to 
orientation with the patient or blocking of the orifice [68] [69].
1.33.2. Non-rigid matrix systems.
Non-rigid matrices are based on hydrophilic matrices. Terminology in the area of 
hydrophilic matrix release systems has been confused and misused in the literature. 
Hydrophilic matrices are commonly considered to be hydrocolloidal. However, true 
hydrogels are water swellable macromolecular networks which maintain their shape
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due to covalent cross-linking between macromolecules rendering them insoluble. 
Although hydrophilic matrix and hydrogel are terms which have been used 
synonymously, many of the polymers used in pharmaceutical formulations are 
swellable and soluble and could better be described as swellable polymers which after 
wetting do not maintain a permanent shape [70].
Hydrophilic controlled release polymers should not disintegrate on contact with 
aqueous media; rather the matrix should allow water to penetrate and hydrate the 
polymer in an ordered manner. The hydrated polymer swells and relaxes to form a 
gelatinous barrier around the surface of the dosage form. It is this layer which often 
acts as a barrier slowing the further ingress of water and forming a diffusion barrier 
to the dissolved drug. Below the hydrated layer there is a dry glassy core of material 
which behaves as a reservoir of both drug and polymer. The new polymer acts to 
replace the gel layer as existing gelled polymer dissolves or erodes away. The new 
drug acts to replace drug in the depleted gel zone [71]. These processes are 







Figure 1. Schematic diagram of swelling processes in hydrophilic polymers.
The viscosity modifying and gel-forming characteristics of hydrophilic excipient 
systems produce a variety of possible release controlling mechanisms in any particular 




Where ------ is the fractional solvent absorbed or drug released; t is the solvent
M oo
absorption or drug release time; k and n are kinetic constants which depend on, and 
can be used to characterise, the mechanism of solvent sorption and drug release. If 
n=0.5 then the release is Fickian diffusion. Where n is between 0.5 and 1.0 the 
release kinetics are non-Fickian and are characteristic of solvent/drug solution 
diffusion and polymer relaxation. As n approaches 1.0 it approaches zero-order 
release which is achieved at n=1.0 (Case II drug release) [75].
A more reliable analysis is one vriiich considers drug release as a result of two 
processes, the drug diffusion and the swelling of the matrix due to the dissolution 
media. This model was proposed by Peppas and Sahlin and quantifies the two 
phenomena controlling the release (Equation 1.3.4) [76].
The first term of the right side of the equation represents the Fickian contribution and 
the second term represents the Case II relaxational contribution to drug release.
Swelling of matrices can be calculated according to the swelling index ,SI.
where Xo is the initial diameter or height of the tablet and Xt is the height and 
diameter of the tablet at time t. This expresses SI as a percentage. Wan et al found 
that if this was plotted against the square root of time for a range of HPMC matrices 




1.3.3.2.1. Polysaccharide hydrophilic matrices.
The majority of hydrophilic materials used in pharmaceutical controlled release are of 
semi-synthetic or natural origin [78]. A wide variety of different natural gel-forming 
materials have been used in controlled release and are reviewed later.
1.3.4. Chemically-controlled systems.
1.3.4.1 . Bioerodible and biodegradable systems.
The rate of release from these fatty or wax matrices is controlled by matrix 
breakdown and erosion. Where this breakdown occurs it should be reproducible and 
have enough structure to maintain the release specification over the required time. 
Breakdown of the matrix is dependant upon the porosity, presence of hydrophobic 
additives, wettability and the particle surface. Fatty matrices undergo pH and 
enzymatic hydrolysis of fatty acid esters, therefore it is difficult to control release in 
yiyo due to variations in pH and enzyme content of the gastro-intestinal tract. The 
release rate from wax matrices is usually slow, therefore the initial dose can be 
contained in a coating [79] [80]. Drugs have been mixed and compressed in 
combination with natural hydrophobic carriers such as beeswax, camauba wax, 
glycerol monostearate and glycerol palmitostearate [81]. Synthetic biodegradable 
polymers may undergo depolymerisation in the tissue of an organism, other polymers 
undergo microbial degradation. These types of polymer are mainly employed in 
implants [82].
1.3.4.2 . Pendant chain systems.
In these systems the drug molecule is chemically bonded to the polymer backbone 
and is released by hydrolytic or enzymatic cleavage. This approach is used 
particularly in drug targeting when the drug is aimed at a particular cell-type or 
tissue. Natural polymers such as polysaccharides as well as synthetic polymers have
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been used as drug carriers. The rate of drug release is governed by the rate of 
cleavage from the polymer backbone [83],
1.3.4.2.1. Ionic binding.
Ion exchange resins are insoluble cross-linked polymers with ion groups capable of 
forming salts at repeated chain positions. By bringing the resin into close contact 
with the drug in solution the ionic groups form complexes with drugs. Drug release 
occurs when a high concentration of an appropriately charged ion comes into contact 
with the ion exchange site, the drug is exchanged and diffuses out of the resin. 
Release rate depends on the pH and electrolyte concentration of the dissolution 
medium. It can also be subject to variable results as the ionic content of the gastro­
intestinal tract can vary due to diet and water content [84]. More recently rate 
controlling coatings have been applied to the resins to offset the environmental effect 
[85]. Ion-exchange resins have been used in conjunction with antitussives such as 
dextromethorphan, [86] sympathomimetics such as phenylpropanolamine,[87] 
antiarrhythmics such as propranolol [88] and many others.
It is also possible to extend the release profile of a drug by simply formulating in the 
usual way but preparing a complex or salt of the drug which has a reduced solubility 
in the gastro-intestinal tract. This has been used as an approach for formulating 
amine drugs which form slightly soluble salts with tannic acid the tannate is then 
compressed with standard excipients [89].
1.3.4.3. Drug/excipient and excipient/excipient interactions.
It is possible for interactions to occur between the polymer network and added 
excipients which can change the performance of the dosage form. Touitou et al. 
observed three types of interaction, between polymers and a second component 
material, which could affect the hydrophilic dosage form. The three effects were 
disintegration, erosion and non-erosion or stabilisation of the gel. Premature
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disintegration of HPMC dosage forms has been reported due to simple salts 
increasing the ionic strength and approaching the cloud point of the polymer [90]. 
Another study suggested that simple anions are the important factor in reducing the 
cloud point and as the ionic strength of the dissolution media was increased the drug 
dissolution rate decreased until failure of the device occurred [91]. Other studies 
have suggested that the nearer the dissolution temperature is to the thermal gelation 
temperature, the greater the contribution of erosion to the drug release mechanism 
[92], The interaction of calcium ions with alginate is well known and has been used 
to delay release [93]. It has been observed that although the cross linking occurs 
down at the molecular level the changes that occur can be observed at the 
macromolecular level in the gel layer formation [94] [95].
Drugs used within the matrices have also been observed to interact with the 
hydrophilic polymers. Ibuprofen formed bonds with hydroxypropylmethylcellulose 
which could be detected using differential scanning calorimetry [96]. Propranolol 
interacts with HPMC and increases the cloud point and interferes with the hydration 
processes [97] which in turn interferes with the development of the gel in the 
hydrated layer [98]. In some cases the release has been shown to interfere with the 
rate of release of the drug. Lapidus and Lordi showed the release rate of 
chlorpheniramine from sodium carboxymethylcellulose was slower than sodium 
salicylate and attributed this to drug polymer interactions [99]. Chlorpheniramine has 
been shown to have a much slower rate of release from sodium alginate, than from an 
alginate cross-linked by calcium. The chlorpheniramine is thought to form the 
crosslinks instead of the calcium ions [100]. Another polymer shown to form ionic 
crosslinks with a drug is xanthan gum. Neomycin forms crosslinks with the xanthan, 
reducing the solubility of the polymer [101]
These effects all have the potential to affect a change in the release characteristics of 
a dosage form and possibly even cause the failure o f a system. The cause of this may
27
be another excipient within the dosage form, the drug itself or incoming ions within 
the dissolution media.
1.4. Polysaccharides.
Many natural or semi-synthetic polysaccharides can be used as hydrophilic matrix 
forming carriers. A wide range of such materials has been investigated in recent 
years including those of plant origin, pre-gelatinized starches and alginates [102]. 
The most widely used and investigated are semi-synthetic cellulose ethers; in 
particular hydroxypropylmethylcellulose which is probably the most widely studied 
and used [103].
Polysaccharides are carbohydrate polymers made up of repeating, monosaccharide, 
sugar units, and can be sub-divided into two main groups: the homopolysaccharides 
which have one type of sugar unit in the backbone and the heteropolysaccharides 
which incorporate at least two different sugar rings in the backbone. The sugar units 
incorporated into polysaccharides are mainly pyranose rings and the linkages between 
the sugar units are principally glycosidic i.e. a water molecule suppressed between 
the hydroxyl group at C-l of the leading sugar ring and a hydroxyl group on the 
following residue. In natural polysaccharides the majority are (l-*4) or (l-*6) linked 
but (l-*3) and (l-»2) linkages also exist. The hydroxyl group on the C-l position 
may be in the axial or equatorial position and this designates the link as either a  or 0 
and the position of the bond dictates the configuration, shape and flexibility of the 
molecule [104],
In general there are three configurations that the polysaccharides can take: Branched 
polysaccharides which can be further broken down into : (a) Highly branched 
polysaccharides such as gum arabic (acacia) and (b) Long chain polysaccharides with 
numerous short side chains which have properties of both the linear and highly 
branched molecules (substituted linear polysaccharides).
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The other group are the linear polysaccharides where there is a single chain structure 
e.g. cellulose. Polysaccharides do not only exist in the neutral form, some are 
naturally anionic, containing acidic functions such as carboxyl groups, sulphate 
groups or phosphate groups. Methyl esters, ethers and acetals substituted polymers 
are also found naturally [105],
1.4.1. Branched polysaccharides.
1.4.1.1 .______ Gum arabic.
Gum arabic was first used commercially by the Egyptians 4000 years ago. The gum 
is the dried exudate of various species of the genus Acacia, subfamily Mimosoideae 
and family Leguminosae. Although there are approximately 500 species of Acacia all 
over the world growing in hot, dry, elevated locations only a few are of commercial 
importance. The gum is produced by tapping, where the outer bark is broken 
horizontally by making a shallow cut. The bark is then stripped back above and 
below to form wounds in which the gum droplets form in six to eight weeks and 
gradually dry in the atmosphere. The gum is then harvested by hand and processed 
into granular, powder and spray dried forms [106],
Figure 2. Schematic representation of the highly-branched structure of gum arabic.
The complex structure of gum arabic is still not completely understood. The 
backbone is composed of (1 —>3)-linked D-galactopyranose units some of which are 
substituted at the C-6 position with various side-chains such as a(l-*4)-L- 
rhamnopyranosylglucuronic acid, jft(l-*6)-D-glucopyranosyl-D-galactose and <*(!-»
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3)-D-galactopyranosyl-L-arabinose These side-chains produce a highly complex 
extensively branched structure [ 107][ 108] (Figure 2). Light scattering studies 
suggest that the gum arabic molecules are in short, stiff spirals with numerous side 
chains [109] [110].
It is highly soluble in water and produces a viscous solution which has been used 
extensively in the pharmaceutical industry as a suspending and emulsifying agent and 
is listed in the U.S. Pharmacopoeia for this purpose [111]. It has also been used as a 
binder in tablets and coating on pills [112].
/. 4.2. Linear polysaccharides.
1.4.2.1. Cellulose.
Cellulose is a naturally occurring organic substance and is found as the principle cell- 
wall constituent of higher plants in which it is the main structural element. It is found 
in an almost pure form in cotton fibre (98% of the dry weight) and used in the textile 
industry. Other materials such as flax, jute and wood contain about 40-50% 






Figure 3. Structure of the cellulose molecule.
The molecules consist of a /3-D-glucose in the pyranose ring form (l-»4) linked in the 
chair conformation (Figure 3). The molecules comprise between 1000 and 15000 
glucose units depending on the origin and the extent of degradation during the 
isolation process. Infrared spectroscopy, NMR and X-ray diffraction studies have
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shown that there are intramolecular bonds formed between the hydrogen atom of the 
OH-group on the carbon at position 3, and the pyranose ring oxygen. Other studies 
have shown the possible existence of another intramolecular hydrogen bond between 
the hydroxyls on the carbon atoms at positions 2 and 6. There are also
intermolecular hydrogen bonds between the hydroxyl groups on the carbon at 
position 3 and position 6. The intramolecular and intermolecular hydrogen bonding 
is the cause of the stiff and rigid nature of the cellulose molecules and stabilises the 
"two fold helical" structure and account for its almost complete insolubility in 
water[114][115].
The ether derivatives are the commonest forms of cellulose used pharmaceutically for 
controlled drug delivery purposes.
1.4.2.1.1. Cellulose ethers.
The cellulose ethers are the most important commercially produced group of 
polymers for controlled drug delivery purposes and there is a large variety available 
on the market. In general they can be described as chemicals based on the natural 
polymer cellulose, being water soluble and having a thickening action in aqueous 
media [116]. Etherification involves partial substitution of the hydroxyl- groups, (up 
to a maximum of three per cellulose molecule), by methoxyl or other functions. The 
effect of the methoxyl groups is to sterically force apart the cellulose chains and 
disorder them enough for water molecules and other solvents to permeate them and 
hydrate the molecules [117]. The solubility increases as the degree of substitution 
increases. For example methylcellulose is soluble in cold water at a degree of 
substitution between 1.3 to 2.6 [118].
The properties of the cellulose ether depend on several factors including the degree 
of substitution, which is the number of hydroxyl groups per molecule replaced with 
other groups. The uniformity of substitution along the polymer chain and the nature
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of the new group introduced also affect the properties of the ether. The solubility 
depends upon the degree of substitution, the molecular weight, the distribution of 
substitution and the substituting group. With the notable exception of ethyl cellulose 
most are water soluble [119]. Methylcellulose can swell to forty times its dry volume 
and has been used extensively in pharmaceutical tabletting as a granulating agent, a 
coating agent and a disintegrant.
The most important of the polysaccharides used for controlled release delivery are 
the cellulose ethers which include hydroxypropylmethylcellulose (HPMC), 





Figure 4. Structure of sodium carboxymethylcellulose.
Hydroxypropylmethyl cellulose has been studied extensively by many researchers and 
there has been great variation in the reported performance of different batches of the 
same HPMC and the same grade from different manufacturers despite the excipients 
having the same USP monograph specification [120], It has been suggested that 
these differences were due to differences in physical characteristics such as particle 
size and secondly to differences in hydroxypropyl content of the semi-synthetic 
polymers. However the biological source of the cellulose starting material is also a 
potential reason for the differences observed. Alderman [121] showed that drug 
release could be extended by increasing polymer concentration or viscosity grade and 
that different relative concentrations of methyl and hydroxypropyl substitution could 
result in different hydration rates which affect the performance of the polymer in the
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initial stages of tablet hydration. It was also found that different substitution levels 
give rise to different drug release profiles as a result of gel strength differences and 
susceptibility to erosion. However subsequent studies [122] [123] suggested that 
the choice of model drug, solubility, physical difference between the polymer samples 
and differences in the formulations used, all contribute to the effects described by 
Alderman and his conclusions were therefore questioned. Shar et al. have reported 
obtaining a bimodal release profile which is discussed later with different commercial 
forms of HPMC (Dow Methocel F4M and Shin-Etsu). Studies were carried out both 
in vitro and in vivo using the drug adinalozam. Bi-modal release is an unusual but 
highly desirable profile for certain groups of drugs [124].
1.4.2.2. Carrazeenans.
Carrageenans are derived from the red seaweed (Rhodophyceae) family found along 
the south coast of Ireland and their use dates back 600 years as a gelling agent for 
milk amongst other uses [125]. Lambda (X) carrageenan consists of a backbone of (3 
-D-galactose 2-sulphate linked through the (l->3) positions and 2,6, disulphate a-D- 
galactose linked through the (l-*4) position.
These links in X-carrageenan give the molecules the configuration of a zigzag ribbon 
structure which does not allow the formation of helices. X-carrageenan is readily 
soluble in cold conditions as it possesses 3 sulphate groups per 2 galactose residues, 
giving a strong anionic character. The sulphate groups cause ionic repulsion between 
the polymer chains so they cannot align and form a network. These two factors mean 
X-carrageenan has no gel forming ability but hydrates and can be used as a thickening 
agent.
The main backbone of iota- (t)-carrageenan and kappa- (/c)-carrageenan molecules 
consist of /3-D-galactose 4-sulphate linked through the (l-»3) position and 3,6,
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anhydro-galactose linked through the (1-^4) position shown in figure 5. The 
difference between the two molecules is the presence of a sulphate group on the 2 
position carbon of the 3,6, anhydro-galactose. Iota- (i-) carrageenan has 2 sulphate 
units per 2 galactose units and this imparts intermediate properties between X- 
carrageenan and x-carrageenan in that it will form weak gels and is partially soluble in 
cold water. x-carrageenan has only 1 sulphate for every 2 galactose residues and is 





Figure 5. Structure of carrageenan where iota- carrageenan R= SO3" and kappa- 
carrageenan R= H.
The network formed by the t-carrageenan and x-carrageenan is due to the formation 
of helices with other macromolecular chains, the sulphate groups are located only on 
the outer part of the macromolecular chain thus the inner part of the chains can 
aggregate together to form double helices (Figure 6). The bonds between the 
molecules also make the formation of a helix favourable.
Loose gel networkRandomly coiled macromolecules Molecular "kinkrng" {  J  s
Figure 6 . Gel network formation by iota-carrageenan.
34
Macromolecules of carrageenan are not pure but are mixed and the 3,6, anhydro- unit 
is replaced by a 6-sulphated galactose. When this occurs a "kink" is formed in the 
helix which interrupts the regular sequence. The kinks allow the chains to form 
helices with other chains and so a loose network is built up.
x-carrageenan has only 1 sulphate for every 2 galactose residues and is only soluble in 
hot conditions, however it is capable forming a gel in the same way as the iota- 
carrageenan. However on addition of potassium cations there is a hardening and 
shrinkage of the gel. The small hydrated cation partially neutralises the sulphate 
groups and allows the double helices to cluster together and form aggregates (figure 
7). The calcium cation can behave as a binding factor by neutralising two sulphate 
groups on different polymer chains [126][127], The loose gels behave 
thixotropically, being destroyed by application of a shearing force but becoming re­
established when at rest.
Randomly coiled macromolecules Molecular "kinking" { r -\  
allows formation \ /
4 of double helices x x
Addition of 
ionic species Aggregates of 
double helices
Figure 7. Structure of gel formed by kappa-carrageenan with the addition of ionic 
species.
Carrageenans have been widely used in the food industry and by pharmaceutical 
technologists as thickening agents however there are few examples of it being used as 
the basis for matrix controlled release formulations [128], Recently carrageenan was 
examined as a controlled release excipient and studies have been performed using the 
non-gel forming but swellable X-carrageenan at gastric pH's and it showed the 
advantage of insensitivity to changes in pH. In formulations with low dose, freely
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soluble drugs such as salbutamol sulphate, the initial burst of drug release observed 
with other hydrophilic polymers like HPMC is not observed with lambda- 
carrageenan, irrespective of the pH of the dissolution medium [129], Studies have 
also been done on a combination of kappa-carrageenan and galactomannans.
Commercial grades of the alginates are derived from the extracellular matrix of the 
brown seaweed or algae group. There use has been recorded back to ancient times 
when the Chinese and the Romans used them in medicines and for cosmetic purposes
[130], Alginates are composed of two different uronic acids j3-D-mannuronic acid 
and a-L-guluronic acid connected through the (l-»4) positions. The two monomer 
residues do not occur in a random distribution but in blocks of around 20 units which 
may be continuous blocks of either mannuronic acid (Figure 8) or guluronic acid 




Figure 8. Homo-mannuronic acid segments of alginates.
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Figure 10. Structure of mixed mannuronic acid and guluronic acid segments of 
alginates.
The distribution of these blocks dictates the gelling properties of the alginate as only 
the guluronic acid segments form the buckled ribbon structure shown in figure 11
[131]. Mannuronic-rich alginates are primarily found in the flexible parts of the 
seaweed whereas the guluronic-rich alginate gives strength and structure to the plant 
and is commonly encountered in the stem of the seaweed.
One of the important properties of the alginates is the ability to form gels in the 
presence of calcium salts.
Figure 11. Appearance of the "buckled ribbon" guluronic sections of alginate 
polymer chains when forming an "egg box" type gel with calcium ions.
Corrugated ribbon structure ofCa**" ions
“Egg box " model of gel formation
a t io n s  
guluronic acid segments HO'
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In the presence of the divalent calcium cation the continuous segments of guluronic 
segments associate and stack together forming aggregates in a structure known as the 
"egg box" type (Figure 11). The calcium ions fill the spaces formed by the two 
buckled ribbons neutralising the charges on the carboxyl groups of the guluronic acid 
segments [132], It is likely that the continuous blocks of mannuronic acid may be 
involved in a small amount of bonding but the alternating blocks take no part at all.
Each of the positive charges on the calcium ion acts to neutralise a negative charge 
on the guluronic section of two different polymer chains. As a result it is easy to see 
why alginates with a higher quantity of guluronic acid sections posses the greater 
gelling capacity. The strength of the gel is affected by several factors : the quantity 
of homogeneous guluronic acid segments and the concentration of the cation 
available. Low quantities of calcium increases the pseudoplastic behaviour of the 
alginate before a gel structure is formed and if the concentration of the cation is too 
high initially Precipitation can occur on reaction with the alginate and this should be 
avoided. The alginates are readily soluble in cold water as the carboxyl group on 
each sugar unit of the chain is fully ionised and produces a strong repulsion between 
the chains. This solubility is reduced by the presence of calcium ions which promotes 
the formation of junction zones and so reduces the alginate solubility [133],
In solution alginates can be use as either thickening or gelling agents depending on 
the presence of calcium ions and calcium cross-linked alginate gels have been studied 
extensively for sustained release. 0stberg et al. showed that the guluronate content 
of the alginate, the calcium concentration and the amount of drug added, were the 
most important variables in controlling the release rate of theophylline. Increasing 
any of the three factors slowed the release rate of the drug [134], Sodium alginate 
has also been used as a coating material in press-coated ibuprofen tablets to control 
the release rate of the drug [135].
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1.4.3. Substituted linear polysaccharides.
1.4.3.1. Pectin.
Pectin is a general term, derived from the Greek "Pectos" which means dense, 
thickened or coagulated, for a group of polysaccharide substances found in the cell 
walls of all plant tissues. It is found in combination with cellulosic material and 
functions as an intercellular cementing material. The main commercial source of 
pectin today is the peel of citrus fruits but it is also extracted from apple pommace, 
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Figure 12. Chemical structure of the pectin molecules.
The structure of pectin is complex and varies with the biological source as well as the 
conditions used for extraction. Pectin is a heterogeneous polysaccharide composed 
of galacturonic acid and its methyl ester [137]. The degree of methoxylation 
determines many of the properties of the pectin as a high degree of methoxylation 
makes a poorly soluble polymer and a low degree of methoxylation increases the 
solubility and can be cross-linked using calcium cations Side chains made up of 
neutral residues such as galactans, arabinans and xylans are attached through 
equatorial bonds and the secondary hydroxyl group of the main chain. These side 
chains are usually present in blocks and provide breaks in the regular structure of the 
homogalacturonic backbone. The regular structure is also interrupted with (3-L- 
rhamnose units which are linked by the 1 and 2 position carbons, this gives the chain 
a "kink". In the solid state or in solution the pectic chains display a three-fold helical 
configuration figure 12 [138].
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Pectin solutions exhibit low viscosities but they are commercially important because 
of their ability to form gels. High-methoxy pectins form gels by association of 
homogalacturonic acid sections of the molecules in junctions. Electrostatic 
repulsions have to be reduced and this is achieved by acidification of the system, 
(Figure 13). The junction zones are limited by the presence of the "kinks" due to the 
presence of 0-L rhamnose sugar units, linked through the Cl and C2 positions and by 




Figure 13. Acid induced hydrogen bonding in high-methoxy pectin gels.
De-esterified pectins also form gels with calcium ions or other divalent metal ions and 
these gels are less dependant on the presence of sugar or the pH Low-methoxyl 
pectins, pectinic acid and pectic acid produce gels in a similar way to alginate gels. 
There are non-esterified homogalacturonic acid sections which show the buckled 
ribbon structure and so form the "egg box " type gel in the presence of calcium ions 
(Figure 14). The junction zones are again limited by the "kinks" in the structure and 
the presence of side chains making the length of the demethylated section important. 
As the pectin is more demethylated so the gel is more rigid [140],
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Figure 14. Egg-box structure of low methoxy pectin gels cross linked with calcium 
ions.
In the gastro-intestinal tract pectin is resistant to the gastric and intestinal enzymes 
but it is almost completely degraded by the enzymes produced by the colonic bacteria 
[141]. Rubinstein et al. demonstrated that the release rate of indomethacin was 
increased by pectinolytic enzymes [142], Ashford et al. concluded that the 
effectiveness of pectin as an agent for delivery to the colon is dependant on several 
factors including the type of methylation as the higher the degree of methylation the 
lower the solubility and the better the protective action. The presence of calcium and 
the solubility of the calcium salt of pectin are also important factors [143], In other 
studies a tablet core of normal excipients compression coated with USP grade pectin 
was shown capable of mouth to colon transit in simulated gastric conditions, allowing 
protection of the drug until release in the colon [144],
1.4.3.2. Xanthan.
Xanthan gum is produced as an exocellular polysaccharide by the Gram negative 
microorganism Xanthomonas campestris. It is produced industrially, by a 
fermentation process culturing the micro-organism with glucose as the substrate, a 
nitrogen source and other essential elements, under aerobic conditions. After 
fermentation is complete the broth is heated to kill the bacteria and then the xanthan 
is recovered usually by alcoholic precipitation [145],
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Xanthan is an anionic heteropolysaccharide consisting of a backbone of /3-D-glucose 
linked through the (l-*4) positions in an identical manner to cellulose. A tri­
saccharide side chain is linked to every second glucose residue. The side chain 
consists of two main units separated by a glucuronic acid residue. The mannose 
residue attached to the cellulosic backbone is variably acetylated at the C6 position, 
and the terminal mannose may contain a pyruvate group and this is joined to the 4-, 
6- position carbons by a ketal link. The macromolecule of xanthan is a repeating and 







Figure 15. Structure of the xanthan gum molecules with celluloisic backbone and the 
trisaccharide side chain.
The distribution of the tri-saccaride side chains is perfectly regular for each two 
glucose units of the backbone, however the proportion of acetyl and pyruvate 
substituents is irregular and is determined by the strain of the culture and post­
fermentation conditions. The glucuronic acid unit and the pyruvate group impart an 
anionic character and commercially this is neutralised by cations such as Na+, K+ and 
Ca2+ [146] [147],
Studies have suggested that the molecular weight for xanthan is approximately two 
million which is roughly two thousand repeating units per molecule. Values for 
molecular weight as high as fifty million have been reported, however this is probably
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due to intermolecular association between polymer chains [148]. In the solid state, 
xanthan gum has a molecular conformation o f a right handed five fold helix. It was 
widely believed that the side chain was folded back onto the backbone and stabilised 
the structure with non covalent interactions [149]. This aspect will be discussed in 
further detail below.
The ionic nature and the presence of the side chains means that xanthan hydrates 
easily and dissolves in hot or cold water. In solution, xanthan gum does not produce 
a true gel at any concentration; however it undergoes a temperature-induced 
conformational transition from an ordered helical structure, to a disordered structure. 
This transition is not to be confused with thermal gelation. The transition 
temperature is dependant on the pH, ionic strength and nature of electrolyte but in 
deionised water it usually occurs around 60-70°C, and at higher temperatures in the 
presence of electrolytes [150]. The ordered conformation of xanthan is still 
controversial despite many investigations since the transition was first identified as an 
anomalous increase in viscosity by Jeanes et al. [151].
Norton et al proposed a single-stranded ordered structure at low temperature and 
high ionic strength with the molecules forming a helix with the side chains packed 
along the backbone. They suggested the ordered and disordered states coexist in the 
same molecule [152]. Milas and Rinaudo also supported a single stranded structure. 
They too suggested the existence of xanthan in two different ordered states, a native 
ordered conformation and a denatured ordered structure which occurs when native 
material has been heated and cooled. They argued that the side chains are associated 
with the cellulosic backbone but after heating and cooling the same pattern of 
backbone-chain interaction is not re-established and this altered the properties [153],
Liu et al. proposed a double stranded helical model for the ordered species. On 
heating the helix unwinds from both ends but not completely. This forms an
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expanded dimer in which the "worm like" chains are connected by short helical 
sections [154][155], Other workers recently claimed that the chains could be made 
to completely unwind and separate after prolonged heating at high temperature (95°C 
for 9 hours) [156], Nuclear magnetic resonance studies support this expanded dimer 
theory and also provide evidence of the side chain involvement in the transition 
[157], Many now favour the expanded dimer concept at this time.
The unusual structure of xanthan produces some interesting properties. At 
concentrations above 0.3%w/v it forms free flowing solutions with gel like 
characteristics which made it appropriate for stabilising suspensions and emulsions. 
In visco-elastic studies using small deformation oscillatory measurements, the elastic 
response (G) far exceeded the viscous flow component (G") [158]. At higher 
deformations the structure breaks down and the solution begins to flow [159].
The weak gel-like properties of xanthan are thought to be due to association between 
the chains of the ordered xanthan which form complex aggregates, in dilute solution, 
through hydrogen bonds and polymer entanglement. The solutions are highly 
pseudoplastic and exhibit decreasing viscosity with increases in applied shear stress. 
Molecules become disrupted and aligned with the direction of the shear stress 
producing a decrease in viscosity. However, this non-Newtonian behaviour is time 
dependant thus, when the shear is removed the polymers reaggregate and the 
viscosity increases again over time. The presence of ions such as Ca2+, K+ and Na+ 
can destroy or reduce the gel-like properties of the solution [160]. The presence of 
sodium ions has been shown to produce the disordered conformation in the xanthan 
[161].
Many methods have been used to examine the structure of xanthan. Recently atomic 
force microscopy has been used to examine the molecules. Molecular bundles of 
aligned xanthan molecules have been identified however the resolution o f the
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apparatus is not sufficient to identify the role of side chains and the branching of 
polymers [162], ESR has also been used to examine the order- disorder transition of 
xanthan gum by attaching the spin label to the carboxyl groups on the xanthan side 
chain. The side chain associates with the backbone of the molecule to a greater 
extent at high ionic strength and decreased with increasing temperature as the 
association is disrupted during the conformational change [163],
Xanthan gum has been widely used as a thickening agent in the food industry and as a 
thickening agent and suspending agent in pharmaceutical formulations [164], More 
recently it has been utilised as a sustained release excipient, for the formulation of  
swellable matrix tablets, either alone or in combination with another polysaccharide 
[165] [166] [167] [168] [169]. It has been shown that xanthan not only retards in 
vitro drug release but also works efficiently in vivo to produce constant blood plasma 
levels of drug [170].
Xanthan has been shown to retard release at levels as low as 5% of the total 
formulation which allows a high dose of drug without a large increase in the weight 
of the dosage form. This efficiency can be explained by xanthan's high affinity for 
water and the rapid and high extent of swelling of the polymer when hydrated. It has 
been proposed that because of the extensive swelling, initially well-separated particles 
of gum come into contact and as a result of this contact and the rheological 
properties of the hydrated polymer, the swollen particles coalesce. This results in a 
continuous viscoelastic matrix which fills the interstices and behaves as a barrier 
retarding the further penetration of the surrounding fluid and retards the drug 
diffusing out through the hydrated layer. The high elastic modulus of the polymer 
helps to maintain the diffusion path by providing resistance to erosion which would 
otherwise wash away such a purely viscous material quickly [170], Other studies 
suggest that the swelling of xanthan gum matrices show a reciprocal relationship with 
salt concentration and this in turn can influence the rate of drug release. Depending
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on the solubility of the drug the release is controlled by the swelling of the xanthan. 
Talukdar et al. found the release of insoluble drugs followed a direct relationship with 
the swelling of the matrix because the release mechanism is erosion while a reciprocal 
relationship is observed with soluble drugs which are released by diffusion. They also 
discovered the swelling followed a square root of time dependence whilst the drug 
release was time independent or zero order for all the drugs used[171],
1.4.S.S.______ The galactomannans.
The galactomannans are a class of polysaccharides usually found in the plant cell 
walls or endosperm's of mature seeds of non-leguminous plants. More water soluble 
or heavily hydrated galactomannans are found in the endosperms of seeds of 
leguminous plants. One type of galactomannan, locust bean gum (LBG), is extracted 
from the endosperm of the seed of the Ceratonia siliqua or Carob tree which is a 
large leguminous evergreen found on the shores of the Mediterranean. The fruit of 
the carob tree is a pod 10-20 cm long and 2-4 cm wide. Each pod contains ovoid 
seeds and the energy reserve contained in the endosperm is locust bean gum. The 
recorded use of locust bean gum dates back to Ancient Egyptian times when the 
thickening properties of the polysaccharides, were used as an adhesive paste in the 
binding of the wrappings of mummies [172]. Another galactomannan, guar gum is 
extracted from the endosperm of the seeds of the Cyamopsis tetragonolobus, an 
annual plant which also produces pods and is grown mainly in Pakistan and India. 
Tara gum from the plant Caesalpinia spinosa is a much less commonly used 
galactomannan gum [173]. Locust bean gum and its soluble hydroxyethyl and 
carboxymethyl derivatives have been used extensively in several different industries. 
It is used in the food industry to stabilise ice cream and enhance the texture and in the 











Figure 16. The chemical structure of the galactomannans with the mannose backbone 
and the galactose side chain.
Galactomannans contain two sugars units of similar nature, /?-D-mannose and a-D- 
galactose. The main chain or backbone consists of (l-*4)-linked /3-D-mannose 
residues and thus galactomannans are considered a homopolysaccharide. Attached to 
this are the side chains of (l-»6) linked a-D-galactose units. The ratio of these 
galactose units to mannose units differs for each of the galactomannans (Figure 16)
[175].
The approximate ratios of galactose to mannose differ according to biological source, 
being 1 to 3.5 for locust bean gum; 1 to 3 for tara gum and 1 to 2 for guar gum
[176]. Investigations carried out into the structure of locust bean gum shows that the 
galactose substituents are not distributed uniformly along the mannose backbone but 
are grouped together in blocks o f -25 units[177] [178], The polymers therefore 
exhibit an alternating sequence of "smooth” regions which are unsubstituted and 
"hairy" regions which have galactose residues substituted along this portion of the 
mannan backbone. It is thought that tara gum exhibits a similar block structure as its 
behaviour is similar to locust bean gum [176]. Studies have shown however that 
guaran, the predominant polysaccharide in guar gum, does not exhibit this block 
structure but a regular alternating structure with the molecule displaying a "smooth
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side" and a "hairy side" [178] although there is still evidence to suggest that a mixture 
o f structures exists [176].
Dea et al. [176] used a freeze-thaw cycle to induce interchain association of the 
galactomannan polymer. As ice formed, the effective polymer concentration of the 
residual unfrozen solution is raised and this promotes association of the polymers. 
These junctions normally dissociate on thawing. However, if the barrier to 
association is only kinetic rather than thermodynamic, the junctions may remain 
intact. Using this method guar gum showed no evidence of associations, whereas 
tara gum formed weak gels at a concentration greater than 0.75%. Locust bean 
forms weak cohesive gel networks at concentrations of 0.5%. The locust bean gum 
gels did not show a true melting point but did lose their structure over a small 
temperature range. They also formed gels by inducing intermolecular association by 
lowering the water activity by adding 50% aqueous ethylene glycol or 50% glycerol 
or 60%w/v sucrose. On the basis of this work, they proposed a model for the 
structure of the galactomannan gel. This involved the association of the 
unsubstituted regions of the mannan backbone to form interchain junctions whilst the 
substituted regions are extensively hydrated. As the guaran does not have "hairy" 
regions to terminate the junctions, the polymers do not hydrate and gel, but instead 
precipitate [179].
The degree and arrangement of the substitution on the backbone has a profound 
influence on the physical properties of the gums. Guar gum is readily soluble in cold 
water because the high degree of substitution of the backbone prevents the chains 
from self associating allowing the water easy access. Locust bean gum does not 
disperse in water at room temperature as the smooth, unsubstituted sequences on its 
backbone allows self association and makes water penetration and dissolution 
difficult. This structure can be disrupted by raising the temperature and an increase 
in the viscosity can be seen from a temperature o f approximately 45 °C but full
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hydration does not occur until a temperature of approximately 85°C is reduced. 
Locust bean gum dispersions, like xanthan, do not form gels even at raised 
temperatures [180]. Dispersions of locust bean gum show pseudoplastic rheology 
profiles and since locust bean gum is a neutral polysaccharide, pH has little effect on 
the viscosity in the pH range 3 - 11 [181]. Increasing the ionic strength (NaCl) of a 
1% w/v locust bean gum dispersion made in cold water, decreases the measured 
viscosity [182],
In the pharmaceutical industry locust bean has been used as a stabilising agent for 
creams and lotions and investigated as a binding and granulating agent for tabletting 
[ 183], Increasingly the gels formed by locust bean gum when combined with another 
polysaccharide such as xanthan[184], carrageenan[ 185] [186] and agar[187] [188] 
are being examined and developed for pharmaceutical uses. The interaction of locust 
bean gum with xanthan is covered in more detail in a later section 1.5.
1.4.4. Non polysaccharide hydrogel polymers.
1.4.4.1. Carbomer.
Carbomer is a polymer of acrylic acid and has been used as a rheological modifier 
[189][190], a tablet binder [191] and a bio-adhesive [192], The polymers tend to be 
linear as there is only one double bond in a side group and are produced by 
polymerising the acrylic acid in an inert solvent (Figure 17).






Figure 17. Acrylic acid polymer structure.
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Carbomer disperses in water and hydrates readily to give low viscosity solutions. If 
an alkali is added to neutralise the pH, it causes the carboxyl groups to ionise and so 
repel one another, this in turn causes the molecular volume to increase and this 
expansion leads to an increase in the viscosity [193], The resulting hydrogels are 
networks of cross-linked acrylic acid held apart in a web-like construction by 
electrostatic repulsion in a continuous aqueous phase. This structure imparts the 
Theological characteristics. Addition of electrolyte can screen the ionic groups from 
each other and neutralise the repulsion which causes the gel to collapse [194],
Carbomer has been used to produce controlled release tablets as their hydrophilic 
nature and ability to swell rapidly can form the swollen barrier layer that controls 
release by diffusion and swelling. It has been used extensively in recent years but 
much of the work is related to patents and little data is available on the effect of 
technological variables. Controlling factors which have been identified are the cross- 
linking and swelling properties of the individual carbomers. It has also been shown 
that acidic , neutral and basic drugs can all diffuse through the gel structure but 
hydrophilic drugs will diffuse more quickly and efficiently as the hydrophobic drugs 
will be attracted to the methylenic groups of the polymer backbone.
1.4.5. Polymer combinations.
Many combinations of polysaccharides have been studied for use as sustained release 
excipients however the literature is mainly confined to patent publications.
1.4.5.1. Hvdroxvpropvlmethvl cellulose (HPMC) and sodium carboxvmethvl
cellulose (NaCMC).
Combinations of NaCMC and HPMC have been investigated thoroughly as 
controlled release excipients. The initial burst of release which is a common feature 
of release from hydrophilic matrices is reduced by optimising the polymer ratios and
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the dissolution release profile can be altered from a root-time relationship to a zero 
order profile [195],
Dilute solutions of anionic sodium CMC and non-ionic HPMC polymers show 
viscosities higher than those expected from individual contributions and it has been 
proposed that this synergy is due to hydrogen bonds forming cross-links between 
component polymer chains [196]. More recent work has disputed this theory and 
proposed that the synergy is entirely due to coil expansion of the polyelectrolyte in 
the mixed environment [197].
Another interesting phenomenon is that freely soluble cationic drugs apparently show 
a slower release rate than the combination of two polymers, which is attributed to the 
drug interacting with the matrix. Less soluble drugs are released principally by 
erosion [198].
1.4.5.2. Hydroxvpropvl cellulose (HPC) and carbomer (acrylic acid).
Carbomer, in combination with HPC, forms an insoluble complex when mixed in 
dilute solutions. Interpolymer interactions have profoundly adverse effects on the 
hydration and performance of a hydrophilic device. Tablets made of a pre-prepared 
complex disintegrate rapidly whereas those prepared from a physical mixture behave 
as a normal hydrophilic device showing that the interaction between the polymer 
chains significantly alters the hydration behaviour o f the system. This interaction of 
the polymer chains has implications for the release rate of drug from the matrix [199].
1.5. Xanthan and Locust Bean Gum Combinations.
The behaviour of these two polysaccharides has been reviewed individually above. 
When xanthan macromolecules are mixed with the galactomannan, locust bean gum, 
there is a marked change in the properties of the combined polysaccharides. The
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most obvious of which is a dramatic and synergistic increase in the viscosity of the 
solution at low concentration and formation of a thermoreversible and highly 
cohesive gel [200].
1. 5.1. Gelation o f xanthan / locust bean gum.
Most researchers agree that the synergistic increase in viscosity of mixed xanthan / 
locust bean systems is due to intermolecular associations. The gel strength of a 
combination of locust bean gum with xanthan is much greater than the gel formed by 
combining xanthan with tara gum which in turn is greater than the strength o f gels 
formed with xanthan and guar. The increasing gel strength in this progression almost 
certainly occurs as a result of decreasing galactose substitution of the galactomannan 
[201]. McCleary et al. showed that the D-galactose content and distribution in the 
galactomannan played and important part in binding process. He discovered that the 
interaction of xanthan with guar gum could be substantially increased by decreasing 
the D-galactose content. This also supported the theory that the interaction took 
place between the xanthan and the unsubstituted regions of the galactomannan 
molecules [202].
The exact mechanism o f the association between the xanthan and galactomannan 
macromolecules has been the subject of considerable debate, research and 
speculation, with several theories proposed. One of the first models was proposed by 
Dea et al. who suggested an association between the ordered helix of xanthan 
molecules with unsubstituted regions of galactomannans [203][204]. They proposed 
that the regions poorly substituted with D-galactose interacted with the cellulosic 
backbone of the helical conformation of the ordered xanthan and by decreasing the 
D-galactose content the gel forming ability increases (Figure 18). Moorhouse et al. 
proposed that the helical structure of xanthan presented two sides to the helix, one 
with the side chains and charged groups and the other essentially backbone and the 
interaction occurred between the similar backbones of the two polymers [205].
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Galactomannan with galactose free section
-D -galactose units
Xanthan in the ordered helical form
Figure 18. Dea et al proposal for interaction between xanthan and locust bean gum 
molecules
This was later modified by McCleary [206] who proposed that the interaction could 
also occur between xanthan and parts of the galactomannan backbone which were 
substituted on only one side (Figure 19).
v  Galactomannan with galactose free section 
G - J  D-galactose units
Xanthan in the ordered helical form
Figure 19. McCleary modification of Dea et al theory of xanthan locust bean gum 
gel structure with galactose substitution on one side of the molecule.
The second model was evolved from X-ray diffraction studies of solutions, where the 
helical conformation and the disordered conformation were present. The results 
showed that the two polysaccharides only formed a gel when the solution was heated 
above the order / disorder transition temperature of xanthan and then cooled. The X- 
ray diffraction patterns of the combination xanthan and locust bean gum were more 
intense than either of the components in isolation.
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X an than  m ole  cule
X a n th a n  m o le c u le
A.
X a n th a n  m o le c u le
X a n th a n  m o le c u le
B.
Figure 20. Arrangement of xanthan / locust bean gum molecules proposed by Cairns 
et al. in the gel structure.
From this it was confirmed that an interaction occurred between the backbone of the 
two molecules and claimed the junctions formed between the D-galactose free 
sections of the galactomannan and the disordered xanthan molecule. They also 
suggested that when the conditions were suitable the remaining xanthan re-adopted 
the ordered helical conformation [207][208][209],
They also proposed that the xanthan forms side chains on either side, sandwiching 
galactose free sections of galactomannan molecules and to achieve this the xanthan 
side chains must be staggered and disordered. The junctions may consist of several 
galactomannan molecules sandwiched between the xanthan backbones (Figure 20A). 
Partially substituted galactomannan chains with one unsubstituted face are also 
accommodated by this theory as in figure 20B, however fully substituted 
galactomannan chains cannot be accommodated.
Cheetham and Mashimba carried out an extensive series of experiments and they also 
reached the conclusion that these sandwich type junctions are formed They also
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suggested that the ordered and disordered structures exist together in sequences 
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Figure 21 Cheetham and Mashimba proposal for structures which are possible in the 
xanthan / locust bean gum polysaccharide combination.
These disordered regions are capable of forming junctions at room temperature, 
without heating to the conformational transition temperature in the presence of 
potassium chloride and form junction zones between the backbones to form cross- 
linked structures or gel islands (Figure 21 )[210] On heating the gel islands, the 
ordered conformation is largely destroyed and the junction zones rearrange and a 
firm gel results
Tako et al proposed a lock and key mechanism for interaction between the side 
chains of the ordered xanthan and the backbone of the galactomannan They
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proposed that one molecule can react with two locust bean gum molecules. They 
suggested that hydrogen bonding occurred between the hemi-acetal oxygen atom of 
the inner D-mannose side chain and the hydroxyl group at C-2 The univalent cation 
associated with the carboxyl group on the xanthan side chains are inserted into the 
adjacent unsubstituted segments of the mannan backbone which is extended into a 
two-fold ribbon like structure (Figure 22) [211 ][212]
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Figure 22 Theory of structure of gel from Tako et al
In another experiment they discovered that deacylation of the xanthan produced 
much stronger gels [213] They concluded that incomplete interaction occurs due to 
side chain intramolecular association between side chain acetyl residues and the 
xanthan backbone. The reason for this is not well understood although there are 
three possibilities, steric hindrance, suppression of intermolecular hydrogen bonding 
or by altering the conformation of the xanthan as the acetyl is thought to stabilise the
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ordered helix which does not favour gel formation. Other workers have also shown 
that deacylation enhances xanthan reactivity. Shatwell et al. found that if the xanthan 
lacked the terminal mannose on the side chain, very weak gels result which supports 
the argument for side chain involvement [214]. Alternatively the loss of the terminal 
mannose may prevent helix formation and so the Dea et al. [176] theory where the 
ordered conformation is required for gel formation. The Tako et al., lock and key 
theory is the least favoured theory for xanthan locust bean gel formation.
More recently, Mannion suggested that two distinct interaction mechanisms for 
xanthan and locust bean gum exist. The first was considered to take place at room 
temperature, yielding weak elastic mixed gels which are almost independent of 
galactomannan mannose to galactose ratio. The second mechanism required heating 
of the mixture beyond the xanthan transition temperature and is highly dependant on 
the mannose galactose ratio [215],
1.6. Dissolution Considerations.
1.6.1. Factors affecting drug dissolution rate in vitro.
1.6.1.1 ._____ Physicochemical properties o f  the drug.
The influence of the physicochemical characteristics of the drug on the dissolution 
rate has been comprehensively reviewed. Solubility of the drug under sink 
conditions, plays an important role in controlling drug dissolution rate from dosage 
forms [216][217].
Drug dissolution rate can be directly related to the surface area of drug exposed to 
the surrounding dissolution media [218]. Reducing particle size, increases the 
surface area of drug particles and this increases the dissolution rate. The reduction of 
drug particle size by milling however can throw up the problem of cohesion, large 
aggregates may be formed defeating the aim of milling.
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The dissolution rate of the salt of a drug is greater than the dissolution rate of the 
parent drug. Forming the salt of a drug can be a valid method of increasing the 
bioavailability where the rate limiting step for absorption by the stomach is the 
dissolution of the drug [219]. This can have implications for drug stability and the 
cost of processing.
The hydration state of the drug compound is also important as the aqueous solubility 
of anhydrous forms is greater and show a faster dissolution rate. This dictates that 
the anhydrous forms have a greater bioavailability and are therefore more active than 
their hydrated forms [220].
Polymorphism is the ability of a compound to exist in more than one distinct 
crystalline arrangement with different molecular organisation of the crystal lattice. 
This molecular arrangement affects the physical properties of the compound 
including solubility, melting point, density, hardness, crystal shape, optical and 
electrical properties. Each form can behave as distinctly different chemical entities 
and polymorphic differences can also affect the dissolution characteristics [221][222].
1.6.1.2. Formulation factors.
Inert excipients are incorporated into tablets which are designed to give appropriate 
and specific pharmaceutical performance characteristics, including dissolution 
properties. Binders and granulating agents such as polyvinylpyollidone, are usually 
polymeric materials added as either dry powders, in solution or in suspension during 
wet granulation . These can affect the dissolution as drug particles become coated 
and influence the release depending on the properties of the binder [223]. 
Disintegrants such as starch, draw fluid into the tablet and burst it open by swelling. 
This break-up is critical to the rapid dissolution as it exposes a large surface area of 
the drug to the dissolution media and can increase the dissolution rate between 5%
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and 20% [224]. The effect of lubricants such as magnesium stearate or talc, on the 
dissolution characteristics has been extensively investigated and is related to the 
properties of the material. The most commonly used lubricants are hydrophobic and 
a water repellent film forms around the tablet and the granules which can slow the 
ingress of water and delay drug dissolution. Water soluble lubricants such as sodium 
lauryl sulphate, can be used to increase the dissolution rate as they improve the 
wetting characteristics and increase the fluid penetration rate [225],
1.6.1.2.1. Diluents and bulking agents.
Diluents, fillers and bulking agents such as lactose, are used to give a formulation a 
higher volume of powder mix when the drug and other components do not produce a 
high enough bulk material for managing during processing. They are inert non toxic 
substances, cheap to purchase and readily available. In controlled release dosage 
forms, the bulking agent is usually an essential component in the modification o f the 
release rate. Many of these have been mentioned in previous sections but include 
natural products such as fats, waxes and polysaccharides and the chemically modified 
natural products such as the cellulose ethers. Synthetic materials include the ion 
exchange resins and polymers such as polyvinyl chloride used for inert matrices. 
Generally formulation factors are critical in achieving any desired drug dissolution 
profile and several competing effects have to be balanced to achieve the desired result 
[226].
1.6.2. Chronopharmacology.
In human beings, biological rhythms are regular variations in bodily processes or 
functions, in which the intervals between repetitions are relatively exact. The 
variations in a process can result in a drug being absorbed, distributed and eliminated 
at different rates and to different extents, depending on the administration time. 
Chronopharmacology is the study of these biological rhythms and their interaction 
with drug therapies [227].
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At present, treatment of a disease involves trying to achieve a steady blood level 
within a therapeutic window using administration schedules and dosage forms 
designed for this purpose. There is an assumption that the patients' need for 
medication is constant throughout a twenty four hour period and that the effect that 
the drug is having at the site of action is constant. By understanding the predictable 
and periodic changes in the response and tolerance of the body to a drug, the 
optimum therapeutic effect can be achieved with a reduced risk of side effects [228],
In therapy terms, zero order has previously been the goal of the formulato. However 
more recently a bimodal pattern of release from dosage forms has become the aim. 
In the chronopharmacological context, it can be desirable to produce two peaks of 
release to coincide with times when the patients sensitivity to a drug may be reduced 
and a higher blood plasma concentrations would be beneficial to avoid symptom 
breakthrough. This pattern of release can also compensate for variations in the rate 
and extent of absorption of the drug from different regions of the gastro-intestinal 
tract and so produce constant drug level in the blood where a zero order formulation 
would fail. A series of cellulose ethers used in a swelling hydrophilic matrix system, 
achieved bimodal release and by varying the polymer viscosity and the drug/polymer 
ratio it is possible to manipulate the release profile to accommodate the requirements 
of a particular drug or condition [229], Asthma is a good example of a condition 
which would benefit from this type o f treatment, as nocturnal bronchoconstriction is 
triggered by circadian patterns in the body. Martin found corticosteroids for patients 
with nocturnal asthma should be administered in two daily doses, one in the morning 
and a second at three in the afternoon for more effective control [230].
1.6.3. In vivo drug release.
Variations in the behaviour of dosage forms can often be traced back to their 
environmental conditions. When designing a dosage form a good understanding of 
the anatomy, physiology of longitudinal and lateral gastro-intestinal tract variations
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require consideration along with other factors which affect quantitative absorption 
and rate of absorption.
/. 6.3.1.______ The stomach and gastric emptying.
The stomach is a pouch like structure and has four regions : cardiac; fundus; body
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Figure 23. Schematic diagram of the gastro-intestinal tract (From [231 ]).
Both the fundus and body store food and begin the acid digestion process while the 
antrum is the grinding tool of the stomach. Acid is produced by the parietal and the 
oxyntic cells which are in the fundus and the body while the lubricant mucin is 
produced by the goblet cells. Stomach mucosa is devoid of villi having a relatively 
smooth epithelial surface containing only gastric pits which increase the surface area
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to a limited extent but because of the relatively small surface area it is not considered 
a primary absorptive site [232],
The rate of gastric emptying is regulated by a feedback mechanism located in the 
duodenum and the terminal ileum which can slow down gastric emptying and transit 
of food down the intestine [233] [234]. The primary factor in determining the rate of 
gastric emptying is the calorific content of an ingested meal [235], The greater the 
energy density in the gastric contents, the slower the volume rate of transfer to the 
duodenum [236], Emotional state, exercise and co-administered drugs can all 
influence the rate of gastric emptying as control of the stomach is under neural and 
hormonal control [237] [238], Emptying rate can be accelerated by an increase in 
gastric motility due to stress and aggression [239], A frequently seen symptom of 
depression is constipation due to delayed emptying [240], while vigorous exercise 
reduces the rate of gastric emptying [241], One controversial point is the effect of 
posture, with different research groups publishing contradictory results on this 
subject [242] [243].
One of the major problems in oral drug delivery and especially controlled drug 
delivery is the uncertainty of the location of the dosage form within its environment 
at any given moment in time. It is well known that there are two different patterns of 
gastro-intestinal motility behaviour when the stomach is in a fed state or a fasted 
state.
In the fasted state the pattern is commonly known as the migrating motor complex 
(MMC) and is organised into alternating sequences of activity and quiescence. The 
periodic behaviour of the MMC cycle is under neural and hormonal control and the 
pattern is similar both day and night. This cycle can be interrupted by the presence of 
food or the presence of nutrient in the small intestine and the duration of this 
disruption depends on the composition of the meal, it being longer for solid meals
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rather than liquid intake. In the fed state there is continuous motor activity with no 
quiescent state [244][245],
1.6.3.2. The small and large intestine and intestinal transit.
The area for maximal absorption for most solutes is the small intestine because of the 
relatively large surface area due to the presence of villi, microvilli and submucosal 
folds which increase the surface area by more than thirty times over that which would 
be present if the small intestine were simply a smooth tube [246], The small intestine 
is also the most important region within the intestinal mucosa for active and 
facilitated transport mechanisms for some drugs. Even weak acids which are largely 
non-ionised at gastric pH are more rapidly absorbed from the from the small intestine 
because of the large surface for absorption.
The fed and fasted state motility patterns which influence gastric emptying can also 
influence the nature of chyme and the transit of dosage forms along the small 
intestine. In the fasted state the movement of solids down the tract is governed 
primarily by activity in phase three of the housekeeper wave. The intestinal transit of 
dosage forms is variable as the dosage form may be missed by the propulsive wave or 
possibly the wave dies before it reaches the position of the dosage form [247] causing 
slow movement down the tract but this may also be due to the quiescent phase and 
its associated lack of motility. The type of dosage form being examined should also 
be taken into account as multiparticulate dosage forms behave in a very different way 
in the fed and fasted states [248].
In numerous studies performed in humans the mean small intestinal transit time 
regardless of particle size has been 3-4 hours in both the fed and fasted state [249]. 
This predictability has been used in drug targeting however this is a mean value and 
variation between patients means that problems occur with the reproducibility of
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dosage form performance. In total, transit times of nutrients and dosage forms 
through the stomach to the ileocarcal junction is 4-8 hours in the fasted state and 8 - 
12 hours in the fed state. The difference is primarily due to the rate of gastric 
emptying and factors influencing this, not the rate of intestinal transit [250],
The large intestine is a storage organ for undigested food solids and like the stomach 
has a considerably less irregular mucosa than the small intestine which reduces its 
absorptive capacity. This area serves as a reserve area for the absorption of drugs 
that have escaped absorption proximally because of their physiochemical properties 
or the design of their dosage form, for example controlled release products aimed at 
the colon [251], In general it is likely in most solid dose formulations that incomplete 
absorption will occur if a large fraction of the dose reaches the large intestine.
There are a number of disease states which can affect gastro-intestinal transit by 
delaying gastric emptying including gastric ulcers, gastric carcinoma and 
gastroesophageal reflux [252], Disease states of the colon also have a significant 
effect on the transit of material through the small intestine. Transit of a meal has 
been measured as being twice as fast in patients with functional diarrhoea which is a 
very common complaint [253], The two most common diseases of the gastro­
intestinal tract are Celiac disease and Crohn's disease [254], Celiac disease has 
several consequences such as increasing the gastric emptying rate, increased gut wall 
permeability, enzymatic deficiencies and altered intestinal drug metabolism. For 
Crohn's disease there is a reduced surface area for absorption, a thickening of the 
bowel wall, the bowel flora changes and there is a slower rate of intestinal transit. All 
these factors may influence the absorption and so the activity of many drugs.
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1.6.3.3._______ Other factors affecting drug absorption from the gastro-intestinal
tract.
Many factors can influence the rate and the extent of drug absorption when a dosage 
form is swallowed. The pH of the stomach at the beginning of digestion is 4-6 due to 
the buffering capacity of the food however this is quickly reduced to 1-2 [255], by 
the secretion of gastric acid. In the small intestine the acidic chyme is rapidly 
buffered by bicarbonate secretion and the pH is raised to around 7.75 [256]. The pH 
of the liquid environment influences the concentration of drug available for 
absorption as well as the rate of release from the dosage form. The boundary layer of 
unstirred fluid next to the mucous membrane and has to be traversed for the solute to 
reach the villi surface [257] and the thickness of the layer depends on factors which 
include the viscosity of the luminal contents, the length and radius of the segment of 
gut and the diffusion and permeability coefficient of the solute.
Mucus is a thick gel-like substance which is secreted throughout the gastro-intestinal 
tract by goblet cells [258]. Its primary function is to protect the surface mucosal cells 
by its lubricant action in during the passage of solids [259], but it also maintains 
tissue hydration [260], acts as a buffer zone between stomach acid and mucosal 
tissue [261] and a barrier to damaging luminal contents including enzymes, antigens, 
bacteria and viruses [262]. Mucus can also behave as a diffusion barrier as part of 
the boundary layer and can complex some drugs, slowing the rate of absorption 
[263]. Other factors influencing the rate of drug absorption include the permeability 
of the mucosal membrane [264], the bacterial contents [265] and the immunology of 
the gut [266] [267]. In vitro dissolution studies act only as a guide in assessing 
external influences on the behaviour of any formulation or drug delivery system. It is 
essentially a design tool which has to be extended by in vivo studies to ensure that in 
terms of the patient the design parameters are being achieved.
65
M a t e r ia l s  & M e t h o d s
66
2. Materials and Methods
2.1. Materials.
2.1.1. Polysaccharides and polymers.
The biosynthetic polysaccharide, xanthan gum (TIMERx Technologies, New York, 
U.S.A., Lot P4985) and a galactomannan, locust bean gum (TIMERx Technologies, 
New York, U.S.A., Lot B7924), were supplied as powders and used to form 
granules for subsequent direct compression blends. Other polysaccharides included a 
second galactomannan, tara gum (Luxara 4685®, Arthur Branwell & Co. Ltd, 
Essex, U.K., Lot 478457B ), /c-carrageenan (Satiagel ®> Sanofi Bio-Industries, 
Berkshire, U.K., Lot A368457C1), agarose (Aldrich Chemical Co. Ltd., U.K., Lot 
3034219) and citrus fruit pectin (Sigma, U.K., Lot 79F0189). Cellulosic 
polysaccharides included sodium carboxymethylcellulose (TIMERx Technologies, 
New York, U.S.A., Lot 85342), hydroxypropylmethylcellulose of three different 
viscosity grades : (a) 2% sol = 0.05Pas, (Sigma, U.K., Lot 62H0585), (b) 2% sol = 
0.1 Pas, (Sigma, U.K., Lot 87F0148), (c) 2% sol = 4Pas, (Sigma, U.K., Lot 
70H0296). A non-polysaccharide polymer, carbomer, (cross linked acrylic acid 
polymer) of various grades was also used, (Carbopol 934P®, Lot B981083; 
Carbopol 971P®, Lot AJ001D3; Carbopol 161®, Lot 3907364, BF Goodrich, 
Ohio, U.S.A.).
2.1.2. Non-polysaccharide ternary adjuvants.
Different third component materials were incorporated into polysaccharide/polymer 
formulations in order to study their release-modifying characteristics. Some third 
component materials were introduced to help elucidate release-controlling 
mechanisms in drug-loaded polysaccharide matrices. Dextrose USP (Tabfine 100®> 
Mendell, New York, U.S.A., Lot 14x), sorbitol BP (Karion®, supplied by Merck, 
U.K. Lot M639003 344) and xylitol (Xylitab®> American Xyrofin Inc, U.S.A., Lot
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2K903F11) were all used as adjuvants which help improve compressibility. Surface 
active agents such as sodium lauryl sulphate (BDH Chemicals, Poole, U.K., Lot 
0937990), polysorbate 60 (Tween 60®, ICI Speciality Chemicals, Surrey, U.K., Lot 
B278) and stearic acid, (Sigma, U.K., Lot 39F3479) were used as ternary adjuvants. 
A group of ionic compounds, sodium chloride, (B.D.H. Chemicals, Poole, U.K., Lot 
45908826), calcium sulphate, (B.D.H. Chemicals, Poole, U.K., Lot 92918620), 
potassium chloride AR, (Fisons, U.K., Lot 108551C294) and urea, (B.D.H. 
Chemicals, Poole, U.K., Lot 9833090F) were also used in some parts of the study.
2.1.3. Dissolution media.
Distilled water (pH 6.5) was used for all dissolution tests except were specified. 
Buffers when required were prepared at pH 7 with a controlled ionic strength 
according to Table 3. The buffer components were di-sodium orthophosphate 
dodecahydrate, (Fisons AR, U.K., Lots 91054064 and 91054483), citric acid, (Fisons 
AR, U.K., Lot 33564323), potassium chloride, (Fisons AR, U.K., Lot 108552B364).
2.1.4. Model drugs.
Unless otherwise indicated the model drug used to prepare tablets containing an 
active component, was the aromatic compound benzamide (Aldrich Chemical Co. 
Ltd., U.K., Lots 4307204, 623472, 0261992) shown in figure 24. Benzamide was 
selected as the model drug for several reasons. Firstly it absorbs in the ultra-violet 
region and can therefore be conveniently assayed using ultra-violet 
spectrophotimetry. Secondly, the solubility of benzamide is not significantly affected 
by changes in either solvent pH or ionic strength. Thirdly, the polarity of the 
compound does not tend to induce undesirable effects on water uptake by the gum 
matrix [268]. Lastly and critically, to determine if drug could be bound to 
polysaccharides in the hydrocolloid matrix, derivatives of benzamide were used. 
Four different para-substituted molecules were selected in order to study the
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hydrogen bond forming ability of the molecules. The four para-substituted 
benzamides were: 4-fluorobenzamide (Aldrich Chemical Co. Ltd., U.K., Lot 
31111002164), Figure 24 (II); 4-hydroxybenzamide (Aldrich Chemical Co. Ltd., 
U.K., Lot BZ 06015PY), Figure 24 (III); 4-aminobenzamide (Aldrich Chemical Co. 




Figure 24. Benzamide (I) and its para-substituted derivatives, 4-fluorobenzamide 
(II); 4-hydroxybenzamide (III); 4-aminobenzamide (IV).
2.2. Experimental Methods.
2.2.1. Production o f tablets.
2.2.1.1 .______ Direct compression.
In order to form a good quality and viable tablet having acceptable weight uniformity, 
the powder blend used must flow well and possess good compaction characteristics. 
The more spherical formulated powders of a given particle size distribution show 
reduced interactions and improved flowability, largely due to reduced particle surface 
contact with the hopper, die walls and within the powder itself. Most pharmaceutical 
materials are not spherical however and often have a very small mean particle size
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which can lead to problems with weight variation, disintegration times and friability in 
the final product. Very few crystalline substances can be compressed directly into 
tablets. The majority of medicinal substances require some modification or addition 
of excipients, in order to produce a compressed tablet. The simplest method for 
producing tablets is to compress free flowing powders directly. This process usually 
requires the use of a directly compressible diluent or exipient which confers all the 
necessary properties of good flow and compressibility on medicinal substance which 
otherwise is an un-processable dry powder.
Directly compressible excipients offer the advantage of removing the necessity to 
undergo wet granulation and drying phase from the tablet manufacturing processes. 
This leads to a reduction in energy consumption, a reduction in the processing time 
and space requirements which can yield a more economically desirable product [269], 
The first directly compressible excipient, spray dried lactose, was produced in the 
early 1960's [270] since which time, many direct compression excipients have been 
produced. Direct compression continues to be an area of intense research, with 
excipient companies trying to produce products with the advantages o f direct 
compression and desirable and beneficial biopharmaceutical characteristics.
Beneficial properties of direct compression excipients include being physiologically 
inert and chemically stable, tasteless, capable of producing the required 
dissolution/disintegration profiles, in an economically advantageous and readily 
available material. However, probably the most important requirements o f direct 
compression diluent materials include compactibility and flowability as mentioned 
previously. More information on these requirements can be found elsewhere [271], 
Direct compression excipients based on a given chemical or chemicals are often used 
in a physically or physico-chemically modified form, in order to optimise performance 
characteristics. For example, a-lactose monohydrate is milled and then sieved to
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produce a range of size fractions for different requirements [272], spray dried lactose 
consists of spherical, porous particles of consistent controlled size [273],
2.2.1.2.______ Granulation
In cases where direct compression processing cannot confer the required physical or 
biopharmaceutical characteristics of a tablet formulation, a process of wet granulation 
is often used. Pharmaceutical granulation acts as a remedial process for both flow 
and compactibility in formulations which are otherwise unusable. Wet granulation 
binds individual powder particles together into larger secondary agglomerates as a 
result of addition of liquid and use of agitation. The liquid phase aids the formation 
of bonds between primary particles by either intermolecular attraction or solid 
bridges of material. Binders are often incorporated at this stage to increase the 
strength of these bonds or to aid the formation of compacts [274], The granulate is 
then dried and the solvent used to form the aggregates is then removed, resulting in a 
dried granulate having improved properties in terms of particle size, porosity and 
mechanical strength.
In the present study, polysaccharides were wet granulated, sometimes with a ternary 
adjuvant to produce a compressible composite. These composites can then be 
blended with a drug component and compacted effectively without further 
processing. However, it is also possible to re-granulate these inert composites with 
the drug component thereby incorporating the drug into the granule.
The weighed polysaccharide/polymer component and any ternary adjuvants were 
placed into the bowl of a Kenwood Gourmet food processor and blended together 
for five minutes to blend the components. A food processor was used because it is 
known to provide an acceptable small scale model of high speed mixer granulation 
[275]. Water was added gradually until granules formed, care being taken not to
71
over-wet as the granules then become very difficult to screen and size reduce to the 
required usable grade. The volume of fluid required, varied depending on the 
chemical and physical composition of the components and examples are shown in 
Table 1. Xanthan and locust bean gum required addition of 61ml and two minutes 
mixing time, to lOOg of the premixed polysaccharides. The wet granules were 
transferred to aluminium foil covered trays and dried at 50°C overnight in an oven. 
Granules were then screened through a 1mm apeture sieve and any oversize granules 
were broken down in the food processor.
% Xanthan Gum %Locust Bean Gum % Third Component Volume of Fluid
50 50 _ 61ml
25 25 50 % dextrose 36ml
47.5 47.5 5% Tween 60 45ml
45 45 10% CaS04 52.5ml
45 45 1 0 % carbomer 33ml
45 45 10% NaCMC 55ml
Table 1. Table of formulations of excipient granules and the volume of granulation 
fluid required to produce them. Calcium sulphate (CaSC>4 ) and sodium 
carboxymethylcellulose (NaCMC).
The composite granules were weighed into a plastic bag, with the model drug and 
any components to be incorporated externally. These components were blended 
vigorously for two minutes. The formulations were then ready for compression. 
Lubricants and glidants, usually included at the final blending stage, were left out to 
prevent possible interference with any forces and interactions within the excipient.
2.2.1.2. Compaction.
Tablets were compacted using a Manesty F3 single stroke or reciprocatory power- 
driven tablet machine (Manesty F3, Manesty, U.K.), capable of producing tablets up 
to 22mm in diameter with a maximum output of 85 tablets per minute. The machine
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can apply a maximum load of 4 tonnes. The weight of the tablet is determined by the 
depth of fill, controlled by the lower regulating collar. Pressure applied by the upper 
punch forms the tablet in the die and can be adjusted using a scaled locking gear on 
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Figure 25. Diagram of Manesty F3 Single Punch Tablet Press.
Figure 26. Manesty F3 single punch tablet press.
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The dry blends of gums and model drug were then compressed into tablets using 
8 mm flat faced punches. The maximum pressure attainable on the machine, before 
overload, was found to be required to produce polysaccharide alone tablets. 
However, these pressures were modified on incorporation of ternary adjuvants which 
improved the compaction properties of the material. The number of components 
used was minimised in an attempt to reduce unknown interaction effects during 
swelling and drug release studies. For this reason, lubricants were excluded from 
these formulations.
2.2.1.4._____ Phvsico-mechanical characterisations.
A number of key physico-mechanical characteristics were determined in the present 
study, for different formulations.
2.2.1.4.1. Tablet weight.
The tablet weight was chosen to given a 1:5 drug to polysaccharide ratio and still 
give a measurable U/V reading at the wavelength of maximum absorption. The total 
tablet weight was lOOmg of which 16.67mg was drug. Each tablet was weighed on a 
four figure analytical balance (Type B120S, Sartorius, U.K.) to ensure each tablet 
was within ±  5mg of nominal weight.
2.2.1.4.2. Crushing force.
The most commonly employed quality control method for quickly determining tablet 
crushing force, is a rapid diametral crushing test (Type 2E, Schleuniger, Germany.). 
A plate is driven horizontally by an electric motor so as to apply a constant load rate 
to a tablet held against a stationary anvil. The tablet is loaded diametrally until failure 
and is a fast and reproducible test method. The test method can be prone to variable 
results for several reasons including operator variations, lack of equipment calibration 
and manufacturing variables [276] and care should be taken to minimise these effects. 
Formulations were compressed to provide tablets with a mean crushing force of
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approximately lkp, unless otherwise specified. Although such a low crushing force 
would not normally be acceptable for manufacturing purposes it was considered 
appropriate here. The basic combination o f the polysaccharides xanthan and locust 
bean gum had poor compaction characteristics and all formulations were compacted 
to give a similar low crushing force to allow comparisons.
2.2.2. Drug dissolution studies.
The aim of most in vitro dissolution testing is not to mimic exactly the conditions met 
during gastro-intestinal transit but to provide a means of comparing and 
characterising different formulations and their release profiles under constant 
conditions which relate to the in vivo situation. It is therefore important to specify 
and control the agitation, temperature, pH and solvent, all of which can influence the 
drug dissolution profile and the behaviour of the dosage form. Many different 
apparatuses have been proposed some of which are included in the British 
Pharmacopoeia, the United States Pharmacopoeia and these have been reviewed 
elsewhere [277], The apparatus used in the present study was the USP Type II.
2.2.2.1. United States Pharmacopoeia Type II Paddle Apparatus. .
The United States Pharmacopoeia paddle apparatus used in these experiments, is a 
commonly used official method for dissolution testing. The paddle consists of a 
metal shaft coated with an inert material which rotates smoothly within 0 .2 cm of the 
centreline of the vessel, and 2.5 + 0.2cm above the base of the vessel. The paddles 
rotate without "wobble" in order to produce constant fluid dynamics and a ensure 
reproducible result. For similar reasons, the dissolution vessels themselves should be 
matched and uniform with respect to the dimensions, weight and curvature of the 
glass. Samples should be drawn from a point midway between the surface of the 
media and the upper edge of the paddle and midway between the wall of the vessel 
and the stirrer shaft [278]. Movement of the dosage form under the paddle should
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also be kept to a minimum as variable agitation may alter the dissolution effects. Any 
variation in all these characteristics may cause significant differences in the results 
obtained for the same product [279].
2.2.2.2._____ Automated tablet dissolution testing system.
The dissolution apparatus used in these studies was an automated dissolution system 
including dissolution bath (Model PTW S 3C, PharmaTest, Germany.), 
spectrophotometer (Model 8625, Unicam, U.K.), pump (Model MS-FIXO, IsmaTec 
Sa. U.K.), valve station (PharmaTest, Germany.), all of which operate under 
computer control (486 IBM compatible personal computer, Twist Technology, 
U.K.). An automated method was chosen for this study because such systems are 
known to be more efficient, rapid and precise.
The dissolution bath consisted of a temperature controlled water bath holding a total 
of eight glass vessels (Figure 27, A), made up of six vessels to hold sample tablets, 
one vessel to hold distilled water or any other blank solution and a vessel to hold a 
standard drug solution.
The blank vessel is set up in an identical manner to the sample pots with a paddle and 
a sampling probe however no tablet sample is added, but readings are taken during 
the tests as a control measure. There is also a temperature probe, in the blank vessel, 
which continually takes temperature readings at designated intervals throughout the 
run period. In the standard vessel there is a known concentration of the model drug 
dissolved in the dissolution media and again this behaves as a useful control, ensuring 
any drug degradation effects or mechanical failures in the system can be identified. 
The absorbance values, for the known standard solution in the standard vessel are 
incorporated into the calculation by the computer software, to quantify the amount of 
drug released at any time point.
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Figure 27. Schematic diagram of PharmaTest automated dissolution testing system.
Figure 28. Photograph of PharmaTest automated dissolution testing system.
The peristaltic pump (Figure 27, B) draws sample fluid from each vessel in turn 
through the tubing (Figure 27, C), via a valve switching station (Figure 27, D). The 
switching station consists of eight lines entering, a connecting valve and one line 
leading from the valve to the sample flow cell (Figure 27, E) in the 
spectrophotometer (Figure 27, F). Fluid is pumped from each vessel in turn and 
absorbance readings recorded. The fluid is then pumped to waste in this system 
(Figure 27, G).
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The whole dissolution system was operated under computer control (Figure 27, H). 
In this way the pump was switched on and off at pre-determined time intervals, the 
valve station sequenced sampling from vessel to vessel and the spectrophotometer 
under computer control selected the wavelength and zeroed the baseline. The raw 
absorbance data was stored to file as the spectrophotometer readings were taken. 
This data was then recalculated by the software, to account for the loss of dissolution 
media over the sampling period and loss of drug, as the sample fluid was pumped to 
waste, and any drift in the blank reading. Blank readings were taken for each vessel 
at the beginning and at each time point from the blank vessel and these values were 
used to adjust the final absorbance data. The standard solution in the standard vessel 
was used to calculate the drug released, using the linear relationship between 
concentration and absorbance, confirmed by Beer-Lambert data (table 4). The 
calculated data was then graphically saved to floppy disc and/or imported into other 
packages for manipulation and print-out. Dissolution data in the results (section 3) is 
displayed as % drug released / 15 minutes and each data set is the mean of 1 2  results. 
The T5 0  data is in Appendix 3.
Although automated dissolution systems have many advantages, a system such as the 
one used in the present study is particularly restricted in sampling interval variations 
particularly when rapid sampling is required as each vessel has to be sampled in turn 
due to the valve switching mechanism. This means samples can only be taken, from 
the same vessel, once every seven minutes. For sampling to be carried out at faster 
rates requires the use of six matched flow cells and a cell changer system in the 
spectrophotometer. This is a much more expensive hardware set-up than the one 
used, however it also eliminates the requirement for a switching station which due to 
a mechanical breakdown can be a source of error.
The lines and flow cell were kept very clean using 1% sodium hypochlorite solution 
as a disinfecting fluid, to clear debris from the inside of the tube surfaces, on a regular
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basis. During the priming process, all air should be removed from the tubing. Both 
air and debris if they lodge in the cell can interfere with the resulting absorbances.
In the present study, problems were sometimes experienced due to gel-forming 
tablets adhering to the base of the glass vessel, thereby reducing the surface area 
available for dissolution. During the monitoring period of the experiment, the tablet 
sometimes became detached and began to float around in the vessel leading to sudden 
available surface area changes, disintegration and breakdown of the dosage form. To 
prevent this phenomenon tablets were placed in loose cages (Figure 29) 20mm in 
diameter, to raise them off the bottom of the vessel and allow the dissolution media 
to surround the tablet but prevent the gel from floating later in the experiment. The 
cages were also designed to allow the gel to swell and increase in volume unimpeded 
so that the normal drug release processes were unaffected. This method was found 
to be effective in overcoming initial variable results observed in gel forming tablets.
Figure 29. Photograph of wire cages used to prevent sticking and floating problems 
in the sample vessels.
2.2.23. Conditions used for dissolution testing.
The choice of dissolution media was governed by the requirements of a given study. 
For the majority of studies de-gassed, distilled water was chosen for simplicity and 
standardisation reasons. Helium was bubbled through the dissolution fluid for 20 
minutes to remove the dissolved gases. This is an important pre-conditioning step, as 
bubbles can form on the surface of the dosage form creating a gas-liquid interface 
which acts as a barrier hindering the rate of solvent diffusion and solution effusion
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[280], Carbon dioxide in dissolved air can also reduce the pH and bubbles formed on 
surfaces within the dissolution vessel can alter the flow patterns and become trapped 
in the tubes of the testing apparatus causing interference with measurement systems.
The rate of agitation chosen was 50 rpm specified by the USP and it is an important 
standard as it alters the fluid flow patterns within the test vessel, influencing the 
dissolution rate. It has been found that a low rate of agitation can allow the 
formation of a pH microenvironment around the dosage form which can be physically 
removed by increasing the rate of agitation causing a variation in the rate of 
dissolution [281]. The conditions for the dissolution studies are summarised in Table 
2 .
Parameter Value
Media Distilled Water or Phosphate Buffer
Temperature 37°C
Paddle Speed 50 rpm
Media Volume 1 0 0 0 ml
Flow Rate Greater than 10ml / minute
Spectrophotometer Flow Cell Path Length 1 0  mm
Reading Intervals Every 15 minutes
Total Length of Test 10 to 15 Hours
Pump Delay Time 40 seconds
Table 2. Dissolution testing conditions.
The temperature of the dissolution media has a major influence on the disintegration 
and dissolution rates due to the temperature dependant solubility of many materials 
[282] [283], thought to be due to increased kinetic motion increasing diffusion rates 
[284]. The standard temperature used in all experiments of the present study was 37 
°C±1°C (i.e. body temperature). The flow rate generated by the peristaltic pump
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should not fall below the 1 0 ml a minute rate to ensure dissolution fluid from the 
vessel is analysed and not static fluid within the tubing during the sampling interval. 
The flow rate set by the pump was measured at the beginning of the test and 
incorporated into the software to allow calculation of the fluid volume and drug loss.
During the dissolution studies of the para-substituted model drugs (Figure 24), it was 
considered important to maintain the pH and ionic strength throughout the test and 
from day to day. It is well known that the pH of the media can play an important role 
in the dissolution profiles that can be obtained. The dissolution rate of weakly basic 
drugs increases with decreasing pH and conversely the dissolution rate of a weak acid 
increases with increasing pH and this has implications on the absorption and 
bioavailability within the gastro-intestinal tract [285] [286], The maintainance of 
constant ionic strength was of key importance during these studies due to the 
potential significance of ions in the swelling behaviour of the polysaccharides. To 
ensure any differences in dissolution responses were due to the differences in the 
model drugs used, a buffer was used to control the pH and ionic strength conditions. 
The composition of the buffer used in the present study is shown in Table 3.
Components Concentration fednr3) Mass in 9.5 Litres
di-sodium hydrogen ortho 
phosphate dodecahydrate
58.9 559.6
citric acid 3.7 35.2
potassium chloride 5.44 51.7
Table 3. Composition of buffer solution [287],
2.2.2.4.______Calibration plots.
A scanning ultra-violet spectrophotometer (Model Lambda 3B uv/vis spec, Perkin- 
Elmer, U.K.) was used to carry out measurement of calibration samples, between 
wavelengths of 310nm and 2 1 0 nm in order to locate the wavelength of maximum
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absorbance for each of the model drug compounds. The measured wavelength of 
maximum absorption was then selected on the dissolution apparatus 
spectrophotometer, and the absorbances of four replicates of six concentrations were 
determined for a solution held in a 1 0 mm pathlength sample cell. Samples of 
benzamide and its substituted derivatives were calibrated using solutions in 
phosphate buffer as well as in water for benzamide. Absorbance values were plotted 
against concentration to obtain the slope and the intercept according to the Beer- 
Lambert relationship shown in Table 4. Ultra-violet scans of all the gum components 
were carried out to ensure that they would not interfere with the drug response, by 
dissolving slowly in the dissolution media and contributing to the final absorbances. 
This was particularly important at the lower end of the ultra-violet scale as many long 
chain molecules begin to absorb and can be significant when the absorbance peak of a 






Benzamide in water 225 0.07313 -0.01507 0.99976
Benzamide in phosphate buffer 228 0.07298 -0.01578 0.99976
p-aminobenzamide in phosphate buffer 278 0.10377 0.02128 0.99982
p-fluorobenzamide in phosphate buffer 231 0.06002 -0.01438 0.99981
p-methylbenzamide in phosphate buffer 241 0.08505 -0.09495 0.99995
p-hydroxybenzamide in phosphate buffer 253 0.09362 0.01601 0.99995
Table 4. Wavelengths of maximum absorbance (X-max), gradient, intercepts and 
correlation coefficients for benzamide and its derivatives.
2.2.3. Rheology
Newton was the first to develop a mathematical formula to describe the resistance of 
a fluid to flow under an applied stress. This resistance to flow was described as the
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viscosity of the fluid [288]. Water swellable polymer networks are highly elastic, 
solvent-containing bodies with very specific properties and may be either synthetic or 
natural in origin. In gels there is an aggregation of the colloidal sol particles. In 
many gels the forces holding the structure together are weak such as the hydrogen 
bonding thought to be responsible for the increase in the viscosity between xanthan 
and locust bean gum. The randomly extended polymer chains can deform and 
orientate themselves with the direction of the applied shear. These weak bonds can 
be broken under a shear force producing a gel-sol transformation, and the gels 
demonstrate the phenomenon of thixotropy.
In practice only low molecular weight liquids show Newtonian behaviour and 
polymer solutions only show Newtonian characteristics at very low concentrations. 
At high concentrations a gel structure may be formed and produce Bingham plastic 
type flow with a yield value. In the middle of these concentrations the material may 
not show a yield value but on agitation there is an increase in the fluidity and this is 
pseudoplastic behaviour. Polymer solutions show pseudoplastic behaviour where 
there is no constant viscosity but with increasing shear stress there is increasing shear 
rate [289],
Thixotropy can be defined as the isothermal and reversible time dependant loss of 
viscosity as the result of applied shear. Thixotropic materials are inevitably 
pseudoplastic however a pseudoplastic material is not necessarily thixotropic.
2.2.3.1. Rheometrv.
Rotational rheometers generate viscous drag on the test geometry, either on 
concentric cylinders, cone and plate or parallel plates, as the result of rotation in the 
fluid being tested. The majority of rotational instruments are controlled shear rate 
and measure the transmitted shear stress. Rotational instruments have known
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problems: for example, the shear rate is momentarily incorrect due to the lost motion 
of the spring or torsion bar as the rate is increased [290] The development of air- 
bearing viscometers such as the CarriMed Controlled Stress Rheometer, allows stress 
to be used as the independent or programmed variable with the angular velocity 
(which is related to the shear rate) being the dependant or measured variable. There 
are especially useful for non-linear material [291], A cone and plate geometry was 
chosen for measuring the rheological properties of the hydrocolloid solutions used in 
the present study as this is suitable for viscous fluids that do not contain discrete 
particles. The diameter of the stainless steel cone was 4cm and the angle of the 
truncated cone 2 degrees. This system required a working gap of 51 /un between the 
cone and plate, to avoid contact drag effects. A sample of approximately lg of fluid 
was used to fill the gap with no overflow which could generate errors.
Truncated
cone
Sample Radius of cone
Cone angle * System gap
Figure 30. Schematic diagram of cone and plate testing geometry of Carrimed 
Controlled Stress Rheometer.
The temperature is maintained throughout by a Peltier heat-exchange system within 
the flat support ram. The Peltier system uses a thermoelectric effect which behaves 
as a heat pump for temperatures higher than 70°C and fluid circulation heat-exchange 
system for lower temperatures [292], By controlling the magnitude and direction of 
current, any level of heating or cooling can be achieved very quickly. A heat sink is 
required to remove unwanted heat and comprises a reservoir of a few litres of water
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and a pump which provides a flow rate through the Peltier heat exchanger jacket 
which is built into the plate. Any increase in the sample temperature due to friction is 
quickly compensated for by this system.
2.23.2. Sample preparation.
In these studies the effect of changing the xanthan : locust bean gum ratio, (1:1, 2:1, 
3:1, 4:1 and 1:2, in a 0.25%w/v solution) on the shape of the thixotropic loop was 
examined. This was compared to the shape of the curves produced by the xanthan 
gum alone and the xanthan combined with other polysaccharide polymers.
Solutions of 0.1M, 0.5M, 1.0M and 5.0M urea solution were prepared and used as a 
solvent for the polysaccharides, to try to disrupt the hydrogen bonding within the gel 
structure. The xanthan / locust bean was also dissolved in a phosphate buffer of 
varying pH (5.8, 6.2, 6.9, 7.5, 7.8 and 8.0) and sodium chloride solutions of different 
concentrations (0.1M, 0.5M, 1.0M) to examine the effect of ionic strength on the gel 
formation. Work carried out by other groups, on the rheological characteristics of 
xanthan/locust bean gum solutions, has been reviewed in section 3.2.2.
Samples of the polysaccharides were weighed and dissolved in distilled water or 
buffer and agitated until they were fully dispersed. They were then left to stand 
overnight to allow equilibration and hydration. The samples of approximately lg, 
were then mounted centrally onto the sample ram with the minimum of disturbance to 
the sample and the ram raised into position so that the cone is touching gel on all 
surfaces. The sample was then left to rest for 30 minutes to allow it to settle and 
reform any of the structure which may have been lost during the mounting process. 
The temperature was set at 25°C (i.e. room temperature).
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To construct a flow curve, a maximum shear stress of 10 N/m2 was applied to fluid 
samples using ascent and descent times of 1 minute respectively. The controlling 
computer then divides this into 200 equal steps of shear stress; at time zero the flow 
curve is started, the drive system is turned on but the applied stress is zero. The 
sample is then exposed to incrementally increasing shear stresses and the angular 
velocity that this creates is recorded and stored by the computer. The torque rises to 
its highest point and then decreases back to zero allowing construction of a stress- 
shear rate hysteresis loop.
2.2.4. Electron microscopy.
Scanning electron microscopy (SEM) was used to examine the morphology of 
excipient components and modified techniques have been used to try to visualise the 
swelling process. Scanning electron microscopy has been detailed elsewhere [293], 
The major benefit of using scanning electron microscopy in the present study was the 
large depth of field in comparison with light microscopy.
2.2.4.1. Samples for scanning electron microscopy.
Samples of powder were allowed to scatter on to sticky conductive mounting discs 
located on aluminium stubs. Any loose particles were then removed by de-dusting 
using a pressurised air canister. The components required metal coating, as the 
materials are non-conducting and charging can occur which will distort the images 
produced. The vacuum chamber was evacuated to 6xl0"2mbar to remove the air and 
all the fumes from the sample. The pressure was then increased to 1.5xl0mbar and 
the probe energy was set to 20mA, a purple glow filled the chamber as the gold 
source was bombarded with high energy atomic particles The powder samples were 
sputter coated with a thin layer of gold (Model SI50B, Edwards High Vacuum 
Sputter Coater, Crawley, U.K.) for six minutes. Samples were then imaged using
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either model JFM-T330 or JFM-35C, (Japanese Electron Optics Ltd., Tokyo, Japan.) 
scanning electron microscopes.
2.2.4.2._____ Environmental scanning electron microscopy (ESEM).
There are limitations to scanning electron microscopy, in that wet samples cannot be 
imaged directly due to problems with charging. This means sample preparation is 
required such as freezing or drying followed by coating. A major draw back with 
these preparation techniques is that they may induce artefactual changes in the sample 
structure. Environmental scanning electron microscopy (Model E3, Electroscan, 
Wilmington, USA) allows the examination of surfaces of practically any specimen, 
wet or dry, insulating or conducting, without the need for special preparation. This is 
made possible because ESEM utilises a relatively low vacuum in the sample chamber, 
(greater than 26.67x102 Pa) introducing a gaseous environment, while still 
maintaining the necessary high vacuum around the electron gun [294]. The pressure 
difference is possible through the use of differential pumping. The column is divided 
into a series of chambers, each separated by pressure limiting critical apertures. This 
arrangement allows a difference in pressure of several orders of magnitudes between 
the sample chamber and the electron gun. The tolerance o f gaseous pressures allows 
the maintenance of a saturated vapour pressure at temperatures above the freezing 
point and hence the presence of liquid water within the sample chamber. More 
detailed descriptions of the environmental scanning electron microscope and its uses 
are available elsewhere [295][296]. Dynamic processes such as wetting, drying, 
mixing, melting, crystallisation or curing may be visualised in real time by varying the 
temperature and pressure in the sample chamber. Manipulation of the sample within 
the chamber is possible using a micro-manipulator and micro-injector.
2.2.4.2.1. Sample preparation.
Samples of tablets weighing lOOmg, were mounted dry on stubs using carbon dag, a 
conductive paint and placed in the sample chamber of the environmental scanning
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electron microscope for imaging. Water was introduced to the sample using the 
micro-injector attachment in an attempt to visualise the dynamic changes to the tablet 
following wetting. Both surface and cross sectional imaging of tablet samples was 
carried out.
In a separate experiment, tablet samples were mounted securely in a specially 
constructed tablet holder (Figure 31) and placed into 250ml distilled water at 25°C 
(i.e. room temperature) for thirty minutes prior to imaging. This specially 
constructed sample holder exposed only the faces of the tablet to the fluid. When the 
holder was opened the tablet within was automatically broken in half. This action 
revealed the glass-gel boundary and the samples were then mounted onto the sample 
stage, using carbon dag, for further imaging.




Figure 31. Schematic diagram of the tablet sample holder, constructed in perspex 
used for ESEM studies.
2.2.4.3.______Cryogenic scanning electron microscopy (C-SEM).
The examination of specimens, in a scanning electron microscope can damage the 
samples and give poor results in two ways. Firstly, the high vacuum within the 
microscope can cause many hydrated materials to lose water and shrink or otherwise 
distort. Secondly, the electron beam energy could raise the temperature of the 
specimen to a temperature which may melt components of the sample. To overcome
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these problems, which are particularly critical in biological and organic samples, a 
cold stage or cryogenic attachment (Model CP 1500 Cryo attachment to JSM-35C, 
Oxford Instruments, U.K.) was used in the present study. An effective cold stage is 
thermally and mechanically stable and it must maintain samples well below -130°C, 
because above this temperature, samples may gradually ffeeze-dry in the vacuum of 
the microscope specimen chamber due to water sublimation. To ensure that the 
samples do not approach this temperature, the stage is kept at around -180°C using 
liquid nitrogen cooling.
The cryo-scanning electron microscope (C-SEM) system used consisted of two parts; 
a vacuum chamber with a gate valve and a cold stage in the specimen chamber. 
Frozen hydrated samples have poor bulk and surface conductivity and generally 
charge in the electron beam, due to the poor conductivity of ice at low temperatures 
[297]. For this reason the vacuum chamber consisted of two parts: a pre-pumping 
chamber and a metal-coating chamber. This allowed the sample to be maintained 
frozen whilst a thin layer of gold was applied in order to render the specimen 
conductive. More information can be found elsewhere [298],
2.2.4.3.1. Sample preparation
Tablets of the polysaccharide matrices were soaked in water for thirty minutes, to 
allow swelling and gelling of the excipient to occur. The wetted matrix was then 
plunged into liquid nitrogen (-210°C) which instantly freezes the ingressed water 
within the tablet. The frozen tablet was then sectioned laterally to reveal a cross 
section of the wet and dry areas frozen within the tablet. The frozen section was then 
mounted onto the sample holder using carbon dag and inserted into the pre-pumping 
chamber. The sample holder was then transferred to the coating chamber for gold 
sputter coating and was ready for imaging in the microscope whilst maintained at - 
180°C.
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2.2.4.4. Freeze dried samples for scanning electron microscopy.
The freeze drying process is commonly used for materials which lose their viability in 
the liquid state, are heat sensitive or readily degrade if dried in air by reacting with 
oxygen. Stabilisation is brought about by the water content of the sample 
sublimating and going from the solid ice state to the vapour state without passing 
through the liquid state. This occurs at low temperatures and pressures below the 
eutectic point. Below this point the liquid phase is missed completely. The eutectic 
point occurs in different places for different solutes. Freeze drying is always carried 
out at temperatures and pressures well below this point as to avoid any melting which 
may ruin the sample [299].
In this case removing the water, in the form of ice, from the sample was the seen as a 
viable alternative to keeping the samples frozen on a cryogenic stage. This was seen 
as a method of verifying the structures observed in the cryogenic study as complete 
removal of the ice crystals would confirm anything left was polymeric material.
2.2.4.4.1. Sample preparation.
As with specimens prepared for C-SEM imaging, freeze-dried polymer samples were 
allowed to swell in distilled water for a measured amount of time and then were 
transferred whole to 300ml of liquid nitrogen (-210°C) to cool and freeze the 
samples very rapidly. These were then fractured on a cold block with a razor blade 
and placed on an aluminium tray. The whole tray was then transferred to the cold 
stage of a freeze dryer (Edwards-Pearce Tissue Freeze Dryer, Crawley, UK.) at -60° 
C and a vacuum of lO^mbar. The chamber was pumped out and left overnight for 
the water to sublime off The samples were then coated in gold for 6  minutes using 
the sputter coater as before. These samples were then imaged using an JSM-T330 




To examine the change in the dimensions of the polysaccharide tablets in the 
dissolution fluid, measurements were taken using a video imaging system consisting 
of a camera connected to a PC with frame grabbing software (Model 440 Field Store 
and 440A Frame Store, Colorado Video, Inc., Colorado, USA.) and image 
processing software (Visilog, Noesis Vision Inc, Quebec, Canada ). The study was 
designed to allow the tablets to take up the surrounding dissolution media without 
the support structure restricting the movement and swelling process. As the wet gel 
is fragile and it is not possible to handle the material once it is wet it was also 
important to have a non destructive method of measuring the increase in the 
dimensions. In previous swelling studies a tablet was pushed into a glass tube and 
the gel boundaries and drug concentration imaged using fluorescence imaging. This 
method however restricts the swelling to one direction [300],
IBM compatible PC






Link between camera and computer
Figure 32. Schematic diagram of video imaging equipment used to examine the 
swelling behaviour of the tablets.
The tablet was mounted onto a pin attached to a support, with the calibrated measure 
next to the tablet. This was placed into a flat bottomed dissolution vessel modified 
with a flat window so that the tablet could be imaged without the distortion caused
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by the curved glass. A magnetic flea at the bottom of the vessel agitated the 
dissolution media at a constant rate and the temperature of the media maintained at 
37°C to simulate dissolution conditions as closely as possible. To take 
measurements the entire beaker was then placed on to a light box in front of the 
video camera (High Performance CCD Camera, COHU, INC., Electronics Division, 
USA.). This imports a video image into the screen of the monitor (386 IBM 
Compatible P.C.,Viglen Ltd, UK) and using a cursor on the image, the tablet can be 
measured and a figures given for the width and height. The calibrated measure in the 
vessel is used to convert the measurements to the actual dimensions of the swelling 
tablet. At increasing intervals of 2.5, 5 and 15 minutes, measurements of the 
changing and swelling tablets were taken within the beaker and with a minimum of 
disturbance.
Samples of the individual and the combined polysaccharides were compared and the 
effect that the composition of the media has on the swelling behaviour of the 
polymers, was assessed.
2.2.5.2.______Photographic studies.
The analysis software used above (Section 2.2.8.1.) could not save or transfer the 
images to give a visual demonstration of the measurements taken. Still pictures were 
taken using a still video camera (Model ION RC260 Still Video Camera, Canon, 
Japan) which saves the images to floppy disk for easy transfer into other software.
2.2.6. Microcalorimetry.
Calorimetry and microcalorimetry are methods of measuring the heat absorbed or 
evolved during the chemical or physical changes of any process. This methods gives 
the potential to investigate heat flows in processes as diverse as the effect of drugs on 
the growth of micro-organisms[301][302], to the interaction of drugs with
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food[303][304], excipients [305] and blood [306], Information gained on heat 
absorption or production can be used to provide valuable information on both the 
thermodynamics and kinetics of a known process. Microcalorimetry has been used to 
examine the swelling and drug release processes from hydrophilic matrices of HPMC 
[307], Other groups have used microcalorimetry to support theories about the 
conformational structure of x-carrageenan [308] and to provide an understanding of 
the relationship between thermal stability and structure in several natural 
polysaccharides, including xanthan [309]. In the present study, the effect of sodium 
chloride and calcium sulphate on xanthan / locust bean gum, both in solution and 
within the tablet, on the swelling behaviour of the polysaccharides was assessed.
2.2.6. 1. Sample preparation.
The polysaccharide gums were examined alone to give a calorimetrically truer idea of 
the bonds being formed and broken within the gel structure. The polysaccharides 
alone were also used to examine the influence of ions on the structure formed within 
the matrix. It was thought that use of the granules would make very little, if any, 
difference to the results produced by the weak tablets.
lOOmg granules were weighed into a stainless steel measuring ampoule containing 
20ml of water or a salt solution of known ionic content and strength. The same 
volume of solvent was introduced into an empty measuring ampoule as a reference 
standard. Both ampoules were then sealed and placed in the calorimeter chamber 
(LKB 2277 Thermal Activity Monitor, University of Grenoble, France.) and the 
temperature equilibrated for 20 minutes. Data was obtained and recorded after 
equilibration for a period 12 hours. The calorimeter has a thermostated bath 
(temperature stability of + 10"4 oC) and is able to detect temperature differences of 
less than 10-6  °C.
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2.2.7. Electron Spin Resonance (ESR).
Spectrometry in general terms is the recording and measurement of the absorption or 
emission of radiation by atoms or molecules when an energy transition occurs. 
Magnetic resonance spectroscopy differs from other types of spectroscopy in that the 
separation of the energy levels between which electronic transitions occur only exist 
in the presence of a magnetic field. Nuclear magnetic resonance spectroscopy 
(NMR), discussed in more detail later, is the most commonly used magnetic 
resonance technique however the less familiar electron spin resonance (ESR) 
provides an alternative technique for investigating atomic and molecular structure, 
and the environment in which the species are contained [310],
The simplest magnetic unit is the magnetic dipole, electrons and many nuclei which 
are magnetic dipoles, behave like small magnets. These permanent magnetic dipoles 
are due to the spin of unpaired electrons or to the angular momentum of the electrons 
in orbitals of atoms or molecules. In the absence of a magnetic field the magnetic 
dipoles that produce paramagnetism are not oriented however in the presence of a 




Magnetic Field Off Magnetic Field On
Figure 33. Electron Spin Levels in a magnetic field
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The electron spin angular momentum is an intrinsic property of the electron and each 
electron has the same value for this property and can take only two orientations with 
respect to a specific axis i.e. the magnetic field, the a  or +V2 and the (3 or -V2. This 
is represented by figure 33.
As the magnetic field increases, the energy of an a  electron increases and the (3 
electron energy decreases so increasing the separation of the energy levels, however 
only certain energy levels are attainable and this manifestation is known as 
quantization and in electron spin resonance transitions between these energy levels 
are studied. For magnetic fields produced in the laboratory these transitions between 
energy levels for the spin of unpaired electrons occur in the microwave frequency 
range. The magnetic field, B, is typically about 3400 gauss whilst the energy source 
is usually a Gunn diode emitting 3cm radiation of 9.6GHz known as X-band radiation 
and this is known as X band ESR [311].
The electron spin resonance spectrophotometer provides the magnetic field to 
produce the energy levels which only exist when the samples are magnetised and a 
microwave radiation source to excite transitions between the energy levels. When 
the frequencies of the two oscillators, the magnetised electron and the microwave 
radiation, are identical the strong effective coupling which occurs is called resonance. 
The excitation energy which flows between the oscillators is said to resonate and a 
crystal detector detects the energy loss from the microwave, as absorption occurs by 
the sample. This is the precessional frequency or the frequency at which transition of 
the electron from one energy level to another occurs. When this occurs the condition
hv = gefJL&B Equation 2.2.1.
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is satisfied where h is a constant, v is the frequency of the microwave radiation, ge is 
the g  value for a free electron, is the Bohr magneton and B the applied magnetic 
field.
By varying the magnetic field around that required for resonance the ESR spectrum is 
obtained. The basis of the electron spin resonance experiment is to match the set of 
energy levels possessed by the sample to the source of monochromatic microwave 
radiation and to observe the strong absorption which occurs at resonance. The 
spectrophotometers use a modulation technique which superimposes a cyclic 
variation on the magnetic field, to reduce noise in the spectrum. The signal is 
observed with a phase sensitive detector and the resulting ESR spectra is the first 
derivative of the actual absorption spectra [312],
Molecules of different kinds come into resonance at different applied magnetic fields. 
In order to accommodate differences between species the resonance condition is 
written
hv = gfiftB Equation 2.2.2.
where g is an experimental parameter which depends on the molecule under study. 
For a free electron g  = ge = 2.0023 and for many radicals g lies in the range 1.9 to
2.1. The value of g  depends on the electronic structure of the species because the 
applied field has to be able to move the electron through the molecule and so a 
knowledge of its value can give structural information. More detailed information 
can be found elsewhere [313].
In the majority of free radicals the unpaired electron is present in an orbital covering 
several atoms. If one of these atoms i.e. an isotope, has a nuclear magnetic moment, 
then as a result of the interaction between the nuclei and the electron spins the energy
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levels of the unpaired electron undergoes additional splitting and the hyperfine 
structure appears in the electron spin resonance spectrum. The nuclear interaction 
which causes the splitting of one electron level into several sub levels is called the 
hyperfine interaction and the corresponding splitting of the spectral lines, the 
hyperfine splitting. In the particular case of the interaction of an unpaired electron 
with the nuclear spin of nitrogen which takes place in nitroxvl radicals such as 
2,2,6,6-tetramethyl-l-piperidinyloxyl (= TEMPO) radical and the derivatives used 
here, the nuclear spin of nitrogen in a constant magnetic field can assume three values 
+ 1 ,0 , - 1  with which the magnetic moments of the electron will interact, each electron 
level is split into three sub levels. In the electronic transitions that take place, the 
spin flips and transition occurs between levels with the same projections of nuclear 
spin. In accordance with what has been said the ESR spectra of nitroxyl radicals, as 
dilute liquid samples, consists of a system of three equidistant lines of the same 
intensity (Figure 34; I) [314][315].
In dilute liquid samples the radicals are free to reorientate rapidly. The reorientation
averages out any anisotropy in the g  factor and in the hyperfine splittings (A). When
free radicals are also encountered in rigid matrices and when evenly dispersed at a
molecular level in a solid, a new spectrum is observed. Within the molecules the g
and A interactions may not be isotropic but the direction of the magnetic moment is
dependant on the orientation of the orbital containing the electron. Thus the electron
has two components for g and A, the parallel components g|| and A|| and the 
perpendicular components g j_ ? A j_. For this situation the isotopes condition is
given by giso= 2g\\ + gj_ and similarly Aiso= 2A|| + A _l These spectra are referred
to as 'glass' spectra and can be achieved by dissolving the spin label in an appropriate 
solvent mixture and then freezing the sample in liquid nitrogen (Figure 34; II) [316],
In this particular study another factor became important. If the radical is placed in a 
medium where it can still move about but in which the motion is constrained in some
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fashion for example in a very viscous fluid. In figure 34; III we see a spectra 
suggesting a firmly immobilised but well distributed spin label, closely resembing a 
glass spectra. Overlaid on to this are suggestions of the triplet solution spectra 
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Figure 34. ESR spectra : Freely moving solution spectra (I); Partially immobilised 
spin label spectra (II); Immobile glass spectra (III); Spectra with loss of 
hyperfine splitting (IV).
There is one other type of spectrum encountered in this work, shown in figure 34; 
IV. At high concentrations and when in the solid state the free radical give a single 
line spectra, which narrows further at higher concentrations. This arises because of 
an exchange of spin states between the unpaired electrons of two free radical 
molecules. The exchange narrowed spectrum shows that the molecules are in very 
close proximity to one another and the electron spins exchange so fast that the time
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average of the hyperfine field is close to zero. In the pure solids the strong exchange 
arises from the overlap of molecular wave function.
In this study the free radicals used were TEMPO and its analogues Figure 35. Unlike 
many free radicals these molecules are very stable and can be unchanged in solution 
for a period of years. This is due to two things, the methyl groups on the carbon 
atoms adjacent to the nitrogen stabilise the charge by distributing it across the 
molecule. Secondly the methyl groups sterically hinder the nitroxyl free radical group 
making it very difficult for any reactive species to reach the unpaired electron. It is 
however possible to substitute different groups on to the 4-position of the ring to 
vary the properties of the molecule.
TEMPO
(III) (IV)
Figure 35. Structure of TEMPO (I) and its substituted derivatives, TEMPOL (II); 
amino-TEMPO (III); oxo-TEMPO (IV).
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The technique has been applied in the field of pharmacy in several ways. 
Microviscosity measurement is possible as the spin probes produce different 
characteristics in the three line spectra which relate to the environment in which they 
are contained [317]. ESR has been used to examine the microviscosity of water- 
glyceryn mixtures [318], hydrocolloids [319], to follow the water penetration into 
biodegradable polymers and gels which is of particular interest here[320], pH 
sensitive spin probes can detect the pH value within the polymer. The method has 
been used to study the morphology of hydrogels such as poly 2 -hydroxyethyl 
methacrylate (PHEMA) and showed that there are not separate domains of water and 
polymer in which hydrophilic or hydrophobic solutes can exist selectively [321] 
Other studies have shown ESR can be used to measure pH and oxygen concentration 
in biological matrices such as membranes [322]. The method has also been used in 
vivo to detect nitroxides after inhalation [323] and after transcutaneous absorption
[324], Nitroxides are excellent model compounds to characterise the drug releasing 
systems in vivo in a non-invasive manner thus leading to clearer characterisation of 
the drug delivery systems involved and the liberation process. Other steps in the 
bioavailability process can also be studied including the absorption, distribution, 
metabolism and excretion can be studied.
2.2.7.1._____ Sample preparation.
The TEMPO spin label and its analogues were incorporated into the polysaccharide 
matrices by two methods, dry mixing and by wet granulation. The dry mixes where 
formed by blending the spin label into the polysaccharide granules using a pestle and 
mortar. In wet granulation the spin labels were dissolved into the granulating fluid, 
water, then the solution used to granulate the polysaccharide powders. These were 
then dried overnight at 50°C and then screened through a 1mm apeture mesh to 
remove the larger material. Samples of the granules were then inserted into silica 
glass tubes and on an ESR Spectrophotometer (Model ESP-300E spectrometer,
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Bruker, Germany.) and X-band ESR spectra recorded at 293K and 77K in liquid 
nitrogen. The spectra were all measured at 20mW power, modulation frequency of 
lOOKHz and modulation amplitude of 1.015G. Solution spectra of the spin labels 
were obtained by dissolution in a 1 :1  mixture of tetrahydrofiiran and 
dimethylformamide at room temperature. To measure the solid spectra of the evenly 
distributed spin label the mixtures were measured at 77K as a frozen glasses.
To examine the effect of different methods of removing the water, the wet granules 
were placed in an freeze dryer (Modulyo, Edwards-Pearce Tissue Freeze Dryer, 
Crawley, UK.) and lyophilised. This eliminated the use of heat as a drying method 
and so the possibility of chemical reactions being precipitated by heat and producing 
the differences shown by the different spin labels. The granules were then subjected 
to ESR analysis as before.
2.2.8. Nuclear magnetic resonance (NMR) and magnetic resonance 
imaging (MRI).
In nuclear magnetic resonance (NMR) a signal can be obtained from nuclei with a net 
magnetic moment (e.g. hydrogen nuclei) by placing the sample in a strong magnetic 
field and applying radio-frequency electromagnetic radiation. In a strong magnetic 
field the nuclear magnetic moments line up with the applied field and as a result a 
small net magnetisation of the sample is generated. If the nuclei are disturbed from 
alignment with the magnetic field, a torque develops which acts to realign the them 
and they precess about the field direction at a frequency which is proportional to the 
strength of the applied field. These pressessing nuclei induce a voltage in a tuned coil 
which is placed around the sample and this voltage forms the NMR signal. Nuclei 
interact strongly with the radio frequency radiation with the same frequency as 
nuclear precession. A pulse of such radiation can be used to disturb the nuclei from 
equilibrium and set them into precession. The NMR signal does not last but decays 
exponentially as the precessing nuclei return to equilibrium in the magnetic field. The
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exponential decay process is characterised by two time constants or relaxation times 
T i and T2 The T j is the time it takes for the magnetic moments to become realigned 
with the magnetic field and the T2 is the time for the nuclear signal to decay after 
application of the radio-frequency pulse. NMR is covered in more detail elsewhere
[325][326],
Many things influence the NMR signal and thus the T2. These can be categorised 
into inhomogeneous (reversible effects) and homogeneous (or irreversible effects) 
mechanisms. If we remove the effects of inhomogeneous interactions, we are left 
with a longer lasting signal. The main way of doing this is to "refocus" the 
inhomogeneous effects with a series of 180° radio frequency pulses following the 
excitation pulse. The result is formation of a signal called an echo- thus the cluster of 
methods is known as the spin echo technique. The curve that can be created by 
plotting the echo intensity against the interval between the echoes is the transverse 
relaxation curve from which data the T2 value can be extracted (Figure 36).
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Figure 36. Schematic diagram of the signals used in spin echo NMR and the 
transverse relaxation curve used to calculate the T2
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In MRI the use of a spin echo scheme permits one to sample the signal long after it 
would have decayed following a simple pulse. Imaging of controlled release tablets 
involves the use of spin-echo schemes to obtain the basic image, called an 
"equilibrium magnetisation image" or "Mo image". In this case, a certain time is 
selected, called the "echo time" at which the signal is sampled. Then an image is built 
up by the usual scheme. This image only corresponds to one value of 2m and thus 
can discriminate against regions of the sample that have a short T2 (long echo time) 
or against regions of the sample that have a long T2 (short echo time). This image is 
T2 weighted.
If the above experiment is repeated with other values of 2nr, a series of images 
results. If we plot the intensity at pixel location (xj, yj) as a function of 2nr, we get 
the transverse relaxation curve for position (xj, yj) and hence the T2 (xj, yj). If we 
repeat this for all positions of (xj, yj) and turn the values of T2 into colours, we now 
have a "T2 map". The map is the spatial distribution of T2.
Bright here because of long T2
Dark here because of long T2 
Figure 37. Schematic example of a T2 map.
These T2 maps demonstrate structural details within the hydrating tablet. At the base 
there is more solid polysaccharide so greater potential for hydrogen bonding, more 
exchangeable protons and smaller diffusive spaces which result in shorter T2 and a 
dark area. Closer to the surface water is present at low concentrations but the T2 is 
still short for similar reasons to the solid polysaccharide. At the gel front the polymer 
is very dilute but the difference in the T2 compared to bulk water is easily detectable.
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This is due to the influence of the polysaccharides on the water proton T2 as the 
nuclei of interest is H, located in the water molecule and images show the spatial 
variation of local water concentration within a sample. [327]
NMR-imaging studies have been used to examine the dimensional changes in the gel 
layer and core of hydrating HPMC tablets [328][329] and the penetration rate of 
water into HPC slow release capsules [330],
2.2.8.1._____ Sample preparation.
The samples were examined using a NMR system (Model Biospec X32, Bruker, 
Germany).The sample was placed into a 1 0 mm, internal diameter, quartz tube, filled 
with water and then positioned upright in the centre of the imaging magnet at room 
temperature (25 °C). A water only blank was used to optimise the sample position 
and equipment settings. The experimental procedure was to acquire a T2 relaxation 
time weighted data set and to repeat at timed intervals. The samples were examined 
using a NMR system (Model Biospec X32, Bruker, Germany) operating at 4.7 T 
(200 MHz) for proton observation and all data analyses were obtained using IDL 
(Research Systems, Inc, Boulder CO, USA).
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3. Results and Discussion.
3.1. Individual Components of Controlled Delivery 
System.
3.1.1. Physical characteristics o f powders.
The heteropolysaccharide, xanthan gum is a fine free flowing cream or off white 
powder, soluble in cold or warm water but insoluble in ethanol. The solubility gives 
the polysaccharide excellent water wicking properties and forms viscous solutions. 
Solutions are stable over a wide range of pH's and stable in the presence of enzymes, 
salts, acids and bases. Xanthan has good compression characteristics and alone can 
form satisfactory tablets (Figure 38).
Figure 38. Scanning electron micrograph of xanthan gum raw material. Coated using 
a gold source and viewed at a magnification of x 50.
The particle size distribution shows over 40% of the particles are greater than 63 /un 
and less than 180jiim shown in figure 39.
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Less than 63/am 1 8 0 /m  2 5 0 /m  355/am Greater than
63/am 500M«n
Figure 39. Particle size data for xanthan gum powder sample using sieves and 
agitation
The locust bean gum is also a fine off white powder It is not readily soluble in cold 
water however if the dispersion is warmed the polysaccharide will dissolve. The 
scanning electron micrograph figure 40 shows the irregular particle shape of the 
locust bean gum
Figure 40 Scanning electron micrograph of locust bean gum raw material Coated 
using a gold source and viewed at a magnification of x 50
Its particle size distribution differs from that of xanthan in that over 80% of the 
particles are greater than 63/xm and smaller than 180/xm and is a much narrower 
distribution shown in figure 41. It is an elastic material and is poorly compressible.
63 p m  180^m  250Jim 355 / im  Greater thanLess than
63/tm  500/im
Figure 41. Particle size data for locust bean gum using sieves and agitation.
Overall the particle size and therefore the surface area of the powders are of a similar 
order of magnitude. As wetting of the powder surfaces is related to surface area, 
markedly differing particle sizes could affect dissolution rate as the properties of the 
polysaccharides are varied. As was noted above in the introduction, similar orders of 
magnitude for particle size and surface area can be ignored as a factor likely to 
significantly influence controlled drug delivery data obtained in the present studies.
The model drug benzamide, (Figure 42) is a finely divided (less than 180/xm) white 
powder, odourless and soluble in water, producing a clear and stable solution. The 
structure of the molecule shows that it is has a chromophore in the amide group 
which produces a Xmax at wavelength 225nm, meaning it is suitable for analysis by 
ultraviolet spectroscopy. It also has the advantage that it will not influence the 
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Figure 42. Scanning electron micrograph of benzamide the model drug. Coated 
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Figure 43. Graph of cumulative drug release versus time for tablets using individual 
polysaccharide components as excipients. Conditions : 37°C, in distilled 
water, using paddle dissolution method; model drug - benzamide.
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From the graph in figure 43, of cumulative drug release with dissolution time, it can 
be seen that the locust bean gum tablet has a very rapid dissolution rate, with most of 
the drug released within the first fifteen minutes. Following immersion the tablets 
were observed to disintegrate or blow apart immediately on contact with the 
dissolution fluid. This demonstrates that the locust bean gum alone has little value as 
a controlled release excipient. On the contrary, this type of behaviour is typical of 
tablet disintegrants, designed to achieve rapid drug release. The xanthan gum tablet 
was found to have a more controlled release profile characterised by a time for half 
the drug to be dissolved (T50) of 2V2 hours. The downward drift in the 100% figure 
of drug released from the locust bean gum was thought to be due to adsorption of the 
model drug to plastic dissolution tubing.
The kinetics of the release profile was analysed by re-examining the data when 
plotted for zero order (% cumulative release vs time), first order release (log 10 total 
drug content-amount released vs time) and Higuchi-type kinetics (% cumulative 













Figure 44. Plot of % cumulative drug release against time with regression data for 
xanthan gum alone.
Xanthan






The first order and Higuchi models showed poor linear correlation but the zero order 
model results showed a linear relationship up to four hours at which time over 80% 
of the drug was released (Figure 44). This agrees with other reports of zero order 
release from xanthan matrices [332] [333],
The release from these tablets occurred over a relatively short space of time, although 
reports elsewhere have shown that release for some drugs can be extended for over 
12 hours. The rapid rate observed here may be due to the large surface area to 
volume ratio of the tablet used (lOOmg tablet, 8mm diameter, 2mm thickness), 
allowing a high percentage of the drug to be released from the surface immediately 
on contact with the dissolution fluid before the polysaccharide excipient is able to 
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Figure 45. Changes in shear rate displayed by 0.25% xanthan solution compared to a 
0.25% xanthan / locust bean gum solution. Conditions : Cone with 4.0cm 
diameter and a cone angle of 2 °, 25 °C temperature and a shear stress 
sweep from OPa to lOPa.
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The rheograms in figure 45 illustrate time dependant behaviour of very dilute 
solutions of xanthan and xanthan / locust bean gum mixtures and show that when the 
material is subjected to a shear stress the viscosity decreases with time.
A common feature of these materials, if they are subjected to a gradually increasing 
force followed by a gradually decreasing force, is a hysteresis loop where the down 
curve is displaced to the left of the up curve. This is characteristic of plastic and 
pseudoplastic materials. The hysteresis loop indicates that a breakdown in structure 
occurs and the area of the loop indicates the degree of breakdown. This is often 
described as thixotropy which literally means "to change by touch" and any material 
which exhibits a reversible time dependant decrease in the apparent viscosity is 
generally described as thixotropic. Thixotropy is usually exhibited by systems which 
are capable of forming numerous secondary bonds, in a loose three dimensional 
structure of entangled macromolecules so that the material is gel-like when 
unsheared. The shear energy which is passed to the system disrupts the bonds, the 
macromolecules become aligned and the viscosity falls as a gel-sol transformation 
occurs. Often when the shear stress is removed the structure reforms slowly and 
viscosity increases with time. The molecules move and re-entangle by a process of 
Brownian motion.
A useful measure of thixotropy can be obtained by integration of the area contained 
within the loop however to fully describe a result, an estimate of the area is 
accompanied by a yield value as the area does not take into account the shape of the 
curves. As we see the xanthan and the xanthan / locust bean gum both display the 
hysteresis loop indicating the existence of a three dimensional structure. In the 
xanthan / locust bean gum combination the area of the hysteresis loop is greater 
indicating that the bonds formed in this gel are of a stronger more complex nature. 
The yield value of the xanthan / locust bean gum sample is also higher at 5.932Pa 
compared to 1.525Pa for xanthan alone, which also indicates the formation of a
112
stronger gel requiring a greater shear stress to begin the sample moving. At the peak 
shear stress of lOPa for the polymer combination, the shear rate is 404.2 Vs but 
unusually the shear rate continues to increase when the shear stress is decreasing. 
Possibly this is due to the momentum of the system which means there is a continual 
acceleration until a peak shear rate of 638.0 Vs at a stress of lOPa. There could also 
be a continuing increase in the shear rate as the structure breaks down and the 
polymers become aligned in the direction of movement. The solutions used in these 
studies were 0.25%w/v concentration and represent the most dilute form of the 
swollen polymers. In the tablet form the swollen controlling gel layer is very 
concentrated and the behaviour in the two situations may be very different. This will 
largely occur because of sterically driven interactions which limit the degrees of 
freedom for molecular re-orientation and therefore influence the rate of formation 
and disruption of the gel network. However, other factors such as the structure of 
water and solution phenomena are also considered likely to contribute to a variation 
in the Theological properties of these systems as the solids concentration increases.
3.1.4. Gel swelling studies.
The images shown in figures 46, 47 and 48 show visually the behaviour of the tablets 
when they are in contact with the dissolution fluid. The tablet produced from the 
polymer combination formed a strong, resilient gel which remained intact on the pin 
at 3 hours. Xanthan tablets wet and swell (Figure 47) and the gel is resilient enough 
to maintain some integrity up to 3 hours. At this point the hydrated mass collapsed 
onto the support. The xanthan / locust bean gum combination swells more slowly 
and to a lesser extent (Figure 46) then xanthan alone and maintains its integrity in 
excess of four and a half hours (Figure 59). This behaviour relates to the stronger gel 
formed by the combination and the slower rate of dissolution of xanthan from the 
combination. The locust bean gum images support the release behaviour shown by 
the dissolution data in figure 43. As the tablet comes into contact with water, the 
locust bean gum molecules expand and the tablet immediately disintegrates leaving
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the pin empty. The behaviour of the locust bean gum alone suggests that it could be 
useful as a disintegrating agent in conventional tablet formulations.
Time: 0 minutes. Time : 1 hour 30 mins. Time : 3 hours.
Figure 46. Swelling profile of xanthan / locust bean gum tablet in distilled water.
Time: 0 minutes. Time : 1 hour 30 mins. Time : 3 hours.
Figure 47. Swelling profile of xanthan gum tablet in distilled water.
Time: 0 minutes. Time 5 minutes
Figure 48. Swelling profile of locust bean gum tablet in distilled water.
3.1.5. Discussion
Xanthan shows a limited ability to produce zero order sustained drug release by 
producing a slowly hydrating and dissolving polymer mass. The locust bean gum has 
no ability to produce controlled release and disintegration of the compacts occurs 
immediately on contact with fluid. The elastic nature of the locust bean gum dictates 
the tablets produced from the polysaccharide combination alone are weak at lkp.
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The rheology study shows the xanthan molecules are capable of forming secondary 
bonds and a three dimensional network which breakdown on application of shear 
stress. The swelling behaviour of the xanthan and the disintegrating action of the 
locust bean is confirmed by the visualisation study. The xanthan is shown to expand 
and breakdown more quickly than the combination of the two polysaccharides. The 
combination of the two polysaccharides produces a system where the characteristics 
of each of the contributing polymers are modified. The indications are that a firmer 
more resilient gel is produced by the combination. This theoretically should slow 
down drug release.
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3.2. Binary Component Controlled Delivery.
In this section the physicochemical characteristics of tablet formulations containing 







Figure 49. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and granulated xanthan alone as tablet 
excipients. Conditions : 37°C, in distilled water using the paddle 
dissolution method; model drug - benzamide.
Figure 49 shows the release of the model drug benzamide from a combined xanthan / 
locust bean gum tablet in comparison with release from a tablet containing xanthan 
gum alone as the excipient. The results show that at 15 minutes the xanthan tablet 
has released significantly less than the combination. This is due to the rapid hydration 
of xanthan on contact with water, due to its high solubility, preventing the initial 
burst of release shown by the combined polysaccharides. The initial burst of drug 
release is a frequently found feature of hydrophilic release systems [334].




In the combination of xanthan / locust bean gum, it appears that viscolyzation takes 
longer due to the presence of the locust bean gum but that when eventually formed, 
the true gel is more efficient as a controlled release system than the pseudo-gel 
formed by xanthan alone. The significant difference in the time for 50% of the drug 
to be released from the gel shows us that the xanthan alone allows the drug to escape 
at a much faster rate than any of the combinations. It is thought that xanthan 
dissolution is slower from the combination than when alone, due to the bonds 
forming a firmer more resilient gel structure. It is postulated that the presence of 
bonds may delay the hydration of the combined gums and so delay the dissolution of 
the xanthan thus slowing the breakdown of the gel.
Xanthan Gum Tablet 
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Figure 50. Graph of % dissolution per 15 minutes versus time of a granulated 
xanthan/locust bean gum tablets of differing xanthan/locust bean gum ratios 
as tablet excipients. Conditions : 37°C, in distilled water using the paddle 
dissolution method; model drug - benzamide.
Figure 50 shows the effect of altering the ratio of xanthan to locust bean gum. It has
been widely reported that altering this ratio changes the rheological characteristics of
the gel formed and this has been examined in the rheology work (Figure 56). Later in
the dissolution study, the effect of the ratio of xanthan to locust bean gum on the rate
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of release of the drug is examined. At 15 minutes the slowest releasing formulation 
was the xanthan alone which as previously stated is due to the rapid formation of the 
gel layer around the surface. The other results are all significantly faster than the 
xanthan alone, showing the characteristic "burst effect" at 15 minutes indicating that 
the locust bean gum initially slows the formation of an efficient controlling gel. For 
the release of 50% of the drug there is no significant difference in the 1:1 and 2:1 
however there is with the 3:1 which suggests the there is efficient formation of a 
strong gel up to a ratio of 3:1 with the large proportion of xanthan forming a gel 
quickly and then producing a durable gel and extending the release. At a ratio of 4 :1 
the locust bean gum is less effective and the efficiency is decreased as the xanthan 
then dissolves away more rapidly.
1 6 -
1 4 -
Xanthan /  Locust Bean Gum 1:1 Ratio 
Xanthan/Locust BeanGum2:l Ratio 
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Figure 51. Graph of % dissolution per 15 minutes versus time of a granulated 
xanthan/locust bean gum tablets of differing xanthan/locust bean gum ratios 
as tablet excipients. Conditions : 37°C, in distilled water using the paddle 
dissolution method; model drug - benzamide.
The optimum ratio for gel formation confirmed by the viscosity studies is 1:2
(xanthan/locust bean gum). It was initially assumed that increasing the strength of
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the gel would impede diffusion and slow the release, and therefore the strongest gel 
would produce the best extended release tablets. Figure 51 shows initially the 1:2 
ratio releases at a much faster rate, which suggests that the formation of a gel which 
is efficient in terms of extending the release profile maybe much slower at this ratio. 
The T50 is reached more quickly also which suggests the gel formed by this 
combination may be "stronger" but is less efficient. From figure 50 and 51 it appears 
that for dissolution the most efficient gel is formed at ratios between 1:1 and 2:1 
xanthan / locust bean gum.
In this study we compare the behaviour of the xanthan : locust bean gum combination 
with other similar polysaccharide combinations.
Figure 52. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and granulated xanthan/tara gum tablets 
and a combination of all three as excipients. Conditions : 37°C, in distilled 
water using the paddle dissolution method; model drug - benzamide.
Figure 52 shows how the release behaviour of the gel is affected by the use of a 
different galactomannan. In the first 15 minutes the formulations containing locust
Xanthan: Locust Bean Gum, 1:1 Ratio 
Xanthan : Locust Bean: Tara Gum, 1:1:1 Ratio 
Xanthan: Tara Gum, 1:1 Ratio
Time (Hours)
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bean gum show significantly greater release than the formulation with tara gum and 
xanthan alone. This is possibly due to the more soluble nature of the tara gum giving 
greater molecular mobility which means that gel formation is quicker than the locust 
bean gum formulation, however the locust bean gum containing formulations have 
much slower T50's which again show the more durable and controlling nature of the 
xanthan / locust bean gum combination. In an attempt to produce bimodal release, 
the tara gum was incorporated with the other two polymers, to produce a gel 
network of xanthan cross-linked with two different galactomannans. This, however 
appeared to reduced the efficiency of the locust bean gum and did not produce the 
desired change of profile.
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Figure 53. Graph of % dissolution per 15 minutes versus time of a granulated 
xanthan/locust bean gum tablets compared to xanthan granulated with 
other polymers as tablet excipients. Conditions : 37°C, in distilled water 
using the paddle dissolution method; model drug - benzamide.
Two dissimilar polysaccharides, agarose and /c-carrageenan were studied in 
combination with xanthan gum and the dissolution behaviour compared with that for 
xanthan / locust bean gum (Figure 53). Neither of the non-galactomannan
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polysaccharides produced controlled release formulations in combination with 
xanthan unlike the veiy efficient xanthan / locust bean gum system. Indeed both 
agarose and x-carrageenan containing systems were found to cause the compact to 
disintegrate immediately on contact with the dissolution media. This was considered 
due to polymer expansion on contact with the fluid being similar to the action of the 
disintegration agent, starch, used to break up compacts of immediate release 
formulations. This further indicates that the modification in the disintegrating action 
of locust bean gum was probably due to a physical process occurring when combined 
with xanthan gum. The process is thought to be bond formation.
To investigate the influence and importance of processing factors on drug release rate 
and profile, the model drug was blended into the polysaccharides and then wet 
granulated instead of dry blending with dried polysaccharide granules. The result of 
this was a reduction in T5 0  from the internally incorporated drug within the 
granulated matrix (Figure 54).
The solubility of drug in the granulating media means the drug can dissolve and 
produce a large surface area for redissolution as the granulation dried. This 
processes will also lead to an even distribution of drug within the matrix allowing 
diffusion as the gel is formed. Where the drug is dry blended the gel may form 
around areas of drug, locking it into a pocket and thereby slowing the diffusion 
process. Unless otherwise stated the model drugs were incorporated into the 
matrices by dry mixing so that the polysaccharides potential for use as direct 
compression controlled release excipients could be evaluated.
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1 0 - Denzamide blended with dry granules. 
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Figure 54. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet dry blended and granulated with model 
drug. Conditions : 37°C, in distilled water using the paddle dissolution 
method.; model drug - benzamide.
3.2.2. Rheometry.
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Figure 55. Rheogram of flow behaviour displayed by 0.25% xanthan solution 
compared to a 0.25% xanthan / locust bean gum solution and a 0.25% 
xanthan / K-carrageenan solution. Conditions : Cone with 4.0cm diameter 
and a cone angle of 2°, 25 °C temperature and a shear stress sweep from 
OPato lOPa.
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It can be seen from figure 55 that not all combinations of xanthan with other 
polymers exhibited the large increase in hysteresis loop area that results from the 
formation secondary bonds like that of xanthan / locust bean gum. Xanthan / k -  
carrageenan shows a very similar shaped loop to the xanthan solution alone and there 
is for example, no discernible increase in structure or strength due to the combination 
with carrageenan.
The effect of individual polysaccharide ratios on the rheological characteristics of 














Figure 56. Rheogram of flow behaviour displayed by 0.25% xanthan / locust bean 
gum solutions with differing xanthan / locust bean gum ratios. Conditions : 
Cone with 4.0cm diameter and a cone angle of 2°, 25°C temperature and a 
shear stress sweep from OPa to lOPa.
The peak shear rate of the xanthan / locust bean at a ratio of 1:2, was found to be the 
smallest of all, indicating that this gel was the strongest. However the yield value 
was also slightly lower. As the proportion of locust bean increased, the gel strength 
was found to decrease. The area of the thixotropic loop for the 1:2 ratio of 
xanthan/locust bean gum was much smaller than the loop areas for the other samples.
Xanthan : Locust Bean 1:1 Ratio 
Xanthan : Locust Bean 1:2 Ratio 
Xanthan : Locust Bean 1:3 Ratio 
Xanthan : Locust Bean 1:4 Ratio 
Xanthan : Locust Bean 1:5 Ratio
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This indicates that under these conditions this gel is less prone to the structural 
breakdown possibly because of the stronger nature of the gel formed.
Other studies suggest that changes in viscoelasticity also occur as a result of changes 
in the xanthan / locust bean gum ratio. Tako et al. showed in a viscoelasticity study 
that the elastic component, G’, was at its greatest at a xanthan : locust bean ratio of 
1:2 which they attribute to bond formation being at its maximum [335]. Mannion et 
al. examined the effect on the G' (elastic component) and the G" (the viscosity 
component) of increasing the xanthan concentration from nothing to a ratio of 1 :1  
with locust bean gum. In the study, the elasticity, G', increased to a peak at a 
concentration 7:3 xanthan : locust bean gum but altering the ratio had no effect on 
the viscosity component, G". This effect of this change on the drug release 
characteristics for ibuprofen was then examined and they concluded that the release 
was modulated by the strength of the gel rather than the viscosity of the surface gel 
layer [336]. This would explain why initially the matrix although swollen is less 
efficient as a controlled drug release matrix but efficient once a strong gel structure is 
formed.
The time-dependant nature of these gel structures is also a potentially important 
functional characteristic. Figure 57 shows the effect of repeatedly shearing a xanthan 
locust bean gum solution using a different rest time between runs. It can be seen that 
after only five minutes rest the solution will still produce a hysteresis loop meaning 
that some of the structure has reformed and the macromolecules have become re- 
entangled, although the loop is not superimposable on the initial shear loop. After 15 
minutes rest we can see that the solution is beginning to reform the structure that the 
gel prior to initial shear possessed, increasing the peak viscosity and the area of the 
loop. This is possibly due to the re-formation of structure which relies on not only 
the physical entanglement of the molecules but also the time based re-formation of 
intermolecular bonds when the chains have been allowed to come into static contact.
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Figure 57. Rheogram of flow behaviour displayed by 0.25% xanthan / locust bean 
gum solutions after repeatedly shearing following differing recovery times. 
Conditions : Cone with 4.0cm diameter and a cone angle of 2°, 25°C 
temperature and a shear stress sweep from OPa to lOPa.
Figure 58 shows another polymer combination, xanthan with /c-carrageenan, which 
was repeatedly sheared with a rest period between. The thixotropic loop was still 
apparent although the structure which was lost on initial shearing, was found to 
reform rapidly (less than 5 minutes).
This suggests that the structure being lost is mostly due to entanglement of the 
molecules and less dependant on bond formation. After shearing, the molecules 
when at rest, move and re-entangle by Brownian motion. As previously suggested, if 
the gel structure relies on entanglement and bond formation then re-establishing the 
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Figure 58. Rheogram of flow behaviour displayed by 0.25% xanthan / /c-carrageenan 
0.25% solutions after repeatedly shearing following differing recovery 
times. Conditions : Cone with 4.0cm diameter and a cone angle of 2°, 25° 
C temperature and a shear stress sweep from OPa to lOPa.
3.2.3. Gel swelling studies.
This semi-quantitative study was carried out using a xanthan / locust bean gum tablet 
to investigate swelling over a 4^2  hour period (Figure 59), in distilled water. 
This allowed visual observations of the process taking place during dissolution; 
images were recorded using a digital imaging system.
On contact with the dissolution fluid, the surface of the tablet immediately hydrated 
and rapidly produced a relatively large increase in dimensions. As the study 
progressed the dilute outer gel layer of dissolving polymer, was visible as a "halo" 
around the tablet. This is not thought to be involved in the control of drug 
dissolution. This relies on the more concentrated gel layers below which are 
progressively established as the dissolution medium penetrates the tablet.
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Image 1 : Dry 
Tablet. Time 0 
minutes
Image 5 : Wet 
Tablet. Time 
15 minutes
Image 9 : Wet 
Tablet. Time 1 
lour 15 min.
Image 13 : Wet 
Tablet. Time 2 
lour 15 min.
Image 17 : Wet 
Tablet. Time 3 
hour 15 min.
mage 6  : Wet 
Tablet. Time 
30 minutes
Image 10 : Wet 
Tablet. Time 1 
hour 30 min.
Image 14 : Wet 
Tablet. Time 2 
hour 30 min.
Image 18 : Wet 
Tablet. Time 3 
hour 30 min.
Image 15 : Wet 
Tablet. Time 2
Image 19 : Wet 
Tablet. Time 4 
hour 30 min.
Image 3 : Wet 
Tablet. Time 5 
minutes
Image 7 : Wet 
Tablet. Time 
45 minutes
Image 11 : Wet 
Tablet. Time 1 
lour 45 min.
Image 4 : Wet 
Tablet. Time 
1 0  minutes
mage 8  : Wet 
Tablet. Time 1 
lour.
Image 12 : Wet 
Tablet. Time 2 
hours.
Image 16: Wet 
Tablet. Time 3 
hours.
Image 2 : Wet 
Tablet. Time 0 
minutes
Figure 59. Images of swelling xanthan / locust bean gum tablet over a four and a half 
hours in distilled water, at 37°C with continuous agitation.
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As previously reported xanthan alone swells rapidly indicating a gel which is more 
readily hydrated and eroded than the xanthan : locust bean gum combination (figure 
46 and 47). Dissolution would be predicted to be more rapid over an extended 
period through this type of gel structure and was shown to be so in figure 49. The 
xanthan/locust bean gum tablet above was found to increase to over 400% its original 
depth and 4320% its original volume but still remain a cohesive mass after 3 hours 
which is a factor in achieving controlled drug release (Figure 60). The diameter 
increases to over 150% of the original which is a larger increase than would be 
expected. This is thought to be due to the poor compression characteristics of the 
xanthan : locust bean gum combination and the weakness of the resulting tablets 
allowing greater radial expansion.
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Figure 60. Percentage increase in the dimensions of a swelling xanthan / locust bean 
gum tablet in distilled water.
3.2.4. Scanning electron microscopy.
The scanning electron micrographs shown in figures 61 and 62 show examples of 
typical particles formed during the granulation process. The granulated particles as 
expected are also much larger and more regular in shape than the original component
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particles (after screening to remove the oversized material in order to improve the 
flow and the compression characteristics)
Figure 61 Electron micrograph of xanthan / locust bean gum 1.1 granules
Figure 62 Electron micrograph o f xanthan / locust bean gum granules
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Xanthan and locust bean gum particles have become wetted and combined to 
produce more spherical particles than the individual component particles. This aspect 
is also important because the surface porosity of each agglomerate is lower than the 
equivalent apparent porosity of a homologated particle blend. The surface porosity 
and unit bulk density are likely in some way related to the diffusive release 
characteristics of drugs from such matrices. For example, there are clearly visible 
pores and cracks in the granular material which may aid water penetration into tablets 
during dissolution.
3.2.4.1. Environmental scanning electron microscopy.
Figures 63, 64, 65, 66 and 67 all show environmental scanning electron micrographs 
of both the surface and cross sections of a xanthan locust bean gum tablet in the dry 
and wetted states. It should be emphasised that the ESEM specimens shown were 
imaged live and did not require replica imaging through gold coating or other means 
to improve the conductivity as normally required. For this reason the specimen could 
be wetted in situ in the imaging chamber, and in real time.
Figure 63 Environmental scanning electron micrograph o f dry xanthan / locust bean
gum tablet surface.
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Figure 63 shows the flattened and smooth areas of the tablet surface where the 
polymer appears to be solid and fused as a result of ductile flow occurring during the 
compression process. Defects and cracks can also be seen at grain boundaries and 
these offer the possibility of fluid penetrating into the tablet core on initial wetting
Figure 64 shows the dry interior of a tablet revealed by diametral fracture, together 
with pores present in the interior which may allow fast fluid penetration deep into the 
tablet. However, ESEM studies of wetted gels suggest that these cracks are quickly 
sealed when the gel is formed across the surface but until this gel is fully formed and 
controls the hydration of the sample, the pores may fill with fluid.
Figure 64. Environmental scanning electron micrograph of dry xanthan / locust bean 
gum tablet fracture surface
In figure 65 the tablet surface was exposed to water within the vacuum chamber of 
the ESEM Instantaneously as the gums came into contact with fluid, a smooth 
surface of gel formed across the wetted surface of the tablet It was possible to 
observe this process, using the ESEM in real time, with the tablet in situ This gel
layer will form a barrier across the surface preventing any further rapid ingress of 
water and becomes a factor in the control of drug release
Figure 65 Environmental scanning electron micrograph of wet xanthan / locust 
bean gum tablet surface showing some pores.
Figure 65 also shows pores formed in the surface of the gel which may allow water to 
penetrate further into the glassy core of the tablet at a faster rate than through the 
surface gel barrier. In effect, such pores may act as shunt routes through which 
solvent-solution exchange can occur more rapidly by by-passing diffusional transfer 
across gelled structures This has been studied more extensively in section 3.2.6. 
below
In figure 66 and 67 the wet / dry interface was exposed in cross section. This was an 
attempt to visualise any intermediate structures which may be formed during the 
gelling phase, in the hydrated layer and during the processes by which the polymer 
wets and the gel forms. The electron micrographs clearly show the smooth wetted 
areas and the dry glassy polymer The two adjacent regions appear distinct and
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discrete and there does not appear to be a third junction or transition layer between 
the two
Figure 66 Environmental scanning electron micrograph of wet xanthan / locust bean 
gum tablet in cross section.
Figure 67 Environmental scanning electron micrograph o f wet xanthan / locust bean
gum
m
It should be noted that the tablet cross-sections were obtained by breaking the wetted 
tablets as the holder was removed, but this meant that the tablets were likely to break 
down the weakest lines through the tablet and gel structure. This would mean that 
the break would be along the hydrated material and any internal structure or 
unhydrated material could be hidden by the smooth gel surface For this reason, a 
cryogenic SEM method was developed as a way of freezing liquid in the wetted 
tablet core and preventing any further ingress of water at any selected point 
Subsequent cross sectioning of the sample was carried out in order to show all the 
layers that may have been present without causing damage to the sample in the 
process.
3.2.4.2.______ Cryogenic scanning electron microscopy.
Figure 68 shows the dry xanthan / locust bean gum tablet, frozen in liquid nitrogen 
and visualised on the cryogenic stage of the SEM. In the dry frozen state it has the 
glassy porous structure already observed in the ESEM's samples after cross section.
Figure 68 Cryogenic scanning electron micrograph o f a dry xanthan / locust bean
gum tablet frozen at -130°C in liquid nitrogen at low magnification.
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Figure 69 shows the frozen wetted tablet in low magnification, sectioned laterally. 
Clearly visible and exposed are a central dry core and a smooth frozen layer of gel at 
the surface. A third region in between the two already identified is also apparent. It 
has already been proposed that a third, partially hydrated layer exists in hydrated 
material [337],
Figure 69. Cryogenic scanning electron micrograph of a wet xanthan / locust bean 
gum tablet frozen at -130°C in liquid nitrogen showing the interface 
between the wet and dry layer
Increased magnification in figure 70, 71 and 72 shows the honeycomb structure 
typical of hydrated matrices and indicates the presence of water in the structure The 
honeycomb is formed when the water freezes and forms ice crystals within the 
polymeric material. The more hydrated areas at the surface are clearly identified by 
large cavities in the structure. It is important to realise the honeycomb structure 




Figure 70. Cryogenic scanning electron micrograph of a wet xanthan / locust bean 
gum tablet frozen and fractured, at -130°C in liquid nitrogen showing the 
interface and possible dry islands of unwetted material within hydrated 
material
BATHU
Figure 71. Cryogenic scanning electron micrograph of a wet xanthan / locust bean 
gum tablet frozen at -130°C in liquid nitrogen showing the interface and 
possible dry islands of unwetted material within hydrated material
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Figure 72 Cryogenic scanning electron micrograph of a wet xanthan / locust bean 
gum tablet frozen at -130°C in liquid nitrogen showing the interface and 
possible dry islands of unwetted material within hydrated material.
As we move away from the surface the gel is shown by a smaller honeycomb 
structure but within this hydrated material there are solid looking areas which do not 
have the characteristic ice crystal formation suggesting that these are dry areas within 
the gel structure. Figure 72 shows one of these "dry islands" in close up. It is also 
seen that the frequency of the dry islands increases closer to the centre of the tablet 
indicating that a slow process of wetting is occurring and that they hydrate slowly.
3.2.4.3. Freeze-dried scanning electron microscopy.
In order to confirm the structures identified within the frozen hydrated tablet another 
method was developed to ensure the "dry islands" were not an artefact of the 
cryogenic processing After freezing in liquid nitrogen the water was removed by 




Figure 73. Scanning electron micrograph of a wetted xanthan / locust bean gum 
tablet frozen at -130°C in liquid nitrogen, fractured and freeze-dried 
showing the wetted and dried layers.
Figure 74 Scanning electron micrograph of a wetted xanthan / locust bean gum 
tablet frozen at -130°C in liquid nitrogen, fractured and freeze-dried 
showing the wetted and dried interface
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Figure 75 Scanning electron micrograph of a wetted xanthan / locust bean gum 
tablet frozen at -130°C in liquid nitrogen, fractured and freeze-dried 
showing the existence of a third layer with dry islands of gums
Figure 76 Scanning electron micrograph of a wetted xanthan / locust bean gum 
tablet frozen at -130°C in liquid nitrogen, fractured and freeze-dried 
showing the dry islands of polysaccharide
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In figures 73, 74, 75 and 76 the honeycomb structure formed by the ice crystal 
formation is still visible after freeze-drying and more importantly these studies 
confirm the previous findings, that there are solid, non-hydrated areas within a 
partially hydrated matrix and these "islands" of glassy gum matrix wet out at a slower 
overall rate. This has implications for the release profiles obtained and why this 
material is effective as a controlled release excipient and the way that the water 
penetrates through the gel to the core.
3.2.5. Electron spin resonance studies.
The spin labels selected for study here together with xanthan / locust bean gum 
controlled release formulations, produce different spectra depending on the physical 






Figure 77. TEMPO dissolved in 1:1 tetrahydrofuran and dimethylformamide 
mixture.
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Figure 77 shows the spectrum of TEMPO dissolved in 1:1 tetrahydrofuran and 
dimethylformamide mixture. The characteristic spectrum of three equidistant lines of 
similar intensity is produced by the nitroxide radical freely spinning in any rotation 
without hindrance, because the TEMPO molecule is unassociated in solution.
Figure 78 shows a characteristic immobile spectrum where the spin label is dissolved 
in the same 1:1 tetrahydrofuran and dimethylformamide mixture and then frozen to 
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Figure 78. TEMPO dissolved in 1:1 tetrahydrofuran and dimethylformamide mixture 
and then frozen to 77K using liquid nitrogen.
The spin label is firmly immobilised within the glass and well distributed within the 
solid. These two figures show the standard spectra obtained for a spin label moving 
in solution and when immobilised in a solid.
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In figures 79 and 80, the spin labels, TEMPO and TEMPOL, are granulated together 
with xanthan and locust bean gum. They show differences in the spectra with the 
TEMPO more closely resembling the freely moving solution spectrum whilst the 
TEMPOL resembles the solid spectra. The influence of the molecular composition is 
investigated further in section 3.4. However, we can see that a solution spectrum is 
formed with TEMPO added in the granulating fluid. This indicates the residual 
micellar water may be associated with the polysaccharide components of the matrix. 
Attempts to remove the residual water by extensive and aggressive drying to constant 
weight failed to affect the spectra and suggests that the water is firmly bonded to the 
polysaccharide components.
The presence of such firmly bonded water is a feature of many pharmaceutically 
relevant polysaccharides such as microcrystalline cellulose and starch [338]. The 
effect of the drying process is further investigated in Section 3.3.5, where the 
polysaccharides were combined with dextrose.
Spin label associated with water
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Figure 80. ESR profiles of TEMPOL with a xanthan / locust bean gum 
polysaccharides.
3.2.6. Magnetic resonance studies.
Magnetic resonance studies have given a view of the water distribution within the 
wetted gelling tablet. A magnetic resonance image of the xanthan / locust bean gum 
tablet is shown in figure 81. From the microscopy studies, it was shown that the 
tablets were porous with channels which appeared to penetrate the tablet core.
On contact with water the polymer, T2 is immediately modified (shortened) and 
becomes distinct from the bulk water. These regions have been assigned a warm 
false colour and are imaged as red zones. The dark band at the right of the picture 
has been given cool false colours of blue or black and correspond to the glassy 
matrix. The warmer colours correspond to the shorter T2 of the less mobile water 
bonded to the hydroxyl groups on the polymers.
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Image 1 Time 10 minutes Image 2: Time 1 hour 50 min.
Image 3: Time 3 hours 50 min Image 4: Time 4 hours 20 min
Image 5 Time 24 hours
Figure 81 Map of T2 for xanthan / locust bean gum 1:1 tablet swelling in distilled 
water
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On contact with the dissolution fluid the material at the surface wets and any drug 
dissolves to produce the initial burst of drug release. As the polysaccharides hydrate 
and swell, the water interacts more strongly and becomes less mobile and this is 
visible as the gel layer on the tablet surface. Clearly visible are red pores of hydrated 
material penetrating through the dry glassy core of polymer. This information from 
the internal matrix structure is consistent with surface optical image analysis carried 
out earlier. As time progresses the hydration process continues and what becomes 
very clear is that the tablet wets and hydrates unevenly through the tablet. This is 
consistent with the theory that "dry islands” exist in the gel, based on cryogenic and 
freeze-dried scanning electron microscopy studies. The MRI study shows 
inhomogeneities still exist throughout the gel after 24 hours.
The gel layer formed initially at the surface is thought to be the rate controlling 
diffusion barrier at least during the early period of drug release. However, it is 
considered likely that the uneven wetting contributes to the extension of drug release 
at later periods by glassy polymer becoming trapped in a shell of hydrated 
polysaccharide thus preventing the further ingress of dissolution fluid and slowing the 
drug dissolution rate. At much later time it is thought that drug trapped in these 
islands becomes available and contributes to release towards the end of dissolution.
3 .2 .7 Thermodynamic studies.
The microcalorimetry studies were done to examine the energy released or absorbed 
during the process of drug release from the polysaccharide alone tablets. One of the 
problems with the method is that there is an equilibrium period of 15 minutes at the 
beginning of each experiment. This is a vital period of wetting of the polysaccharides 
and will involve major changes in the energy levels of the system. Thus in order to 
obtain quantitative information concerning heats of wetting, for example, during this 
initial period the method requires modification. After this initial period the 
calorimeter records all the energy absorbed or released by the system.
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Figure 82 shows that there is a burst of energy released at ten hours which is thought 
to result from the polymers becoming fully hydrated and the gel breaking down as 
xanthan dissolution begins occurring. There is also a continuous plateau over a thirty 
two hour period corresponding to a continued energy output which drops away 
possibly as dissolution process is exhausted following wash-out of soluble 
components. Bakri et al. in studies on swelling and drug release from HPMC 
matrices found that the exothermic swelling process occurred between 0.5 and 3 
hours, much faster than with xanthan/locust bean gum matrix, and that there was no 
detectable heat release between 3 and 8 hours [339].
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Figure 82. Energy released by the xanthan / locust bean gum (1:1 ratio) granules 
swelling in distilled water.
The effect of third component materials, ions, on this energy release, is examined by 
this method in section 3.3.6.
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3.2.8. Discussion.
Dissolution and rheological studies indicate an increase in hydrogen and/or ionic 
bonding between interacting heterodisperse polysaccharide molecules, which 
increases the gel strength but does not delay the rate of drug release. Such bond 
formation is very specific to polysaccharide molecule type. Thus, xanthan gum does 
not modify the behaviour of other polysaccharide materials such as acacia, 
carrageenan, tara etc., which have similar physical characteristics to locust bean gum. 
The repeated shear experiment demonstrates the formation of secondary bonds which 
appear to be specific to the xanthan / locust bean gum combination and may be 
implicated in the improved long term diffusion control evidenced in xanthan / locust 
bean gum gels in comparison with other polysaccharide combinations which may rely 
on mechanical interlocking as a means of viscolyzation.
Combining xanthan with tara, another galactomannan, also produced controlled drug 
release, but not as successfully as the locust bean gum, probably due to the higher 
galactose content o f the tara which may interfere sterically with the interaction 
between adjacent polysaccharides. When the drug was granulated into the 
polysaccharides instead o f dry blended, the release rate was increased. This gives 
further information on the mechanisms controlling dissolution. The drug molecules 
when dry blended are held in macro-pockets surrounded by a gel barrier. When they 
are granulated into the polysaccharides the drug is dispersed at a molecular level and 
presents a large available surface area for dissolution and diffusion.
The various microscopies confirm that gel formation is quasi-instantaneous across the 
surface, on contact with fluid, although there are pores in the gel. The presence of 
these pores gives the possibility o f fluid crossing the gel barrier via a shunt route by 
hydrating small channels within the glassy core. These channels may then facilitate 
some drug dissolution from the core. This appears to be confirmed by magnetic
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resonance imaging studies where at 1 0  minutes, channels of hydrated material run 
deep into the tablet, connecting across regions of lower water mobility.
The cryogenic study showed areas where hydrated and non-hydrated polysaccharide 
exist together. This is the gel glass transition area where the dissolution fluid is 
diffusing and hydrating the polymers and drug and then the drug is able to diffuse 
back through the gel. It is in this area it is possible to visualise the existence of 
pockets o f drug surrounded by a hydrated barrier which slows the dissolution and 
diffusion processes. This theory is supported by the MRI study which shows the gel 
hydration is inhomogeneous and uneven wetting occurs. Although the early effect of 
such inequivalent wetting may make drug more rapidly available from deeper in the 
compact, it also retains drug-loaded islands closer to the tablet surface and available 
for release later.
The ESR results show that some water is still present in the excipient even after 
vigorous drying, allowing the spin label freedom to tumble inside the excipient. The 
properties of the spin label also appears to influence the behaviour and this is 
investigated in section 3.4. The thermodynamic results indicate that at 10 hours an 
energy release occurs due to polymer dissolution and the effect o f third components 
on this dissolution process. However, the potential for such water-polysaccharide 
interactions to be modified by the presence of ternary (inert) agents was considered 
to be a potentially significant release modulating effect.
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3.3. Ternary Component Controlled Delivery.
3.3.1. Dissolution.
3.3.1.1. Ions.
The effect of ions was considered to be an important factor as it has been reported 
[335] that ions affect the rheological behaviour of xanthan / locust bean gum 
combinations and this is demonstrated later in Section 3 .3.2.
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Figure 83. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including salts, granulated 
with polysaccharide gums. Conditions : 37°C, in distilled water using the 
paddle dissolution method. Model drug : benzamide
In figure 83, the T50 was significantly shortened, by the presence of the sodium 
chloride, at half the T50 for xanthan / locust bean gum alone. There was no 
significant difference observed between KC1 or CaSC>4 Drug release shows a trend 
of being quicker with the smaller ions, Na+, and slower with the larger ions, Ca2+, 
but in all cases is significantly faster than the polysaccharide combination alone in 
water. It appears that the smaller ions may be able to penetrate between the polymer
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molecules and are attracted to the ionic groups present in the xanthan / locust bean 
gum matrix, which then interferes with the formation of hydrogen bonds by screening 
the bond sites and it is also possible that the xanthan can self-associate. Both these 
effects are likely to cause an increase in the release rate as the efficiency of gel 
formation will be compromised thus allowing the model drug an easier diffusion 
pathway, through larger pores containing less structured water
Time (Hours)
Figure 84. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including ionic species, 
granulated with polysaccharide gums. Conditions : 37°C, in distilled water 
using the paddle dissolution method. Model drug : benzamide.
Figure 84 shows the effect of sodium ions within the matrix. The T5q is significantly 
faster for the NaCMC than for the xanthan / locust bean alone. The formulation with 
NaCl has a faster release rate again. This is important as the aim of incorporating the 
NaCMC was to delay the T50 by incorporating another swelling polymer to provide 
instantaneous viscolyzation in pore spaces within the developing xanthan / locust 
bean gum gel. The result was the reverse, as with small ions, within the third 
component both additives, adversely affected the performance of the formulation in
Xanthan Locust Bean Gum 1:1 
Xanthan Locust Bean Gum NaCMC 10% 
Xanthan Locust Bean Gum NaCl 10%
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terms of extending the release time. It was assumed once again that this was in some 
way related to inhibition of the synergistic interaction between xanthan and locust 
bean gum.
Figure 85 shows a similar trend for additive effects on dissolution efficiency to that 
already demonstrated in figure 84. An increase in drug release rate was found to 
result from the inclusion of NaCl, although this effect was reduced by including 
another swelling polymer. Initially the release of the two formulations containing 
NaCl is the same, however once the carbomer became hydrated the release rate was 
significantly slowed and the T50 occurred significantly later than both the NaCl 
formulation and the xanthan / locust bean alone.
Xanthan : Locust Bean Gum 1:1 
Xanthan : Locust Bean Gum 1:1 
Carbcpd 934P 10%NaCl 10% 




Figure 85. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including ionic species 
and carbomer, granulated with polysaccharide gums. Conditions : 37°C, in 
distilled water using the paddle dissolution method. Model drug : 
benzamide.
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Figure 86 shows the effect that external ions in the dissolution fluid can have. The 
phosphate buffer used contains large amounts of potassium ions which have already 
been shown to increase the release rate when contained within the polysaccharide 
matrix and the T50 also occurred more quickly in the phosphate buffer than in 
distilled water. This again is possibly due to the ions interfering in the interaction 
between the polysaccharides or the polymers self-associating. Both these phenomena 






Figure 86. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablets, dry blended with benzamide as model 
drug. Conditions : 37°C, in distilled water, 0.5M ionic strength, phosphate 
buffer pH 6.9, using the paddle dissolution method. Model drug: 
benzamide.
Another important feature of this result is the impact the test method design may 
have on the results produced by the formulations. Visually it was possible to see the 
change in the behaviour of the polysaccharides. Instead of dissolving and dispersing, 
the polysaccharides remained intact and at the end of the 10 hour experiments the gel
Dissolution Fluid Water 




matrix was still present. This indicated that the gel was more stable and self­
association may have occurred preventing dissolution of the polymer. The reduced 
solubility of the polymer however did not improve the release rate and there was a 
reduction in the efficiency of the gel. In all cases the presence of ionic compounds 
accelerated release of the drug and appeared to compromise the efficiency of the 
controlled release attributes of the polysaccharides. It has been postulated earlier that 
the polysaccharide gel interaction is at least partly due to hydrogen bonding. Urea is 
known to disrupt hydrogen bonds between individual molecules and has been shown 
in this study to have significant influence on the rheological behaviour of the 
polysaccharides. This is discussed later in section 3.3.2.
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Figure 87. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including urea, granulated 
with polysaccharide gums. Conditions : 37°C, in distilled water using the 
paddle dissolution method. Model drug : benzamide.
Figure 87 shows the dissolution profiles comparing xanthan / locust bean gum tablets 
with the same formulation incorporating urea into the granule in an attempt to disrupt
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hydrogen bonding in the controlling gel. Urea does not appear to significantly 
influence the dissolution characteristics in this situation even though the urea was 
incorporated at the granulation stage where likely bond formation between the 
polysaccharides occurs. Although other studies have shown that urea has an 
influence on rheological characteristics, such changes in low solids content structures 
do not appear to compromise the efficiency of the gel as a controlled release 
excipient. It is considered that the molecular interactions at high solids content either 
remain unaffected by the urea or are affected but interact through the urea itself. At 
low solids contents, although an effect of urea is found, the drug release control is so 
low that no practical influence on release kinetics is seen.
3.3.1.2. Sugars.
Xanthan Locust Bean Gum 1:1
Xmthan Locust Bean Gum DeMrose 1:1:1
Xanthan Locust Bean Gum 1:1 Dextrose 50%
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Figure 88. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including dextrose, 
granulated with polysaccharide gums. Conditions : 37°C, in distilled water 
using the paddle dissolution method. Model drug : benzamide.
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Figure 8 8  shows the effect of incorporating dextrose into the formulation. The 
dextrose improves the compression characteristics of the excipient so that it produces 
a more robust and viable product. It is also thought to be a significant factor in 
influencing the type of dissolution profile produced by the tablet.
The most obvious effect that the dextrose has is to increase the wetting properties of 
the excipient due to the higher solubility of the dextrose. At the T5 0  it shows that the 
greater the quantity of dextrose the faster the release of the drug. This is probably 
due to the dissolution fluid penetrating the compact more quickly and thoroughly by 
dissolving the dextrose and allowing faster hydration of the polysaccharides deeper 
within the compact.
An excipient such as dextrose could normally be added to a formulation as a bulking 
agent which was less expensive than the polysaccharide components and give better 
compression characteristics. When attempting to achieve controlled release 
dissolution profiles, the faster hydration rate is not beneficial. In an attempt to offset 
the increased dissolution rate another swelling component was incorporated. The 
xanthan locust bean gum 1:1 dextrose 50% granules were dry blended with the model 
drug and a carbomer (Carbopol 934P) a swelling polymer to try to slow down the 
dissolution process.
The results are shown in figure 89 and the statistics show that the T5 0  is significantly 
delayed by the inclusion of the carbomer, and is slower than the two gums alone. 
This shows that it is possible to produce an excipient with good compression 
characteristics and still manipulate the formulation so that the disadvantages of 
including the dextrose can be offset and the desired dissolution profile achieved.
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Figure 89. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet including dextrose and carbomer (Carbopol 
934P) as tablet excipients. Conditions : 37°C, in distilled water using the 
paddle dissolution method. Model drug : benzamide.
Xanthan Locust Bean Gum 
Xanthan Locust Bean / Dextrose 50 /  50 
Xanthan Locust Bean / Sorbitol 50/50 
Xanthan Locust Bean / Xylitol 50/50
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Figure 90. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet including dextrose, xylitol and sorbitol as 
tablet excipients. Conditions : 37°C, in distilled water using the paddle 
dissolution method. Model drug : benzamide.
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In figure 90 we see the effect of using different sugars and agents on the dissolution 
characteristics of the xanthan and locust bean gum combination. The T50 for all of 
the third component containing formulations shows a significantly faster release 
profile when compared to the polysaccharide gums alone. This is again due to the 
greater solubility of the third components and the transport of dissolution fluid 
through the tablet matrix. There was however no significant difference between the 






Figure 91. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including pectin, sodium 
carboxymethylcellulose as tablet excipients. Conditions : 37°C, in distilled 
water using the paddle dissolution method. Model drug : benzamide.
Figure 91 shows the effect of incorporating pectin and sodium 
carboxymethylcellulose into the matrix to try to add new dimensions to the behaviour 
of the system in an attempt to extend the release profile and possibly achieve bimodal 
behaviour. In the case of both pectin and NaCMC the release rate was speeded up
-» Xantlian Locust Bam Gum 1:1
Xanthan Locust Bean Gum 1:1 Pectin 20%  
Xanthan Locust Bean Gum 1:1 NaCMC 10%
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and the T50 was achieved more quickly than with the gums alone. Both these 
polymers are known to absorb water and to form gels. In the case of NaCMC it was 
thought that the presence of sodium ions could have a bearing on the release profile 
accelerating the release rate of the drug into the dissolution media.
Pectin can form a gel but the presence of calcium ions is required to form the stable 
"egg box" gel structure. In the absence of calcium ions, pectin appears to allow 
faster penetration of the dissolution medium accelerating the dissolution rate and 
does not appear to form any bonds with the other polymers.
—• —  Xmthan Locust Bean Gum 1:1 
* Xanthan Locust Bean Gum 1:1 HPMC A  2% 
Xanlhan Locust Bean Gum 1:1 HPMC B 2% 
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Figure 92. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including 
hydroxypropylmethyl cellulose as tablet excipients. Conditions : 37°C, in 
distilled water using the paddle dissolution method. Model drug : 
benzamide.
Figure 92 shows the effect of hydroxypropylmethylcellulose (HPMC) of differing 
viscosity grades, as a third component, on the release of the drug. None of the 
viscosity grades of HPMC were found to exert a significant effect on the drug release
158
behaviour. However there is a very extensive range of HPMC's available and some 
of the others may have a more significant effect. Adjustments in the proportion of 
HPMC in the matrix and the grade could also be worthy of further study
Figure 93 shows the effect of incorporating the acrylic acid derivative carbomer into 
the formulations. Different grades of Carbopol® were selected to try to manipulate 
the release characteristics after the use of grade 934P was shown to delay release 
when granulated into the gums. Grade 971 was supposed to form a gel faster than 
the grade 934P and grade 161 is an ionic derivative which again has a greater 
solubility and forms a gel quickly. The carbomers were granulated into the gums and 
in later experiments dry blended with the xanthan / locust bean gum granules.
a— Xanthan: Locust Bean Gum 1:1
• Xanthan: Locust Bean Gum 1:1 Gaibopol934P 10%
Xanthan: Locust Bean Gum 1:1 Caibopol 97110%  
Xanthan: Locust Bean Gum 1:1 carbopol 161 10%
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Figure 93. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including several grades 
of carbomer (Carbopols 934P, 971 and 161), granulated with the 
polysaccharide gums. Conditions : 37°C, in distilled water using the 
paddle dissolution method. Model drug : benzamide.
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When the carbomer is granulated into the gums there is a significant delay in the T5 0  
for both Carbopol 934P and the Carbopol 171 formulations compared to the gums 
alone. Both grades form gels and are used in controlled release formulations, 
however there is a difference in these two carbomers in the way they hydrate and 
form gels. The 934P forms a "fuzzball" type of gel structure, whereas 97 IP forms a 
"fishnet” hydrated gel [193]. The fishnet structure is a more homogeneous gel and 
provides more resistance to diffusing molecules. The 934P gel contains larger 
interstitial spaces with low microviscosities which offers less resistance to diffusion. 
The 161 grade however does not show a significant difference to the xanthan locust 
bean gum. This is possibly due to the presence of sodium ions in the carbomer 
affecting the gel formation of the xanthan / locust bean gum.
Both grades 934P and 971 were found to produce more effective rate controlling gels 
than the xanthan / locust bean gums alone and this is a factor in the rate of release. 
As previously mentioned the carbomer molecules may have the capability o f forming 
hydrogen bonds with drug molecules and thus delay diffusion.
Figure 94 shows the effect o f dry blending the carbomer into the xanthan / locust 
bean gum granules. In this case the results for the T5 0  are very similar to the results 
for the granulated versions. Carbopol 161 does however in this case significantly 
delay the T5 0  but not to the same extent as the others. Carbopol 171 delays the 
release to the greatest extent. Again this effect could be due to the Carbopol gel 
forming in the spaces between the xanthan / locust bean gum gel increasing the 
resistance to diffusion for the drug. It may also be due to a more efficient gel being 
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Figure 94. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including several grades 
of carbomer (Carbopols 934P, 971 and 161), dry blended with 
polysaccharide gum granules. Conditions : 37°C, in distilled water using 
the paddle dissolution method. Model drug : benzamide.
To investigate whether it was more effective to granulate the carbomer into the gums 
or to dry blend them later a statistical comparison of the two methods was carried 
out. There was no significant difference in the results obtained by the different 
methods for use of either grade 161 or 934P, although in all cases the T50 was 
delayed most by dry mixing the carbomer.
This may suggest that the effectiveness of carbomer was greatest as a rapid 
viscolyzing material, capable of blocking shunt routes at grain boundaries. Thus 
grade 971 showed a significant delay in the T50 when dry mixed with the gum 
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re 95. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet including carbomer (Carbopol 934P), 
granulated and dry blended with polysaccharide gums. Conditions : 37°C, 




Figure 96. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet including carbomer (Carbopol 971), 
granulated and dry blended with polysaccharide gums. Conditions : 37°C, 
in distilled water using the paddle dissolution method. Model drug : 
benzamide.
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Figure 97. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including carbomer 
(Carbopol 161), granulated and dry blended with polysaccharide gums. 
Conditions : 37°C, in distilled water using the paddle dissolution method. 
Model drug : benzamide.
3.3.1.4. Surfactants.
The inclusion of surfactants such as, sodium lauryl sulphate and polysorbate 60 
(Tween 60) was found to have no significant effect on the behaviour of xanthan / 
locust bean gum controlled release kinetics (Figure 98). It was thought that the 
surfactants wetting properties could alter the rate of penetration of dissolution fluid 
and so change the release profile. In systems containing dextrose together with 
xanthan / locust bean gum polysaccharides, the addition of sodium lauryl sulphate has 
previously been shown to have some influence on release characteristics. However 
there was no significant differences in the release characteristics of the formulations 
studied here. This may have been due to an inherent lack of surfactant effect or else 
to the absence of appropriate conditions in this binary polysaccharide base 
formulation.
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Figure 98. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including surface active 
agents sodium lauryl sulphate and Tween 60, granulated with 
polysaccharide gums, as tablet excipients to delay release. Model drug : 
benzamide.
Stearic acid was included into the xanthan / locust bean gum formulation in an 
attempt to study the effect of retarding matrix wetting on drug release kinetics. It 
was considered that the hydrophobic nature of the stearic acid might alter the wetting 
and rate of penetration of the polysaccharide matrix. In the initial period up to 15 
minutes there was a significant reduction in the release rate found with inclusion of 
stearic acid into the formulation.
This is probably due to the water repellent behaviour of the stearic acid at the tablet 
surface delaying the initial influx of water into pores at grain boundaries. Once this 
had been overcome there was a levelling off and by the T50 the difference had been 
evened out and there was no significant difference in the release characteristics. This 
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Figure 99. Graph of % dissolution per 15 minutes versus time of a granulated 50/50 
xanthan/locust bean gum tablet and formulations including stearic acid, a 
hydrophobic agent, granulated with polysaccharide gums, as tablet 
excipients to delay release. Model drug : benzamide.
3.3.2. Rheometry.
3.3.2.1. Ions
The heterodisperse polysaccharide gels formed from the interaction between xanthan 
/ locust bean gum are usually not considered to be influenced by the pH of the 
system, however in this study the flow curves produced did appear initially, to be pH 
dependant. Figure 100 shows the flow curves produced at different pH's. Although 
this was not expected as a pH effect, it almost certainly resulted from an ionic effect 
noted earlier, explained when the influence of sodium chloride ions on the xanthan 
locust bean interaction was observed in the dissolution, swelling and rheology 
studies.
The potassium phosphate buffers used did not have the ionic strength controlled and 
so contained differing salt concentrations. The ionic strength it appears is a critical
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factor in the formation of the gel structure. This in turn can influence the drug 
release properties of the gel and the viscosity of the gel. In section 3 .3 .3. we also see 
the difference in the swelling characteristics of the tablets when in different ionic 
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Figure 100. Rheogram of flow behaviour displayed by 0.25% xanthan / locust bean 
gum 0.25% solutions with different pH buffers without controlled ionic 
strength. Conditions : Cone with 4.0cm diameter and a cone angle of 2° at 
25 °C temperature and a shear stress sweep from OPa to lOPa.
The flow curves in figure 101 show, the shear rate of xanthan / locust bean gum 
fluids, at any particular shear stress, is significantly increased if they contain sodium 
chloride. The effect appears to be to some extent concentration dependant with a 
peak viscosity spread occurring in 0.5 molar saline. This implies that the structure 
formed or the interaction occurring is interfered with or destroyed by the presence of 
the sodium ions. It has already been observed that the rate of drug dissolution is 
significantly increased by the presence of NaCl.
166
This again provides further circumstantial evidence that the ions may be having their 
effect by screening the ionic groups involved in forming the bonds between the 
polysaccharides so reducing the viscosity of the system.
O .lM N aC l 
0 .5M N aC l 
l.O M N aC l 
D is tille d  Water
Shear Stress (Pa)
Figure 101. Rheogram of flow behaviour displayed by 0.25% xanthan / locust bean 
gum 0.25% solutions with sodium chloride. Conditions : Cone with 4.0cm 
diameter and a cone angle of 2 °, 25 °C temperature and a shear stress 
sweep from OPa to lOPa.
Figure 102 shows the effect of urea on the viscosity of the xanthan / locust bean 
solutions. The peak shear rate achieved was initially increased but as the 
concentration of urea increased, the peak shear rate decreased which was contrary to 
the expected result of an increase in shear rate due to the urea disrupting the 
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Figure 102. Rheogram of flow behaviour displayed by 0.25% xanthan / locust bean 
gum 0.25% solutions with urea. Conditions : Cone with 4.0cm diameter 
and a cone angle of 2 °, 25°C temperature and a shear stress sweep from 
OPa to lOPa.
Tako et al [335] also took this approach to examining the bonds formed between the 
molecules but they did find the viscosity reduced. One important difference in the 
methods was Tako et al. heated the solutions above the xanthan transition 
temperature which was thought to allow the urea access to the bond sites, so 
interfering with the interaction. In this case the urea surrounding the molecules 
probably promoted self-association of the molecules causing the observed increase in 
the viscosity.
3.3.3. Gel swelling studies.
Both qualitative and semi-quantitative image analyses show that tablet behaviour 
alters significantly when a solution of phosphate buffer is used as a dissolution 
medium. This effect was again attributed to the influence of ions in the buffer 
solution. It can be observed from the images in figure 103, that in the presence of
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Figure 103. Effect of different ionic strengths of buffer on the swelling characteristics 
of Xanthan Locust Bean Gum Tablets.
The change in the dimensions of the swelling tablets are shown for comparison in 
figure 104, 105, and 106. The measurements also show that the presence of external 
ions has a significant effect on swelling. The rate of swelling and dissolution of the 
polysaccharides is significantly reduced whereas the release rate of the drug is 
significantly increased in phosphate buffer (Figure 86).
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Figure 104. Graph of swelling index of tablet depth versus time of a granulated 
50/50 xanthan/locust bean gum tablets, dry blended with benzamide as 















Figure 105. Graph of swelling index of tablet diameter versus time of a granulated 
50/50 xanthan/locust bean gum tablets, dry blended with benzamide as 
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Figure 106. Graph of increase in swollen tablet volume versus time, of a granulated 
50/50 xanthan/locust bean gum tablets, dry blended with benzamide as 
model drug. Conditions : 37°C, in distilled water, 0.5M and 1.0M ionic 
strength buffer.
3.3.5. Electron spin resonance studies.
By incorporating the spin probe into the matrix in a similar fashion to the 
incorporation of a low dose drug it has been possible to examine the mobility of the 
probes in a variety of processing conditions.
The standard ESR solution spectrum for TEMPO is shown in figure 77 and is typical 
of a fully mobile spin probe. Figure 78 shows the equivalent solid state spectrum 
where the probe is immobilised in a glass. In figure 77 the classic solution spectra is 
shown where the label can move freely in the solvent.
Figure 78 is the spin label TEMPO in a glass where the label is dissolved in a mixture 
of the solvents THF:DMF and then frozen at 77K, the representative three 
component spectrum for an immobilised spin label, composed of the gl (positive 
peak), the g2 (inflection) and the g3 (negative peak). The glass spectrum shows
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characteristic line widths which indicate the high quality dispersion in the solid 
solution and the lack of interaction with other radicals of the same species.
Different methods of mixing the spin probe into the matrix were examined. When the 
spin probe was dry mixed into the powdered components xanthan, locust bean gum 
and dextrose, the resulting tablets produced very variable results with some showing 
a loss of hyperfine splitting between the nitrogen atom and the proton which indicates 
that the spin / spin relaxation is great. This loss of hyperfine splitting is shown in 
figure 107. Other tablets from the same batches showed no distinguishable spectra 
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Figure 107. ESR spectrum of TEMPOL dry mixed with xanthan locust bean gum and 
dextrose showing the characteristic single line trace where free exchange of 
electrons occurs when the molecules are in close proximity to one another.
A more vigorous mixing method using a hand blender did not significantly improve 
the distribution in the dry mix. This is a characteristic problem of trying to dry mix a 
low dose drug into a bulk powder such as a direct compression excipient. The spin
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probe was also dry mixed into granules of the excipient and this also produced poor 
results. This is strong indication that many of the interactions which occurred in later 
studies are not due to the interactions solely between the excipient components. In 
all of the later experiments the spin probe was dissolved into the granulating fluid and 
then used to form granules.
The spectra in figure 108 and 109 show the effect of dispersing the spin labels by wet 
granulation into dextrose alone. This method of incorporation in the absence of the 
polysaccharide components was found to give very different results to those obtained 
by incorporating the polysaccharides. In dextrose there was a hundred fold reduction 
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Figure 109. Comparison of ESR Profiles of TEMPOL with dextrose.
This very marked decrease in the amount of label present was considered likely to be 
due to a reduction reaction in the presence of the sugar and therefore the degradation 
of the radicals present which allow the spectroscopic analysis by ESR. When the 
matrix also contains polysaccharides this breakdown of the radicals did not appear to 
occur. This indicates that the polysaccharides offer a protective mechanism from the 
presence of reducing sugar and that any interaction is occurring with the
polysaccharides.
To eliminate the possibility that the hydroxyl and amine groups may be forming 
covalent links with the carboxyl group of the xanthan molecule, a freeze drying 
method was employed. This removed the heat input required to form these links, 
during the oven drying process. One batch was split and dried by the two different 
methods and the spectra obtained could not be easily differentiated (Figures 110, 
111, 112, 113). The remaining 3-4% water left in a sample after drying is firmly 
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Figure 113. Tray dried sample of 4-hydroxytempo.
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3.3.6. Thermodynamics.
In this part of the thermodynamic study the influence of different ions on the 
thermodynamic behaviour of the polysaccharides-water interaction was investigated. 
In figure 114 the polysaccharides granules are immersed in solutions of sodium 
chloride and calcium sulphate, and the energy absorbed or generated was measured. 
All the systems showed a release of energy at different times in the experiment. This 
energy release may be due to the gel structure beginning to break down as the 
polymers hydrate and the xanthan dissolves. We have already observed that the 
presence of ions reduces the swelling of the polysaccharide tablets and possibly the 
ions stabilise the gel by a self-association or syneresis type interaction which would 
account for the later release of energy in the microcalorimetry experiments and the 
delayed hydration and extended dissolution profile. The calcium ions appear to delay 
the dissolution for longer than sodium ions. It is possible that the calcium forms 
bonds or bridges between polymer chains and this delays the breakdown and 
dissolution process of the xanthan matrix component thus influencing the drug 
release rate.
Xanthan Locust Bean 1:1 in distilled water. 
Xantlian Locust Bean 1:1 in CaS04 solution.
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Figure 114. The energy released by xanthan locust bean 1:1 in ionic solutions.
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Figure 115 shows the first experiment repeated with the ions present within the 
polysaccharide granules. The most obvious feature is the lack of a release of energy 
from the matrix granulated with sodium chloride. This again indicates that the 
sodium ions interfere or interact with the formation of bonds within the matrix. The 
calcium-containing formulation still releases energy indicating the bonds exist and the 
dissolution process is delayed by the presence of these ions. Further work in this area 
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Figure 115. The energy released by xanthan locust bean 1:1 formulations containing 
ions in ionic solutions.
3.3.7. Magnetic resonance studies.
The MR images show the position of water within the tablets as they are exposed to 
the dissolution media. The results of the study appear to show that the gum-only 
tablet allows a greater degree of initial penetration and faster hydration of the 
polymers and those tablets with the insoluble calcium sulphate incorporated into the 
system wet more slowly due possibly to the calcium forming bonds with the polymers 
or simply because the calcium sulphate is relatively insoluble (Figure 116).
/
/
Xanthan Locust Bean 1:1 
in distilled water.
Xanthan Ixxaist Bean 1:1 10%CaSO.
in CaS04 solution.
Xanthan Locust Bean 1:1 10%NaCl 
in NaCl solution.
-----------y ............. i r—1— ,— .— f
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Image 1: Time 1 hour 50 min Image 2: Time 1 hour 50 min.
Xanthan/LBG tablets alone Calcium Sulphate containing tablets
Figure 116. Effect of Incorporating Sodium and Calcium ions into the Xanthan / 
Locust Bean Gum Matrix on the energy released from the system
3.3.8. Discussion.
The aim of using the third components was to significantly alter the drug release 
characteristics of the tablets in a way which would prove beneficial for in vivo use 
The most profound effect is achieved by the presence of cations The presence of 
ions in the excipient significantly increases the release rate, in particular the sodium 
ion interferes with the control mechanisms involved Cations external to the matrix 
also proved to influence the release rate and this is most important as differences in 
the ionic conditions could significantly alter the release performance of these dosage 
forms in vitro and in vivo. This is further illustrated by the effect of buffers without 
controlled ionic strength on the rheology of the gel system The destructive effect of 
sodium was confirmed in the rheological studies as the maximum shear rate for the 
equipment used was quickly reached and the yield value almost completely destroyed 
suggesting interference in the bonding between the two polysaccharide molecules and 
the importance of the synergistic bonding in the rate-controlling release mechanism 
Urea in this study did not appear to destroy the hydrogen bonding between the
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molecules but promoted self association which increased the viscosity of the system, 
although no influence was found on the dissolution profile to any significant degree.
Materials included to improve the compression characteristics such as dextrose, 
sorbitol and xylitol were all found to increase drug release rate, despite improving the 
quality of the tablets. This was considered due to the solubility of the sugar 
components allowing water to penetrate through the whole compact more quickly 
leading to rapid dissolution without disintegration. Both the increase with sugars and 
the increase in release rate in the presence of ions was found to be reversed by 
inclusion of another hydrating and gelling polymer in this case Carbopol 934P. The 
ability of several polymers to delay the release further was examined but the only one 
found to have the required influence was the group of carbomer polymers tested. 
The most efficient was the 97IP grade tested, which was found to form a 
homogeneous gel network and which was more efficient when dry blended with the 
xanthan / locust bean granules, rather than if wet granulated into the polysaccharides. 
This effect was considered due to several things: Firstly, if incorporated externally 
the carbomer wets and gels immediately and delays release from shunt routes at grain 
boundaries, while the xanthan / locust bean forms a rate controlling barrier through 
its time dependant synergistic interaction. Secondly, the carbomer molecules are 
capable of forming hydrogen bonds which gives rise to the possibility of the three 
polymer molecules joined in a more highly structured three component gel. Thirdly 
the carbomer may act to slow diffusion by binding drug molecules more efficiently. 
Lastly, it is possible that two or more of these effects may together produce the 
overall functionality.
In the ESR study the mixing efficiency of different methods was examined by 
blending the polysaccharides and dextrose with the spin label. A dry mixing method 
proved to be inefficient and a free exchange of electrons occurred. Wet granulation 
of the components with the spin label provided traces which showed the spin labels to
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be well dispersed throughout the excipient. The drying method was also examined 
and it was concluded that the exposure of the granules to heat did not promote the 
formation of any bonds between the polysaccharides or the polysaccharides and the 
drug. Finally the spin label was combined with dextrose alone. It was therefore 
concluded that any interaction occurring was between the spin label and the 
polysaccharides (Section 3.4.3), as the spin label loses activity when combined with 
dextrose alone.
In the thermodynamics and the MRI studies the effect of ions on the polysaccharides 
is studied. When surrounded by solutions of the ions the release of energy is delayed 
by both sodium and by calcium. This delay could be related to the delay observed in 
the hydration and dissolution of the polysaccharides. It has already been observed 
that the presence of ions inhibited the swelling and dissolution process, possibly due 
to self association and repulsion effects. When the ions are incorporated into the 
polysaccharide matrix, the burst of energy observed with the other systems does not 
occur. The sodium ions appear to interfere and destroy bonds between the 
polysaccharides. The calcium ions inside the matrix did not appear to interfere to the 
same degree and still delayed the dissolution process. In the MRI study the calcium 
ions also appeared to delay the hydration process, possibly due to the ions forming 
bonds between the polymers or due to the reduction in the hydration rate due to the 
insoluble nature of the calcium sulphate.
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3.4. Role of Drug Molecules in Controlled Drug 
Delivery.
It has already been stated that interactions have been observed between the 
polysaccharide polymers and drug molecules. The drug neomycin has been shown to 
form cross-links between xanthan molecules to the extent that the polymer becomes 
insoluble [101]. It is possible therefore that cross-linking may then become a 
controlling factor in the release of the drug into the surrounding dissolution media. 
In these studies the ability of the polymer combination, to form hydrogen bonds with 
similar model drugs is examined by different analytical methods.
3.4.1. Dissolution.
This study was designed to examine whether the capacity of a drug to form hydrogen 
bonds is a characteristic capable of further affecting the release rate from a 
heterodisperse polysaccharide excipient over and above the rate controlling effects of 
the excipient alone. The ability to bond may then be a further factor in controlling 
the drug release from the xanthan / locust bean gum excipient and one which can be 
appropriately exploited in designing an overall timed release profile.
The model drugs studied here were all derivatives of the benzamide molecule with 
different groups substituted into the para- position (Figures 117, 118, 119, and 120). 
In order to check that the slightly different substituted benzamides did not influence 
solubility which could be a cause of dissolution differences, calibration plots were 
constructed for each drug (Section 2.2.1.) which were linear for the concentrations 
used in the tablets prepared here.
The attraction which occurs between an electropositive hydrogen atom and an 
adjacent electronegative atom often on another molecule, is known as a hydrogen 
bond. The electronegative atoms are most commonly oxygen, nitrogen or fluorine.
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Figure 120. Molecular model of benzamide.
Figure 121. Molecular model of 4-hydroxybenzamide.
Figure 122. Molecular model of 4-fluorobenzamide
Figure 123. Molecular model of 4-aminobenzamide
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To try to influence the hydrogen bonding ability of the model drug, groups 
substituted onto the 4 position carbon were used separately containing each of these 
three electronegative atoms. The amide group is also capable of hydrogen bonding. 
The molecular models shown in figures 117, 118, 119 and 120, show that the para- 
substituted groups are in the most sterically favourable position for producing 
hydrogen bonds.
Both figures 121 and 122 show the release of the model drugs using different ratios 
of polysaccharide in the excipient. In the case of tablets containing xanthan / locust 
bean gum 1:1 excipient (Figure 121) the T50 of benzamide and hydroxybenzamide 
were the fastest to appear with no significant difference between the two. 
Aminobenzamide has a significantly slower T50 and the fluorobenzamide is 
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Figure 121. Graph of % dissolution per 15 minutes versus time of a granulated 
xanthan / locust bean gum in a 1:1 ratio tablet, with benzamide derivatives 
as model drugs. Conditions : 37°C, in distilled water and 0.5M ionic 
strength, phosphate buffer.
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With the xanthan / locust bean gum in a 1:2 ratio (Figure 122), the benzamide is still 
significantly faster at reaching the T50. There is no significant difference between 
hydroxybenzamide and the aminobenzamide but both were significantly slower than 
unsubstituted benzamide. Significantly slower again is the fluorobenzamide.
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— • —  Hydroxybenzamide 
— * -  Fluorobenzamide 




10:0000:00 02:00 06:00 08:0004:00 
Time (Hours)
Figure 122. Graph of % dissolution per 15 minutes versus time of a granulated 
xanthan / locust bean gum in a 1:2 ratio tablet, with benzamide derivatives 
as model drugs. Conditions : 37°C, and 0.5M ionic strength, phosphate 
buffer.
Both sets of results show the unsubsituted benzamide was released fastest and the 
benzamide substituted with the most strongly electronegative atoms, fluorine, had a 
much slower release rate. This would indicate that the hydrogen bonding capability 
of the model drug can affect the time taken for 50% of the drug to appear in the 
dissolution medium. However a criticism of this is that the solubility of each of the 
models may affect its dissolution properties. To study this possible effect, the results 
for each model drug from the different excipients were compared and the results 
shown in figures 123, 124, 125 and 126.
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Figure 123. Graph of % dissolution per 15 minutes versus time of a granulated 1:1 
and 1:2 ratio xanthan / locust bean gum tablets, dry blended with 
benzamide. Conditions : 37°C, in distilled water and 0.5M ionic strength, 
phosphate buffer.
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Figure 124. Graph of % dissolution per 15 minutes versus time of a granulated 1:1 
and 1:2 ratio xanthan / locust bean gum tablets, dry blended with 4- 
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Figure 125. Graph of % dissolution per 15 minutes versus time of a granulated 1:1 
and 1:2 ratio xanthan / locust bean gum tablets, dry blended with 4- 
hydroxybenzamide. Conditions : 37°C, in distilled water and 0.5M ionic 
strength, phosphate buffer.
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Figure 126. Graph of % dissolution per 15 minutes versus time of a granulated 1:1 
and 1:2 ratio xanthan / locust bean gum tablets, dry blended with 4- 
fluorobenzamide. Conditions : 37°C, in distilled water and 0.5M ionic 
strength, phosphate buffer.
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Earlier it was discussed that the ratio of xanthan / locust bean gum at 1:2 is close to 
the optimum for the synergistic increase in viscosity which is accounted for by the 
formation of hydrogen bonds between the two polysaccharide polymers [335], We 
can therefore propose that the optimisation of the bonds between the polymers 
should reduce the available bond sites where the model drug can bind.
When the release of benzamide, aminobenzamide and fluorobenzamide is compared 
from the two formulations, the T5 0  occurs significantly faster in excipient with the 
1:2 ratio of polysaccharides. The hydroxybenzamide also achieves its T5 0  faster from 
the 1 : 2  ratio excipient than the 1 :1  ratio excipient however the difference is not 
significant. This is in keeping with the theory that the reduced number of bond sites 
in the 1 : 2  ratio excipient reduces the opportunity for the model drug to bind to the 
polysaccharides allowing far faster dissolution and diffusion out of the matrix. This 
evidence suggests that the formation of bonds between the drug molecules and the 
controlled release excipient may be a factor in influencing the release rate. Other 
methods have been used to try to evaluate this theory and these are discussed further 
below.
3.4.3. Electron spin resonance studies.
The dissolution study using different para-substituted groups suggested that bonding 
may occur between the drug molecule and the polysaccharides of the excipient matrix 
thereby affecting the rate of drug release. In order to elucidate the nature of this 
interaction it was decided to use ESR to provide information about the ability of the 
spin labels to move within their environment. As in the dissolution study, spin labels 
substituted with groups having different hydrogen bonding ability, were incorporated 
into the polysaccharide matrix. Molecular models of these spin labels are shown in 
figures 127, 128, 129 and 130 and demonstrate that the shape of the molecules 
makes hydrogen bonding with the matrix possible. Methyl groups on the 
neighbouring carbon atoms sterically hinder the unpaired electron preventing it from
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reacting The group on the 4-position however is not sterically hindered and is 
available to form bonds
Figure 127 Molecular model of TEMPO
Figure 128 Molecular model of TEMPOL
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Figure 129 Molecular model of 4-oxo-Tempo
Figure 130 Molecular model of 4-amino-tempo
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In figures 131, 132, 133 and 134 the ESR spectra are shown for different spin labels 
that have been dissolved and then granulated into the polysaccharide components 
together with 50% dextrose, and subsequently tray dried at 50°C. The broad spectral 
line widths indicates that the rotational correlation time of the spin label is relatively 
slow and certainly greater that 10'7 seconds. This represents a relatively immobilised 
state for the molecules. All the molecules show that substantial proportions of each 
label are in a relatively immobilised state.
Closer examination of figure 131, corresponding to the TEMPO spectra and figure 
133, for 4-oxo-TEMPO, shows the presence of triplet lines between the main peaks. 
The third component for the expected triplet lines occurs under the central inflection 
(g2). These triplet lines are far less apparent in the spectra shown for TEMPOL, 
figure 132 and 4-amino-TEMPO, figure 134. These lines cannot be attributed to 
differences in the solution spectra of the different molecules as they were all identical, 
or to differences in the glassy spectra which were also very similar. These peaks can 
however be attributed to the overlaying of the solution spectra on the solid spectra 
i.e. some of the label appears to have gone into solution within the solid.
The presence of the solution peaks appears to be the result of small amount of 
residual water being present in the matrix possibly forming inverse micromicelles, 
since the three-line spectrum components have different widths (shown by the 
apparent different heights of the outer two components of the spectrum), and that the 
micelles are of moderate size.
It is important to note that the two molecules which appear to be held in an immobile 
state, have hydrogen bonding capacity due to the group substituted onto the 4- 
position i.e. the -OH and -NH4. We are therefore proposing that during the 
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Figure 134. ESR spectrum of 4-amino-TEMPO with a Xanthan / Locust Bean / 
Dextrose Matrix.
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Figure 135 and figure 136 shows the profile of TEMPO and TEMPOL granulated 
into the two polysaccharides alone, without the dextrose present. When the spectra 
in figure 135 is compared to figure 131 the overlying solution spectrum is more 
pronounced with the polysaccharides alone and appears to show large amounts of 
label in solution and not strongly bonded strongly‘to the polysaccharide matrix. 
Figure 136 shows the result for TEMPOL with the polysaccharides alone, the spectra 
is a solid state spectra similar to the formulation incorporating the dextrose in figure 
132. This is consistent with the theory that the hydrogen bonding group binds to the 
polysaccharide immobilising the spin label producing a solid spectra and the non 
binding spin labels show the solution spectra overlaying.
The spectra also show the effects are due to the polysaccharide components within 
the heterodisperse polysaccharide excipient rather than the dextrose.
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Figure 136. ESR spectrum of TEMPOL with a Xanthan / Locust Bean Gum 
polysaccharides.
3.4.4. Discussion
The dissolution study suggested that both the fluorine substituted and the amine 
substituted model drugs could form hydrogen bonds with the xanthan / locust bean 
matrix which affected their release rate from tablets to a significant degree. This was 
supported by the change in the ratio of xanthan to locust bean gum which is thought 
to reduce the number of bonding sites available to the model drug. In all the 1:2 
matrices the drug was released faster. The ESR study confirmed that hydrogen 
bonds were formed but with model drug molecules and the polysaccharide 
components. The spin labels with hydrogen bonding groups showed solid state 
spectra which indicated that the labels were immobilised within the matrix to a much 
greater extent than the non-hydrogen bonding spin labels which showed a much 
greater degree of motion. This could not be accounted for by covalent bond 
formation. These results indicated that the chemical structure and properties of the 
drug molecule may affect its rate of release from the xanthan / locust bean gum
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controlled release excipient by forming non-covalent, hydrogen bonds with the 
polymers.
196
C o n c l u sio n s .
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4. Conclusions.
The results obtained have been examined and a possible model of the mechanism of 
hydration and drug release from a polysaccharide matrix containing the 
galactomannan, locust bean gum and xanthan gum is proposed.
From the ESEM studies and optical image analysis of gel swelling it was observed 
that the glassy matrix in the starting tablet core, undergoes rapid hydration and forms 
a swollen barrier layer at the surface of the tablet almost instantaneously on contact 
with aqueous media. Cracks such as occur at grain boundaries and other 
inconsistencies in the dry tablet surface become sealed as they come into contact with 
the fluid. However pores of hydrated material in the glassy core area, are visible on 
the MRI images after only approximately 2 hours indicating that there are 
inconsistencies in the rate of hydration possibly due to fluid migrating by capillary 
action initially on contact with the fluid or by the synergistic interaction of the gels 
being less efficient in some areas. These pores appear to act as shunt routes and may 
allow more rapid or altered diffusion of fluid into the tablet through pseudo-gel 
regions and counter diffusion of solubilised drug molecules. The swollen polymer 
barrier formed at the surface was found to be not capable of control instantly and 
required time to form the synergistic bonds between xanthan and the locust bean 
gum. The time dependant nature of this interaction was considered to be responsible 
for a burst of drug release in the first 15 minutes of dissolution experiments. After 
this time the synergistic interaction becomes a significant rate-controlling factor as 
bonds progressively tighten and increase the efficiency of the gel, shutting down the 
rapid diffusion pathways through pseudo-gel regions. The presence of these bonds 
has been shown to be fundamental to the rheological and swelling properties of the 
heterodisperse polysaccharide excipient.
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In cases where the drug was granulated into the polysaccharides, a faster release was 
obtained than if dry blending of a drug and excipient particles was used. In order to 
explain this phenomenon further investigations were carried out which led to a 
further extension in the theory of release control for these polysaccharides, that if the 
drug exists in pockets within the polysaccharides, the dissolution fluid has to 
penetrate and hydrate the glassy matrix surrounding the drug before reaching and 
dissolving the drug particles. This development of the mechanistic theory was 
supported by cryogenic scanning electronmicrographs which demonstrated the 
complex and heterogeneous nature of the hydration process occurring within a tablet. 
At the solvent front there was evidence of a layer between the hydrated polymer and 
the dry core, of glassy pockets or "dry islands” surrounded by hydrated material. 
These observations were consistent with the results of other studies such as image 
analysis, freeze drying studies and magnetic resonance imaging.
Once the drug has dissolved it must then diffuse through the interstitial spaces 
between the molecules. Studies here suggested that the viscosity of the fluid in this 
area together with other factors such as the structure of water were all considered to 
have an influence on the diffusion and so drug release rate. The concentration and 
nature of third components included were also found to influence drug release 
behaviour from these polysaccharide gels. Carbomer was found to gel quickly filling 
spaces at grain boundaries and so reducing the initial burst of release associated with 
these "shunt" routes. The effect of Carbopol as a rate reducing additive was 
considered to be further enhanced due to its tendency to increase the viscosity o f the 
fluid between the polysaccharide molecules. Ions appeared to have the opposite 
effect on drug release, possibly causing the polysaccharide molecules to shrink and 
self-associate in a syneresis-type response which opens up the interstitial spaces 
allowing faster movement of the hydrating fluid and drug particles. Sodium ions in 
particular appeared to reduce or destroy the synergistic bonding between the two 
polysaccharides responsible for controlling drug release rates. Rheological and
199
thermodynamic studies suggested that if the sodium ion is brought into close contact 
with the heterodisperse polysaccharides, then bonds between the polysaccharides will 
not be formed. In cases where sodium ions surround the already-combined 
polysaccharides then the gel appears to be stabilised and dissolution delayed. MRI 
studies revealed the pores of hydrated material visible through the glassy core, were 
more abundant with greater fluid penetration in the presence of ions. These studies 
suggested that the divalent ion calcium, was particularly associated with this effect of 
creating shunt routes for high speed diffusion. This supports that part of the 
mechanistic theory that the presence of ions allows faster diffusion of the fluid.
Other third components were also found to have a statistically significant effect 
although not considered to be likely to influence the behaviour of the dosage form in 
vivo.
Another significant factor influencing control of release from these heterodisperse 
polysaccharide matrices was found to be the nature of the drug itself. The ability o f a 
drug molecule to form hydrogen bonds with the polysaccharide component of the 
matrix and thereby slow diffusion, was demonstrated using dissolution and ESR 
techniques. The ESR study showed that model drugs were able to exist in both 
bonded and non-bonded forms, depending on the presence of a hydrogen bonding 
group. The study also indicated that direct bonding was to the polysaccharides and 
not the third component, dextrose. In cases where drug-polysaccharide bonding 
occurred, an additional elution-type delay was added to the release-controlling 
mechanism operating within a given system.
The present study has resulted in a better understanding of the mechanisms of drug 
release and a theoretical model for controlled drug delivery from heterodisperse 
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Calculation for Automated Dissolution System
A = Absorbance
FRB= Absorbance Correction B =( A) X-p-
Where FR=Flow Rate and IV=Initial Volume of dissolution fluid.
IV - ( N  - l )  XFR
C= Volume Correction C
IV
D=Corrected Absorbance Value D=(A+B)xC
E=Corrected Absorbance Including Blanks E=D-Ai -Blank^
Where Aj is the Initial Absorbance an beginning of the test, Blanks is the blank 
absorbance at that time interval.
F=Corrected Reference value F=Ref^-B 1 anlq^
Where Re% is absorbance reading at that time interval for the reference standard
G=mg of Drug G = E xRC
F




The Newman-Keuls Statistical Procedure
The ANOVA test for a series of means can show that significant differences between 
the means occur but it does not indicate where these differences are. Successive t- 
tests may locate the differences but there is a possibility of introducing a statistical 
error which increases with each repeat of the test.
The Newman-Keuls procedure is a development of the ANOVA test which relies on 
arranging the means into a rank order and then testing them pairwise in a specific 
order. To apply the test the differences required for significance for the comparison 
of the means has to be calculated using :
Where Q is a value obtained from statistical tables, N is the sample size of the data 
and S2 is the Within Mean Square for the One-Way ANOVA of data. This is then 
repeated for the different Q values for three, four or five etc means. The values 
obtained are the critical difference values. These are then compared to the difference 
between the ranked means being tested. Any difference which exceeds the critical 
difference can be described as significant.




X50 values from dissolution data in results section.
T50  values for dissolution figures in section 3.1, individual 
components of controlled delivery.
Figure Numbers Formulation TgQfmin) ± s.d.
Figure 43 Xanthan 96.0 ±3.75
Locust Bean Gum 2.3 ±0.42
T 5 0  values for dissolution figures in section 3.2, seondary component 
controlled delivery.
Figure Numbers Formulation Tgofmin) ± s.d.
Figure 49 Xanthan 96.0 ±3.75
Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4.92
Figure 50 Xanthan 96.0 ±3.75
Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4.92
Xanthan : Locust Bean Gum 2:1 Ratio 91.83 ±8 .11
Xanthan : Locust Bean Gum 3:1 Ratio 112.83 ±6.24
Xanthan : Locust Bean Gum 4:1 Ratio 107 ±6.2
Figure 51 Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4.92
Xanthan : Locust Bean Gum 2:1 Ratio 91.83 ±8 .11
Xanthan : Locust Bean Gum 1:2 Ratio 75.0 ±4.67
Figure 52 Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4,92
Xanthan : Locust Bean Gum :Tara Gum 83,8 ±3.25 
Xanthan : Tara Gum 1 :1 Ratio 94.8 ±6.43
Figure 53 Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4.92
Xanthan: Agarose 1:1 Ratio 8.67 ±1.37
Xanthan : K-carrageenan 1 :1  Ratio 17.5 ±1.71
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Figure Numbers Formulation T5o(mm) ± s.d.
Figure 54 Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4.92
Benzamide granulated into gums 
Xanthan : Locust Bean Gum 1:1 Ratio 95.5 ±3.08 
Benzamide diy blended with gums
T^n values for dissolution figures in section 3.3, ternary component 
controlled delivery.
Figure Numbers Formulation TgQfmin) ± s.d.
Figure 83 Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4.92
Xanthan : Locust Bean Gum 1:1 Ratio 69.1 ±3.29
10% CaS04
Xanthan : Locust Bean Gum 1:1 Ratio 51.8 ±2.83
10% NaCl
Xanthan : Locust Bean Gum 1:1 Ratio 6 8 . 8  ±3.47
10% KC1
Figure 84 Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4.92
Xanthan : Locust Bean Gum 1:1 Ratio 81.1 ±3.85
10% NaCMC
Xanthan : Locust Bean Gum 1:1 Ratio 51.8 ±2.83
10% NaCl
Figure 85 Xanthan : Locust Bean Gum 1:1 Ratio 100.3 ±4.92
Xanthan : Locust Bean Gum 1:1 Ratio 81.0 ±3.98
10% Carbopol 934P, 10% NaCl 
Xanthan : Locust Bean Gum 1:1 Ratio 51.75 ±2.83
10% NaCl










Xanthan : Locust Bean Gum 1:1 Ratio 
in phosphate buffer
Xanthan: Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Urea
Xanthan: Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
50% Dextrose
Xanthan : Locust Bean Gum : Dextrose 
1:1:1 Ratio
Xanthan : Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
50% Dextrose
Xanthan : Locust Bean Gum 1:1 Ratio 
45% Dextrose, 10% Carbopol 934P
Xanthan: Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
50% Dextrose
Xanthan : Locust Bean Gum 1:1 Ratio 
50% Sorbitol
Xanthan : Locust Bean Gum 1:1 Ratio 
50% Xylitol
Xanthan : Locust Bean Gum 1:1 Ratio 


























Xanthan : Locust Bean Gum 1:1 Ratio 
10% NaCMC
Xanthan : Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
2% HPMC A
Xanthan : Locust Bean Gum 1:1 Ratio 
2% HPMC B
Xanthan : Locust Bean Gum 1:1 Ratio 
2% HPMC C
Xanthan : Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 934P (in granulation) 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 971 (in granulation) 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 161 (in granulation)
Xanthan : Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 934P (dry blended) 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 971 (dry blended) 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 161 (dry blended)
Xanthan: Locust Bean Gum 1:1 Ratio






















Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 934P (in granulation) 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 934P (dry blended)
Xanthan: Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 971 (in granulation) 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 971 (dry blended)
Xanthan : Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 161 (in granulation) 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Carbopol 161 (dry blended)
Xanthan: Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
1% SLS
Xanthan : Locust Bean Gum 1:1 Ratio 
5% SLS
Xanthan : Locust Bean Gum 1:1 Ratio 
1% Tween 60
Xanthan : Locust Bean Gum 1:1 Ratio 
5% Tween 60
Xanthan: Locust Bean Gum 1:1 Ratio 
Xanthan : Locust Bean Gum 1:1 Ratio 
10% Stearic acid

















T^n values for dissolution figures in section 3.4, the role of drug 







Xanthan : Locust Bean Gum 1:1 Ratio 
Benzamide
Xanthan : Locust Bean Gum 1:1 Ratio 
Hydroxybenzamide
Xanthan : Locust Bean Gum 1:1 Ratio 
Fluorobenzamide
Xanthan : Locust Bean Gum 1:1 Ratio 
Aminobenzamide
Xanthan : Locust Bean Gum 1:2 Ratio 
Benzamide
Xanthan : Locust Bean Gum 1:2 Ratio 
Hydroxybenzamide
Xanthan : Locust Bean Gum 1:2 Ratio 
Fluorobenzamide
Xanthan : Locust Bean Gum 1:2 Ratio 
Aminobenzamide
Xanthan : Locust Bean Gum 1:1 Ratio 
Benzamide
Xanthan ; Locust Bean Gum 1:2 Ratio 
Benzamide
Xanthan : Locust Bean Gum 1:1 Ratio 
Aminobenzamide
Xanthan : Locust Bean Gum 1:2 Ratio 
Aminobenzamide














Figure Numbers Formulation l 5 0 (min) ± sA .
Figure 125
Figure 126
Xanthan : Locust Bean Gum 1:1 Ratio 66.4 ±4.38
Hydroxybenzamide
Xanthan : Locust Bean Gum 1:2 Ratio 65.1 ±4.74
Hydroxybenzamide
Xanthan : Locust Bean Gum 1:1 Ratio 124.7 ±13.01 
Fluorobenzamide
Xanthan : Locust Bean Gum 1:2 Ratio 110.3 ±6.95
Fluorobenzamide
s.d.- standard deviation.
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